Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-15-283901.txt : 20150810 0001193125-15-283901.hdr.sgml : 20150810 20150810074653 ACCESSION NUMBER: 0001193125-15-283901 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150810 DATE AS OF CHANGE: 20150810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 151039206 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 10-Q 1 d939524d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2015

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 001-31791

GALECTIN THERAPEUTICS INC.


Nevada		04-3562325
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA		30071
(Address of Principal Executive Offices)		(Zip Code)

(678) 620-3186

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.05 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No

The number of shares outstanding of the registrant’s common stock as of August 7, 2015 was 22,788,913.

GALECTIN THERAPEUTICS INC.

INDEX TO FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2015


		PAGE
	PART I — FINANCIAL INFORMATION

ITEM 1.	Unaudited Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014 (unaudited)		3
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2015 and 2014 (unaudited)		4
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014 (unaudited)		5
	Notes to Unaudited Condensed Consolidated Financial Statements		6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk		17

ITEM 4.	Controls and Procedures		17

	PART II — OTHER INFORMATION

ITEM 1.	Legal Proceedings		18

ITEM 1A.	Risk Factors		18

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds		18

ITEM 3.	Defaults Upon Senior Securities		18

ITEM 4.	Mine Safety Disclosures		18

ITEM 5.	Other Information		18

ITEM 6.	Exhibits		18

SIGNATURES			19

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)


	June 30, 2015			December 31, 2014
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	26,362		$	29,128
Prepaid expenses and other current assets		305			533


Total current assets		26,667			29,661


Property and equipment, net		—			1
Intangible assets, net		12			15


Total assets	$	26,679		$	29,677


LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	775		$	906
Accrued expenses		1,065			729
Accrued dividends payable		68			68


Total liabilities		1,908			1,703


Commitments and contingencies (Note 8)

Series B-1 12% redeemable convertible preferred stock; 900,000 shares authorized, issued and outstanding at June 30, 2015 and December 31, 2014, redemption and liquidation value $1,800,000 at June 30, 2015		1,740			1,731
Series B-2 12% redeemable convertible preferred stock; 2,100,000 shares authorized, issued and outstanding at June 30, 2015 and December 31, 2014, redemption and liquidation value $4,200,000 at June 30, 2015		3,431			3,325
Series C super dividend convertible preferred stock; 1,000 shares authorized, 176 and 176 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively, redemption value: $5,660,000, liquidation value: $1,760,000 at June 30, 2015		1,723			1,723

Stockholders’ equity:
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at June 30, 2015 and December 31, 2014
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,402,500 issued and outstanding at June 30, 2015 and December 31, 2014, liquidation value $1,402,500 at June 30, 2015		567			567
Common stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2015 and December 31, 2014, 23,788,913 and 22,277,283 issued and outstanding at June 30, 2015 and December 31, 2014, respectively		23			22
Additional paid-in capital		146,217			139,531
Retained deficit		(128,930	)		(118,925	)


Total stockholders’ equity		17,877			21,195


Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$	26,679		$	29,677

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
	(in thousands, except per share amounts)

Operating expenses:

Research and development	$	2,600		$	1,594		$	5,736		$	4,366

General and administrative		2,057			1,781			3,761			3,853


Total operating expenses		4,657			3,375			9,497			8,219


Total operating loss		(4,657	)		(3,375	)		(9,497	)		(8,219	)


Other income (expense):

Interest income		14			13			28			17

Loss from equity method investment in Galectin Sciences, LLC		—			(67	)		—			(337	)


Total other income (expense)		14			(54	)		28			(320	)


Net loss	$	(4,643	)	$	(3,429	)	$	(9,469	)	$	(8,539	)


Preferred stock dividends		(230	)		(245	)		(421	)		(485	)

Preferred stock accretion		(58	)		(57	)		(115	)		(115	)


Net loss applicable to common stockholders	$	(4,931	)	$	(3,731	)	$	(10,005	)	$	(9,139	)


Net loss per common share – basic and diluted	$	(0.21	)	$	(0.17	)	$	(0.43	)	$	(0.42	)

Weighted average common shares outstanding – basic and diluted		23,731			21,983			23,398			21,570

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	Six Months Ended June 30,
	2015			2014
	(in thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(9,469	)	$	(8,539	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4			5
Stock-based compensation expense		1,734			2,394
Loss from equity method investment in Galectin Sciences LLC		—			337
Changes in operating assets and liabilities:
Prepaid expenses and other assets		228			111
Accounts payable and accrued expenses		205			(339	)


Net cash used in operating activities		(7,298	)		(6,031	)


CASH FLOWS FROM INVESTING ACTIVITIES:
Equity method investment in Galectin Sciences LLC		—			(400	)


Net cash used in investing activities		—			(400	)


CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants		4,532			28,178
Proceeds from exercise of common stock warrants and options		—			2,187


Net cash provided by financing activities		4,532			30,365


NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(2,766	)		23,934
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		29,128			10,489


CASH AND CASH EQUIVALENTS, END OF PERIOD	$	26,362		$	34,423


NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock	$	421		$	488

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.	Basis of Presentation

Galectin Therapeutics Inc. (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.

The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of June 30, 2015 and the results of its operations for the three and six months ended June 30, 2015 and 2014 and its cash flows for the six months ended June 30, 2015 and 2014. All adjustments made to the interim financial statements include all those of a normal and recurring nature. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2014.

The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At June 30, 2015, the Company had $26.4 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes that with the cash on hand at June 30, 2015, there is sufficient cash to fund currently planned operations through September 30, 2016. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Immediately prior to March 23, 2012, the Company was traded on the Over-the Counter Bulletin Board (“OTCBB”) under the symbol GALT.OB.

2.	Accrued Expenses

Accrued expenses consist of the following:


	June 30, 2015		December 31, 2014
	(in thousands)
Legal and accounting fees	$	255	$	118
Accrued compensation		377		604
Accrued clinical trial costs		426		—
Other		7		7


Total	$	1,065	$	729

3.	Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:


	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(in thousands)

Research and development	$	226	$	221	$	543	$	860

General and administrative		574		524		1,191		1,534


Total stock-based compensation expense	$	800	$	745	$	1,734	$	2,394

The following table summarizes the stock option activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:


	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2014		3,332,617		$	5.79
Granted		304,000			3.45
Exercised		(95,574	)		1.80
Options forfeited/cancelled		(348,718	)		4.42


Outstanding, June 30, 2015		3,192,325		$	5.83

As of June 30, 2015, there was $3,492,000 of unrecognized compensation related to 828,596 unvested options, which is expected to be recognized over a weighted–average period of approximately 1.67 years. The weighted-average grant date fair value for options granted during the six months ended June 30, 2015 and 2014 was $2.78 and $11.38, respectively. The Company granted 304,000 stock options in January 2015, of which 76,000 options vested upon grant with the remaining 228,000 options vesting over 3 years. Approximately $173,000 of non-cash, stock-based compensation expense was recorded during the six months ended June 30, 2015 related to the options granted in January 2015 that were vested upon the grant date.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:


	Six Months Ended June 30,	Six Months Ended June 30,
	2015	2014
Risk-free interest rate	1.64%	1.58%
Expected life of the options	6.0 years	6.0 years
Expected volatility of the underlying stock	104%	114%
Expected dividend rate	0%	0%

The following table summarizes the restricted stock grant activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:


	Shares
Outstanding, December 31, 2014		416,670
Granted		337,935
Exercised		—
Options forfeited/cancelled		—


Outstanding, March 31, 2015		754,605

On March 12, 2015, the Company granted 81,352 shares of restricted stock to non-employee directors as a component of their compensation. A total of 77,784 shares were issued to seven directors representing non-cash compensation cost of $280,000 which will be recognized on a straight-line basis from the grant date through May 20, 2016, when the restricted shares will vest in full. A total of 3,568 shares were issued to two directors, who were not nominated for reelection, representing non-cash compensation cost of $12,845 that will be recognized on a straight-line basis from the grant date through May 21, 2015, when the restricted shares will vest in full.

On April 8, 2015, the Company granted 177,618 shares of restricted stock to non-employee directors in exchange for cancelation of 222,615 stock options. As the exchange was made at fair value, there was no additional non-cash compensation expense recorded in accordance with FASB ASC 718-20. Additionally, on April 8, 2015, the Company granted 71,378 shares of restricted stock to one non-employee director representing $236,975 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full. Also, in April and May 2015, the Company granted a total of 7,587 shares of restricted stock to four non-employee directors for service as committee chairs or lead independent director representing $23,500 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full.

In January 2014, the Company entered into an agreement with a consultant that provided for the grant of 3,000 shares of common stock. The Company recognized an expense of $25,000, representing the fair value of the common stock, during the three months ended March 31, 2014.

4.	Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2014 through June 30, 2015:


	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2014		5,470,995		$	3.67
Granted		—			—
Exercised		—			—
Forfeited/cancelled		(100,000	)		4.26


Outstanding, March 31, 2015		5,370,995		$	3.64

5.	Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximates their carrying value due to their short-term nature. There were no level 2 or level 3 assets held at fair value at June 30, 2015 or December 31, 2014.

6.	Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:


	June 30, 2015 (shares)		June 30, 2014 (shares)
Warrants to purchase shares of common stock		5,370,995		5,450,995
Options to purchase shares of common stock		3,192,325		3,311,029
Unvested shares of restricted common stock		337,935		—
Shares of common stock issuable upon conversion of preferred stock		2,527,103		2,537,103


		11,428,358		11,299,127

7.	Common Stock

2014 At Market Issuance of Common Stock

On March 30, 2014, the Company entered into an At Market Issuance Sales Agreement (the “2014 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2014 At Market Agreement. As of December 31, 2014, the Company had issued 217,622 shares of its common stock through its 2014 At Market Agreement at an average price of $5.49 per share resulting in gross proceeds of approximately $1,196,000. The Company incurred commissions of approximately $36,000 resulting in net proceeds of approximately $1,159,000 as of December 31, 2014. In three months ended March 31, 2015, the Company issued 1,279,416 shares of common stock for net proceeds of approximately $4,532,000 under the 2014 At Market Agreement. There were no ATM transactions in the three months ended June 30, 2015.

8.	Commitments and Contingencies

Shareholder Class Actions and Derivative Lawsuits

Between July 30, 2014, and August 6, 2014, three putative class action complaints were filed in the United States District Court for the District of Nevada (the “Nevada District Court”) against the Company and certain of its officers and directors on behalf of all persons who purchased or otherwise acquired the Company’s stock between January 6, 2014 and July 28, 2014. By order entered August 22, 2014, the Nevada District Court consolidated the three cases, relieved the defendants of any obligation to respond to the complaints then on file, and provided that defendants may respond to a consolidated amended complaint to be filed following appointment of a lead plaintiff(s) pursuant to the Private Securities Litigation Reform Act of 1995. By order dated January 5, 2015, the Nevada District Court granted the defendants’ motion to transfer the consolidated action to the United States District Court for the Northern District of Georgia (the “Court”). On March 24, 2015, the Court appointed Glyn Hotz as the lead plaintiff (“Plaintiff”). Plaintiff filed his Consolidated Class Action Complaint (the “Complaint”) on May 8, 2015. The Complaint asserts claims on behalf of a putative class of all persons who purchased or otherwise acquired the Company’s common stock between October 25, 2013 and July 28, 2014. The Complaint alleges that the Company and certain of its officers and directors (the “Class Action Individual Defendants”) violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and SEC Rule 10b-5 through allegedly false or misleading statements in certain SEC filings, press releases and other public statements. The Complaint further alleges that the Class Action Individual Defendants and one of the Company’s shareholders face liability for the alleged Section 10(b) and Rule 10b-5 violations pursuant to Section 20(a) of the Exchange Act. The Complaint seeks class certification, unspecified monetary damages, costs, and attorneys’ fees. The Company disputes the allegations and filed a motion to dismiss the Complaint on June 26, 2015.

On August 1 and 25, 2014, persons claiming to be Galectin shareholders filed putative shareholder derivative complaints in the Nevada District Court, seeking recovery on behalf of the Company against certain of the Company’s directors and officers. On September 10, 2014, the Nevada District Court entered an order consolidating the two cases, relieving the defendants of any obligation to respond to the initial complaints, and providing that defendants may respond to a consolidated complaint to be filed by the plaintiffs. On January 5, 2015, the Nevada District Court granted Defendants’ motion to transfer the consolidated putative derivative litigation to the United States District Court for the Northern District of Georgia. The plaintiffs filed a consolidated complaint on February 27, 2015. On April 6, 2015, the Company and defendants filed motions to dismiss the consolidated complaint. Rather than respond to those motions, the plaintiffs sought and obtained leave to file an amended complaint. Plaintiffs filed their amended complaint (the “Complaint”) on May 26, 2015. The Complaint alleges that certain of the Company’s directors and officers (the “Derivative Action Individual Defendants”) breached their fiduciary duties to the Company’s shareholders by causing or permitting the Company to make allegedly false and misleading public statements concerning the Company’s financial and business prospects. The Complaint also alleges that the Derivative Action Individual Defendants violated the federal securities laws by allegedly making false or misleading statements of material fact in the Company’s proxy filings, committed waste of corporate assets, were unjustly enriched, and that certain defendants breached their fiduciary duties through allegedly improper sales of Galectin stock. In addition, the Complaint alleges that the Derivative Action Individual Defendants and one of the Company’s shareholders aided and abetted the alleged breaches of fiduciary duties. The Complaint seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the Complaint on July 8, 2015.

On August 29, 2014, another alleged Galectin shareholder filed a putative shareholder derivative complaint in state court in Las Vegas, Nevada, seeking recovery on behalf of the Company against the same Galectin directors and officers who are named as defendants in the derivative litigation pending in the United States District Court for the Northern District of Georgia (the “Georgia Federal Action”). The plaintiff in the Nevada action subsequently filed first and second amended complaints. The second amended complaint alleges claims for breach of fiduciary duties, unjust enrichment, and waste of corporate assets, based on allegations that are substantially similar to those asserted in the Georgia Federal Action (except that the Nevada action does not allege violations of the federal securities laws and does not assert any claim against the Galectin shareholder named as a defendant in the Georgia Federal Action), and seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the second amended complaint on April 22, 2015. On April 29, 2015, the plaintiffs in the Georgia Federal Action filed a motion to intervene in the Nevada action which, among other things, raised questions regarding the Nevada plaintiff’s standing. Thereafter, the Nevada plaintiff filed a motion to join additional plaintiffs. At a hearing held on June 11, 2015, the Nevada court: (i) granted the Georgia Federal Action plaintiffs’ motion to intervene; (ii) directed the Georgia Federal Action plaintiffs to file a complaint in intervention; (iii) directed the Nevada plaintiff to file a motion for leave to file a further amended complaint to add additional plaintiffs; (iv) stated that the defendants’ motions to dismiss the second amended complaint were denied “at this point;” (v) ordered the Nevada action stayed until December 11, 2015; and (vi) directed the parties to submit a status report on December 11, 2015, updating the court on the progress and status of the Georgia Federal Action.

Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, are in the early stages of the proceedings, and are subject to appeal. In addition, because most legal proceedings are resolved over extended periods of time, potential losses are subject to change due to, among other things, new developments, changes in legal strategy, the outcome of intermediate procedural and substantive rulings and other parties’ settlement posture and their evaluation of the strength or weakness of their case against us. For these reasons, we are currently unable to predict the ultimate timing or outcome of, or reasonably estimate the possible losses or a range of possible losses resulting from, the matters described above. Based on information currently available, the Company does not believe that any reasonably possible losses arising from currently pending legal matters will be material to the Company’s results of operations or financial condition. However, in light of the inherent uncertainties involved in such matters, an adverse outcome in one or more of these matters could materially and adversely affect the Company’s financial condition, results of operations or cash flows in any particular reporting period.

Other Legal Proceedings

The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no other pending legal proceedings except as noted above.

9.	Galectin Sciences LLC

In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as wells the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. As a result, the Company contributed the $93,000, $159,000 and $172,000 needed for the fourth quarter of 2014, first quarter of 2015 and the second quarter of 2015 expenses of the LLC, respectively. As a result, the Company’s ownership percentage in the LLC is 67.3% at June 30, 2015. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. The Company’s portion of the LLC’s net loss for the year ended December 31, 2014, prior to the change in accounting discussed previously, was $400,000, which includes the Company’s proportionate share of the non-cash charge associated with the contributed IPR&D of $200,000.

10.

Subsequent Events

The Company has evaluated all events or transactions that occurred through the date on which the financial statements were issued, with no items noted for disclosure or recording in the consolidated financial statements as of June 30, 2015.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined under Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created therein for forward-looking statements. Such statements include, but are not limited to, statements concerning our anticipated operating results, research and development, clinical trials, regulatory proceedings, and financial resources, and can be identified by use of words such as, for example, “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and “would,” “should,” “could” or “may.” All statements, other than statements of historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding: plans and expectations regarding clinical trials; plans and expectations regarding regulatory approvals; our strategy and expectations for clinical development and commercialization of our products; potential strategic partnerships; expectations regarding the effectiveness of our products; plans for research and development and related costs; statements about accounting assumptions and estimates; expectations regarding liquidity and the sufficiency of cash to fund currently planned operations through September 30, 2016; our commitments and contingencies; and our market risk exposure. Forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which Galectin Therapeutics operates, and management’s beliefs and assumptions. These statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties are related to and include, without limitation,

•

our early stage of development,

•

we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,

•

our dependence on outside capital,

•

we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,

•

uncertainties related to any litigation, including shareholder class actions and derivative lawsuits filed,

•

uncertainties related to our technology and clinical trials,

•

we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,

•

we may be unable to improve upon, protect and/or enforce our intellectual property,

•

we are subject to extensive and costly regulation by the U.S. Food and Drug Administration (FDA) and by foreign regulatory authorities, which must approve our product candidates in development and could restrict the sales and marketing and pricing of such products,

•

competition and stock price volatility in the biotechnology industry,

•

limited trading volume for our stock, concentration of ownership of our stock, and other risks detailed herein and from time to time in our SEC reports, and

•

other risks detailed herein and from time to time in our SEC reports, including our Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2014, and our subsequent SEC filings.

The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of Galectin Therapeutics appearing elsewhere herein.

Overview

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease and cancer. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant materials as starting material in manufacturing processes to create proprietary complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when a program becomes advanced and requires additional resources.

We endeavor to leverage our scientific and product development expertise as well as established relationships with outside sources to achieve cost-effective and efficient development. These outside sources, amongst others, provide us with expertise in preclinical models, pharmaceutical development, toxicology, clinical development, pharmaceutical manufacturing, sophisticated physical and chemical characterization, and commercial development. We also have established several collaborative scientific discovery programs with leading experts in carbohydrate chemistry and characterization. These discovery programs are generally aimed at the targeted development of new carbohydrate molecules which bind galectin proteins and offer alternative options to larger market segments in our primary disease indications, such as subcutaneous or oral administration. We also have established a discovery program aimed at the targeted development of small molecules (non-carbohydrate) which bind galectin proteins and may afford options for alternative means of drug delivery (e.g., oral) and as a result expand the potential uses of our compounds. We are pursuing a development pathway to clinical enhancement and commercialization for our lead compounds in immune enhancement for cancer therapy as well as in both liver fibrosis and fatty liver disease. All of our proposed products are presently in development, including pre-clinical and clinical trials.

Our Drug Development Programs

Galectins are a class of proteins that are made by many cells in the body. As a group, these proteins are able to bind to sugar molecules that are part of other proteins in and on the cells of our body. Galectin proteins act as a kind of molecular glue, bringing together molecules that have sugars on them. Galectin proteins, in particular galectin-3, are known to be markedly increased in a number of important diseases including scarring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the disease and is detrimental to the patient. Published data show that mice lacking the galectin-3 gene, and thus unable to produce galectin-3, are incapable of developing liver fibrosis in response to toxic insult to the liver and in fatty liver disease.

We have two compounds in development, GR-MD-02 and GM-CT-01, both of which have shown promise in preclinical studies in treatment of fibrosis and in cancer therapy. However, we are currently focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (nonalcoholic steatohepatitis or NASH) and in cancer therapy in combination with immune-system modifying agent(s). Both of our proprietary, patented compounds are derived from completely different, natural, readily available, starting materials, which, following chemical processing, both exhibit the property of binding to and inhibiting galectin proteins.

Our product pipeline is shown below:


Indication	Drug	Status
Fibrosis

NASH with Advanced Fibrosis and NASH cirrhosis	GR-MD-02	IND submitted January 2013, FDA indicated on March 1, 2013 that we could proceed with a Phase 1 US clinical trial. Phase 1 clinical trial started Q2-2013. Results from the three cohorts of the Phase 1 clinical trial were reported in 2014, with final results reported in January 2015. End of Phase 1 meeting held with FDA in 2014 and Phase 2 clinical program began in Q2 2015.

Lung Fibrosis	GR-MD-02	In pre-clinical development

Kidney Fibrosis	GR-MD-02	In pre-clinical development

Cardiac Fibrosis	GR-MD-02 and GM-CT-01	In pre-clinical development

Cancer Immunotherapy

Melanoma	GR-MD-02	Investigator IND filed in December 2013. Phase 1B study in process.

We believe the mechanism of action for GM-CT-01 and GR-MD-02 is based upon interaction with, and inhibition of, galectin proteins, particularly galectin-3, which are expressed at high levels in certain pathological states including inflammation, fibrosis and cancer. While GM-CT-01 and GR-MD-02 are capable of binding to multiple galectin proteins, we believe that they have the greatest affinity for galectin-3, the most prominent galectin implicated in pathological processes. Blocking galectin in cancer and liver fibrosis has specific salutary effects on the disease process.

Fibrosis. GR-MD-02 is our lead product candidate for treatment of fibrotic disease. Our preclinical data show that GR-MD-02 has a powerful therapeutic effect on liver fibrosis as shown in several relevant animal models. In addition, in NASH animal models GR-MD-02 is able to reduce liver fat, inflammation, and ballooning degeneration or death of liver cells. Therefore, we chose GR-MD-02 as the lead candidate in a development program targeted initially at fibrotic liver disease associated with non-alcoholic steatohepatitis (NASH, or fatty liver disease). In January 2013, an Investigational New Drug (“IND”) was submitted to the FDA with the goal of initiating a Phase 1 study in patients with NASH and advanced liver fibrosis to evaluate the human safety of GR-MD-02 and pharmacodynamics biomarkers of disease. On March 1, 2013, the FDA indicated we could proceed with a US Phase 1 clinical trial for GR-MD-02 with a development program aimed at obtaining support for a proposed indication of GR-MD-02 for treatment of NASH with advanced fibrosis. The Phase 1 trial was completed and demonstrated that GR-MD-02 up to 8 mg/Kg, i.v. was safe and well tolerated and the human pharmacokinetic data defined a drug dose for use in the planned Phase 2 trials. Additionally, there was evidence of a pharmacodynamic effect of GR-MD-02 at the 8 mg/kg dose with a decrease in alpha 2 macroglobulin, a serum marker of fibrotic activity, and a reduction in liver stiffness. An “End of Phase 1 Meeting” was held with FDA which, amongst other items, provided guidance on the primary endpoint for the Phase 2 clinical trial.

Additionally, an open label drug-drug interaction study was completed during the second quarter of 2015 with GR-MD-02 and it showed that with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observed. This study was required by the U.S. Food and Drug Administration (FDA) and the primary objective was to determine if single or multiple intravenous (IV) doses of GR-MD-02 affect the pharmacokinetics (PK) of midazolam. The secondary objective was to assess the safety and tolerability of GR-MD-02 when administered concomitantly with midazolam. The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial. In addition, should GR-MD-02 be approved for marketing, the success of this study supports a broader patient population for the drug label.

Our Phase 2 program in fibrotic disease consists of two separate human clinical trials. The first clinical trial is the NASH-CX study for patients with NASH with cirrhosis, which began enrolling in June 2015. This study is a randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis. A total of 156 patients at between 45 and 60 sites will be randomized to receive either 2 mg/kg of GR-MD-02, 8 mg/kg of GR-MD-02 or placebo, with 52 patients in each arm. The primary endpoint is a reduction in change in hepatic venous pressure gradient (HVPG). Patients will receive an infusion every other week for one year, total of 26 infusions, and will be evaluated to determine the change in HVPG as compared with placebo. HVPG will be correlated with secondary endpoints of fibrosis on liver biopsy as well as with measurement of liver stiffness (FibroScan^(R)) and assessment of liver metabolism (¹³C-methacetin breath test, Exalenz), which are non-invasive measures of the liver that may be used in future studies. Data readout is expected in the fourth quarter of 2017.

The second clinical trial is the NASH-FX for patients with NASH advanced fibrosis. This 30 patient study is expected to begin enrolling in August 2015, with 15 patients receiving 8 mg/kg of GR-MD-02 and 15 receiving placebo. That study will evaluate the safety and efficacy of GR-MD-02 for a four month treatment period of bi - weekly infusions on liver stiffness as assessed by magnetic resonance-elastography and FibroScan score, and on imaging of liver fibrosis using multi-parametric magnetic resonance imaging (LiverMultiScan^(R), Perspectum Diagnostics). Top-line data is expected to be available in mid-2016.

Our drug candidate provides a promising new approach for the therapy of fibrotic diseases, and liver fibrosis in particular. Fibrosis is the formation of excess connective tissue (collagen and other proteins plus cellular elements such as myofibroblasts) in response to damage, inflammation or repair. When the fibrotic tissue becomes confluent, it obliterates the cellular architecture, leading to scarring and dysfunction of the underlying organ. The goal of the therapeutic program is to stop the progression of and reverse the fibrosis in the liver and, thereby improve liver function and prevent the development of complications of fibrosis/cirrhosis and liver-related mortality.

Cancer Immunotherapy. We believe there is potential for galectin inhibition to play a key role in the burgeoning area of cancer immunotherapy. For example, there have been several recent approvals of drugs that enhance a patient’s immune system to fight cancer. With many additional vaccines and immune stimulatory agents in development, industry analysts forecast that this market could generate over $35 billion in sales over the next 10 years. It is our goal to use a galectin inhibitor to enhance the immune system function to fight cancer in a way that complements other approaches to this type of therapy. Our drug candidates provide a promising new therapeutic approach to enhance the activity of the immune system against cancer cells. Preclinical studies have indicated that GR-MD-02 enhances the immune response to and more specifically increased tumor shrinkage and enhanced survival in immune competent mice with prostate, breast, melanoma and sarcoma cancers when combined with one of the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD-1. These preclinical data have led to the filing of an Investigator-sponsored IND and the initiation of a study of GR-MD-02 in combination with Yervoy ^® (ipilimumab) in a Phase 1B study of patients with metastatic melanoma. This study is being conducted under the sponsorship of Providence Portland Medical Center’s Earle A. Chiles Research Institute (EACRI). A study with Keytruda and GRMD-02 is currently being planned by EACRI.

Results of Operations

Three and Six Months Ended June 30, 2015 Compared to Three and Six Months Ended June 30, 2014

Research and Development Expense.


	Three Months Ended June 30,				Six Months Ended June 30,				2015 as Compared to 2014
	Three Months Ended June 30,				Six Months Ended June 30,				Three Months					Six Months
	2015		2014		2015		2014		$ Change		% Change			$ Change		% Change
	(In thousands, except %)

Research and development	$	2,600	$	1,594	$	5,736	$	4,366	$	1,006		63	%	$	1,370		31	%

We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses, comprised of employee payroll and general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans, at which time we begin tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient dosing and monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin, including payments to vendors for services related to product experiments and discovery, toxicology, pharmacology, metabolism and efficacy studies, as well as manufacturing process development for a drug candidate.

We have two product candidates, GR-MD-02 and GM-CT-01; however only GR-MD-02 is in active development. We filed for an IND for GR-MD-02 in January 2013 and in February 2013 we entered into an agreement with CTI to conduct a Phase 1 clinical trial of GR-MD-02. In March 2013, the FDA indicated we could proceed with a Phase 1 human clinical trial of GR-MD-02, and we began enrolling patients in the third quarter of 2013. In January 2014, we completed the enrollment of the first cohort of patients in the Phase 1 trial with no serious adverse events being reported. We reported initial safety and tolerability results from the first cohort of patients on March 31, 2014. The second cohort of this Phase 1 trial began and enrollment was completed in April 2014. In July 2014, we reported the results from the second cohort of patients. Enrollment of the third cohort of Phase 1 began in July 2014 with interim results presented in November 2014 with the final report on cohort 3 presented in January 2015. The results of the Phase 1 study demonstrate that (i) GR-MD-02 was safe and well tolerated by patients with advanced NASH liver fibrosis after IV administration of four doses of 2 mg/kg, 4 mg/kg and 8mg/kg lean body weight, (ii) Pharmacokinetics revealed drug exposure in humans at the 8 mg/kg dose that was equivalent to the upper range of the targeted therapeutic dose determined from effective doses in NASH animal models, (iii) Disease Serum Marker Effect showed there was a statistically significant, dose-dependent reduction in FibroTest ^® scores due to a statistically significant reduction in alpha-2 macroglobulin serum levels, and (iv) Liver Stiffness Effect, as measured by FibroScan ^® showed that there was a signal of reduced liver stiffness in patients receiving GR-MD-02. The reduction seen in A2M does not necessarily mean fibrosis got better in this short study, but does suggest changes in the fibrogenic process that might lead to an improvement in fibrosis with longer-term therapy. These Phase 1 results in NASH patients with advanced fibrosis provide a firm foundation for entry into a Phase 2 development program.

The company held an “End of Phase 1 meeting” with the FDA and, amongst other things, received guidance on the primary endpoints for a Phase 2 trials. In Phase 2 we plan to explore two indications, NASH cirrhosis and NASH with advanced fibrosis. The NASH-CX trial is designed to target a patient population with cirrhosis due to NASH. The study endpoints will include those that are closely associated with outcomes in patients with cirrhosis with the primary endpoint: chosen as hepatic venous pressure gradient (HVPG). HVPG is reflective of portal pressure and portal hypertension is responsible for most of the complications resulting from cirrhosis; a reduction in HVPG is associated with a reduction in complications of cirrhosis and reduced mortality. Planned secondary endpoints include: morphometric analysis of collagen on liver biopsies, a change in histopathological stage, and other secondary endpoints will include non-invasive tests to evaluate for correlation with HVPG and liver collagen. We have awarded the contract for the NASH-CX trial to a CRO and enrollment began in June 2015 to assess the efficacy of GR-MD-02 in patients with NASH cirrhosis. The timing of initial results from the NASH-CX are dependent upon the trial design, and, amongst other factors, the rate of patient enrollment, but we anticipate top line results by the end of 2017. In the indication of NASH with advanced fibrosis, we are initiating a single site, placebo controlled, randomized clinical trial (NASH-FX) to evaluate 4 months of treatment on patients with stage 3 bridging fibrosis. We anticipate this trial to initiate in August 2015 with top line results available by the mid- 2016. Our Phase 2 clinical program is designed to position the Company for a strong Phase 3 clinical trial program.

Additionally, during the Phase 1 clinical trial, there appeared to be a potential beneficial effect on at least one patient’s moderate to severe psoriasis. As a result, we are planning a single site, 10 patient, open label clinical trial with GR-MD-02 to determine whether more extensive studies in this indication are warranted.

Additionally, an open label drug-drug interaction study was completed with GR-MD-02 and it showed that with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observed. This study was required by the FDA and the primary objective was to determine if single or multiple intravenous (IV) doses of GR-MD-02 affect the pharmacokinetics (PK) of midazolam. The secondary objective was to assess the safety and tolerability of GR-MD-02 when administered concomitantly with midazolam. The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial. In addition, should GR-MD-02 be approved for marketing, the success of this study supports a broader patient population for the drug label.

Based on guidance from FDA and in furtherance of its understanding of the GR-MD-02 molecule, we continue to enhance its chemistry, manufacturing and control procedures on GR-MD-02 active pharmaceutical ingredient (API) as well as on the finished, sterile, pharmaceutical dosage form. Various state of the art and cutting-edge analytical technologies are being utilized, for example, to characterize and quantify the backbone vs. side-chain constituents and their quantitation, use of sophisticated linkage analysis with 2-D NMR to provide both qualitative and quantitative information on the proportion of oligomers, degree of methylation, and other monoclonal specific antibody techniques to map GR oligomer integrity and distribution. The Company has also characterized how the GR molecule behaves under conditions of forced degradation.

Our research and development expenses were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(in thousands)

Direct external expenses:
Clinical programs	$	1,708	$	651	$	3,781	$	1,813
Pre-clinical activities		350		477		791		1,252
All other research and development expenses		542		466		1,164		1,301

	$	2,600	$	1,594	$	5,736	$	4,366

Clinical programs expenses increased primarily due to costs related to our Phase 2 clinical trials during the three and six months ended June 30, 2015 as compared to the same period in 2014. As we enroll patients in the Phase 2 trial we expect our clinical activities costs will increase and may fluctuate from quarter to quarter as the trial progresses. Pre-clinical activities decreased primarily because we are nearing completion of pre-clinical work directly related preparation for our anticipated Phase 2 clinical trial program. Other research and development expense decreased primarily due to decreased stock-based compensation expense.

Both the time required and costs we may incur in order to commercialize a drug candidate that would result in material net cash inflow are subject to numerous variables, and therefore we are unable at this stage of our development to forecast useful estimates. Variables that make estimates difficult include the number of clinical trials we may undertake, the number of patients needed to participate in the clinical trial, patient recruitment uncertainties, trial results as to the safety and efficacy of our product, and uncertainties as to the regulatory agency response to our trial data prior to receipt of marketing approval. Moreover, the FDA or other regulatory agencies may suspend clinical trials if we or an agency believes patients in the trial are subject to unacceptable risks, or find deficiencies in the conduct of the clinical trial. Delays or rejections may also occur if governmental regulation or policy changes during our clinical trials or in the course of review of our clinical data. Due to these uncertainties, accurate and meaningful estimates of the ultimate cost to bring a product to market, the timing of costs and completion of our program and the period during which material net cash inflows will commence are unavailable at this time.

General and Administrative Expense.


	Three Months Ended June 30,				Six Months Ended June 30,				2015 as Compared to 2014
	Three Months Ended June 30,				Six Months Ended June 30,				Three Months					Six Months
	2015		2014		2015		2014		$ Change		% Change			$ Change			% Change
	(In thousands, except %)

General and administrative	$	2,057	$	1,781	$	3,761	$	3,853	$	276		15	%	$	(92	)		(2	)%

General and administrative expenses consist primarily of salaries including stock based compensation, legal and accounting fees, insurance, investor relations, business development and other office related expenses. The primary reason for the increase in general and administrative expenses in the three months ended June 30, 2015 compared to the same period in 2014 is timing of certain expenses in 2015 compared to 2014. The primary reason for the decrease in general and administrative expenses for the six months ended June 30, 2015 as compared to the same period in 2014 is due to a decrease in stock-based compensation expense of $344,000 offset somewhat by smaller increases in certain other general and administrative expenses.

Liquidity and Capital Resources

Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of June 30, 2015, we raised a net total of $112 million from these offerings. We have operated at a loss since our inception and have had no significant revenues. We anticipate that losses will continue for the foreseeable future. At June 30, 2015, we had $26.4 million of unrestricted cash and cash equivalents available to fund future operations. We believe that with the cash on hand at June 30, 2015, there is sufficient cash to fund currently planned operations through September 30, 2016. Our ability to fund operations after our current cash resources are exhausted depends on our ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying our current operating plan, the financial statements do not currently include any adjustments that might be necessary if we are unable to continue as a going concern.

Net cash used in operations increased by $1,267,000 to $7,298,000 for the six months ended June 30, 2015, as compared to $6,031,000 for the six months ended June 30, 2014. Cash operating expenses increased principally due to increased research and development activities related to our clinical trial activity with GR-MD-02.

Net cash provided by financing activities for the six months ended June 30, 2015, of $4,532,000 represents net proceeds from the sale of common stock. Net cash provided by financing activities was $30,365,000 for the six months ending June 30, 2014, consisting of $28,178,000 in net proceeds from sale of common stock and $2,187,000 from the proceeds from the exercise of stock options and warrants.

Other.

We have engaged outside vendors for certain services associated with our clinical trials. These services are generally available from several providers and, accordingly, our arrangements are typically cancellable on 30 days notice.

Off-Balance Sheet Arrangements

We have not created, and are not a party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating parts of our business that are not consolidated into our financial statements. We do not have any arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

Application of Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets, accrued expenses, stock-based compensation, contingencies and litigation. We base our estimates on historical experience, terms of existing contracts, our observance of trends in the industry, information available from other outside sources and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are those policies that affect our more significant judgments and estimates used in preparation of our consolidated financial statements. We believe our critical accounting policies include our policies regarding stock-based compensation, accrued expenses and income taxes. For a more detailed discussion of our critical accounting policies, please refer to our 2014 Annual Report on Form 10-K.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our financial position, operating results or cash flows due to changes in the U.S. interest rates. The primary objective of our investment activities is to preserve cash until it is required to fund operations. To minimize risk, we maintain our portfolio of cash and cash equivalents in operating bank accounts and money market funds. Since our investments are short-term in duration, we believe that we are not subject to any material market risk exposure.

Item 4.

Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934) and concluded that, as of June 30, 2015, our disclosure controls and procedures were effective at a reasonable assurance level. During the quarter ended June 30, 2015, no change in our internal control over financial reporting has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings

None except as discussed in Note 8 to our condensed consolidated financial statements included in this report.

Item 1A.

Risk Factors

The information set forth in this report should be read in conjunction with the risk factors set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially impact our business, financial condition or future results.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not Applicable

Item 5.

Other Information

Not Applicable

Item 6.

Exhibits


Exhibit Number	Description of Document	Note Reference

31.1*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	XBRL Instance Document*

101.SCH	XBRL Taxonomy Extension Schema Document*

101.CAL	XBRL Taxonomy Calculation Linkbase Document*

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB	XBRL Taxonomy Label Linkbase Document*

101.PRE	XBRL Taxonomy Presentation Linkbase Document*


*		Filed herewith.
**		Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 10, 2015.


GALECTIN THERAPEUTICS INC.

By:		/s/ Peter G. Traber
Name:		Peter G. Traber, M.D.
Title:		Chief Executive Officer and President (principal executive officer)

		/s/ Jack W. Callicutt
Name:		Jack W. Callicutt
Title:		Chief Financial Officer (principal financial and accounting officer)

EX-31.1 2 d939524dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Peter G. Traber, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d939524dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Jack W. Callicutt, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d939524dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter G. Traber, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 d939524dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack W. Callicutt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 galt-20150630.xml XBRL INSTANCE DOCUMENT 400000

0.50

22788913 0.030 30000000

280000

12845

23500

236975

23500

34423000

3192325

0.001

50000000

828596

23788913

5000000

1402500

5.83

23788913

1402500

146217000

377000

1065000

1908000

23000

68000

255000

567000

7000

1402500

-128930000

17877000

26679000

775000

12000

26667000

3492000

26362000

26679000

305000

20000000 0.01 426000 8001000

754605

5370995

3.64

228000

176

1000

5660000

1760000

1723000

2100000

4200000

3431000

900000

1800000

1740000

10489000

3332617

0.001

50000000

22277283

5000000

1402500

5.79

22277283

1402500

139531000

604000

729000

1703000

22000

68000

118000

567000

7000

-118925000

21195000

29677000

906000

15000

1000

29661000

29128000

29677000

533000

20000000 0.01 8001000

416670

5470995

3.67

176

1000

1723000

2100000

3325000

900000

1731000

5.49

81352

77784

2016-05-20

3568

2015-05-21

222615

177618

7587

2016-05-20

71378

2016-05-20

P6Y

11299127

0.0158

-6031000

-0.42

11.38

21570000

1.14

0.00

-9139000

-8219000

17000

-337000

-320000

-111000

-8539000

400000

115000

28178000

8219000

485000

30365000

5000

3853000

-339000

23934000

2394000

-400000

4366000

2187000 488000

2537103

3311029

5450995

1534000

860000

10-Q

P6Y

GALT

<div> The following table summarizes the common stock warrant activity from December 31, 2014 through June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,470,995</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.67</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(100,000</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,370,995</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.64</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

0001133416 2015-06-30

Accelerated Filer

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">3.</td> <td valign="top" align="left">Stock-Based Compensation</td> </tr> </table> Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">226</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">221</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">543</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">860</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">745</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,734</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,394</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following table summarizes the stock option activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,332,617</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.79</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">304,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.45</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(95,574</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.80</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(348,718</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.42</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,192,325</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> As of June 30, 2015, there was $3,492,000 of unrecognized compensation related to 828,596 unvested options, which is expected to be recognized over a weighted–average period of approximately 1.67 years. The weighted-average grant date fair value for options granted during the six months ended June 30, 2015 and 2014 was $2.78 and $11.38, respectively. The Company granted 304,000 stock options in January 2015, of which 76,000 options vested upon grant with the remaining 228,000 options vesting over 3 years. Approximately $173,000 of non-cash, stock-based compensation expense was recorded during the six months ended June 30, 2015 related to the options granted in January 2015 that were vested upon the grant date. The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="6%"></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Six Months Ended June 30,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Six Months Ended June 30,</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2015</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2014</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.64%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.58%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.0 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.0 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom" align="center">104%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">114%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> </table>   The following table summarizes the restricted stock grant activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">416,670</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337,935</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">754,605</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> On March 12, 2015, the Company granted 81,352 shares of restricted stock to non-employee directors as a component of their compensation. A total of 77,784 shares were issued to seven directors representing non-cash compensation cost of $280,000 which will be recognized on a straight-line basis from the grant date through May 20, 2016, when the restricted shares will vest in full. A total of 3,568 shares were issued to two directors, who were not nominated for reelection, representing non-cash compensation cost of $12,845 that will be recognized on a straight-line basis from the grant date through May 21, 2015, when the restricted shares will vest in full. On April 8, 2015, the Company granted 177,618 shares of restricted stock to non-employee directors in exchange for cancelation of 222,615 stock options. As the exchange was made at fair value, there was no additional non-cash compensation expense recorded in accordance with FASB ASC 718-20. Additionally, on April 8, 2015, the Company granted 71,378 shares of restricted stock to one non-employee director representing $236,975 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full. Also, in April and May 2015, the Company granted a total of 7,587 shares of restricted stock to four non-employee directors for service as committee chairs or lead independent director representing $23,500 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full. In January 2014, the Company entered into an agreement with a consultant that provided for the grant of 3,000 shares of common stock. The Company recognized an expense of $25,000, representing the fair value of the common stock, during the three months ended March 31, 2014. </div>

11428358

<div> Accrued expenses consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Legal and accounting fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">255</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">118</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accrued compensation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">604</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accrued clinical trial costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">426</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,065</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">729</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

348718

--12-31

P1Y8M1D

3.45

0.0164

<div> The following table summarizes the restricted stock grant activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">416,670</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337,935</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">754,605</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

-7298000

<div> The following table summarizes the stock option activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,332,617</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.79</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">304,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.45</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(95,574</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.80</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(348,718</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.42</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,192,325</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

false

4.42

1.80

95574

-0.43

2.78

GALECTIN THERAPEUTICS INC

23398000

2015

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">8.</td> <td align="left" valign="top">Commitments and Contingencies</td> </tr> </table> Shareholder Class Actions and Derivative Lawsuits Between July 30, 2014, and August 6, 2014, three putative class action complaints were filed in the United States District Court for the District of Nevada (the “Nevada District Court”) against the Company and certain of its officers and directors on behalf of all persons who purchased or otherwise acquired the Company’s stock between January 6, 2014 and July 28, 2014. By order entered August 22, 2014, the Nevada District Court consolidated the three cases, relieved the defendants of any obligation to respond to the complaints then on file, and provided that defendants may respond to a consolidated amended complaint to be filed following appointment of a lead plaintiff(s) pursuant to the Private Securities Litigation Reform Act of 1995. By order dated January 5, 2015, the Nevada District Court granted the defendants’ motion to transfer the consolidated action to the United States District Court for the Northern District of Georgia (the “Court”). On March 24, 2015, the Court appointed Glyn Hotz as the lead plaintiff (“Plaintiff”). Plaintiff filed his Consolidated Class Action Complaint (the “Complaint”) on May 8, 2015. The Complaint asserts claims on behalf of a putative class of all persons who purchased or otherwise acquired the Company’s common stock between October 25, 2013 and July 28, 2014. The Complaint alleges that the Company and certain of its officers and directors (the “Class Action Individual Defendants”) violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and SEC Rule 10b-5 through allegedly false or misleading statements in certain SEC filings, press releases and other public statements. The Complaint further alleges that the Class Action Individual Defendants and one of the Company’s shareholders face liability for the alleged Section 10(b) and Rule 10b-5 violations pursuant to Section 20(a) of the Exchange Act. The Complaint seeks class certification, unspecified monetary damages, costs, and attorneys’ fees. The Company disputes the allegations and filed a motion to dismiss the Complaint on June 26, 2015. On August 1 and 25, 2014, persons claiming to be Galectin shareholders filed putative shareholder derivative complaints in the Nevada District Court, seeking recovery on behalf of the Company against certain of the Company’s directors and officers. On September 10, 2014, the Nevada District Court entered an order consolidating the two cases, relieving the defendants of any obligation to respond to the initial complaints, and providing that defendants may respond to a consolidated complaint to be filed by the plaintiffs. On January 5, 2015, the Nevada District Court granted Defendants’ motion to transfer the consolidated putative derivative litigation to the United States District Court for the Northern District of Georgia. The plaintiffs filed a consolidated complaint on February 27, 2015. On April 6, 2015, the Company and defendants filed motions to dismiss the consolidated complaint. Rather than respond to those motions, the plaintiffs sought and obtained leave to file an amended complaint. Plaintiffs filed their amended complaint (the “Complaint”) on May 26, 2015. The Complaint alleges that certain of the Company’s directors and officers (the “Derivative Action Individual Defendants”) breached their fiduciary duties to the Company’s shareholders by causing or permitting the Company to make allegedly false and misleading public statements concerning the Company’s financial and business prospects. The Complaint also alleges that the Derivative Action Individual Defendants violated the federal securities laws by allegedly making false or misleading statements of material fact in the Company’s proxy filings, committed waste of corporate assets, were unjustly enriched, and that certain defendants breached their fiduciary duties through allegedly improper sales of Galectin stock. In addition, the Complaint alleges that the Derivative Action Individual Defendants and one of the Company’s shareholders aided and abetted the alleged breaches of fiduciary duties. The Complaint seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the Complaint on July 8, 2015. On August 29, 2014, another alleged Galectin shareholder filed a putative shareholder derivative complaint in state court in Las Vegas, Nevada, seeking recovery on behalf of the Company against the same Galectin directors and officers who are named as defendants in the derivative litigation pending in the United States District Court for the Northern District of Georgia (the “Georgia Federal Action”). The plaintiff in the Nevada action subsequently filed first and second amended complaints. The second amended complaint alleges claims for breach of fiduciary duties, unjust enrichment, and waste of corporate assets, based on allegations that are substantially similar to those asserted in the Georgia Federal Action (except that the Nevada action does not allege violations of the federal securities laws and does not assert any claim against the Galectin shareholder named as a defendant in the Georgia Federal Action), and seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the second amended complaint on April 22, 2015. On April 29, 2015, the plaintiffs in the Georgia Federal Action filed a motion to intervene in the Nevada action which, among other things, raised questions regarding the Nevada plaintiff’s standing. Thereafter, the Nevada plaintiff filed a motion to join additional plaintiffs. At a hearing held on June 11, 2015, the Nevada court: (i) granted the Georgia Federal Action plaintiffs’ motion to intervene; (ii) directed the Georgia Federal Action plaintiffs to file a complaint in intervention; (iii) directed the Nevada plaintiff to file a motion for leave to file a further amended complaint to add additional plaintiffs; (iv) stated that the defendants’ motions to dismiss the second amended complaint were denied “at this point;” (v) ordered the Nevada action stayed until December 11, 2015; and (vi) directed the parties to submit a status report on December 11, 2015, updating the court on the progress and status of the Georgia Federal Action. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, are in the early stages of the proceedings, and are subject to appeal. In addition, because most legal proceedings are resolved over extended periods of time, potential losses are subject to change due to, among other things, new developments, changes in legal strategy, the outcome of intermediate procedural and substantive rulings and other parties’ settlement posture and their evaluation of the strength or weakness of their case against us. For these reasons, we are currently unable to predict the ultimate timing or outcome of, or reasonably estimate the possible losses or a range of possible losses resulting from, the matters described above. Based on information currently available, the Company does not believe that any reasonably possible losses arising from currently pending legal matters will be material to the Company’s results of operations or financial condition. However, in light of the inherent uncertainties involved in such matters, an adverse outcome in one or more of these matters could materially and adversely affect the Company’s financial condition, results of operations or cash flows in any particular reporting period.   Other Legal Proceedings The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no other pending legal proceedings except as noted above. </div>

<div> The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="6%"></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Six Months Ended June 30,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Six Months Ended June 30,</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2015</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2014</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.64%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.58%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.0 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.0 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom" align="center">104%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">114%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> </table> </div>

76000

1.04

<div> Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015 (shares)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014 (shares)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,370,995</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,450,995</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,192,325</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,311,029</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested shares of restricted common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Shares of common stock issuable upon conversion of preferred stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,527,103</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,537,103</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,428,358</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,299,127</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

304000

0.00

<div> Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">226</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">221</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">543</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">860</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">745</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,734</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,394</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-10005000

-9497000

28000

-228000

-9469000

115000

4532000

9497000

421000

4532000

4000

3761000

205000

-2766000

1734000

5736000

337935

P3Y

173000

100000

4.26 0 0

2527103

3192325

5370995

337935

1191000

543000

0.673

7587

2016-05-20 3000

400000

-400000

200000

217622

36000

1159000

1196000

25000

159000

1279416

4532000

-0.17

21983000

-3731000

-3375000

13000

-67000

-54000

-3429000

57000

3375000

245000

1781000

745000

1594000

524000

221000

-0.21

23731000

-4931000

-4657000

14000

-4643000

58000

4657000

230000

2057000

800000

2600000

574000

226000

172000

93000

0001133416 galt:GalectinSciencesLlcMember 2014-10-01 2014-12-31 0001133416 galt:MarketSaleAgreementMember 2015-04-01 2015-06-30 0001133416 galt:GalectinSciencesLlcMember 2015-04-01 2015-06-30 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001133416 2015-04-01 2015-06-30 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001133416 2014-04-01 2014-06-30 0001133416 galt:MarketSaleAgreementMember 2015-01-01 2015-03-31 0001133416 galt:GalectinSciencesLlcMember 2015-01-01 2015-03-31 0001133416 galt:ConsultantMember 2014-01-01 2014-03-31 0001133416 2014-08-01 2014-08-06 0001133416 galt:MarketSaleAgreementMember 2014-01-01 2014-12-31 0001133416 galt:GalectinSciencesLlcMember 2014-01-01 2014-12-31 0001133416 galt:GalectinSciencesLlcMember 2014-01-01 2014-01-31 0001133416 galt:ConsultantMember 2014-01-01 2014-01-31 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsFourMember 2015-05-09 2015-05-31 0001133416 galt:GalectinSciencesLlcMember 2015-01-01 2015-06-30 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001133416 galt:UnvestedSharesMember 2015-01-01 2015-06-30 0001133416 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001133416 us-gaap:StockOptionMember 2015-01-01 2015-06-30 0001133416 us-gaap:StockCompensationPlanMember 2015-01-01 2015-06-30 0001133416 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001133416 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001133416 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0001133416 2015-01-01 2015-06-30 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001133416 us-gaap:WarrantMember 2014-01-01 2014-06-30 0001133416 us-gaap:StockOptionMember 2014-01-01 2014-06-30 0001133416 us-gaap:StockCompensationPlanMember 2014-01-01 2014-06-30 0001133416 2014-01-01 2014-06-30 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsThreeMember 2015-04-08 2015-04-08 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsFourMember 2015-04-08 2015-04-08 0001133416 us-gaap:RestrictedStockMember 2015-04-08 2015-04-08 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsTwoMember 2015-03-12 2015-03-12 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsOneMember 2015-03-12 2015-03-12 0001133416 us-gaap:RestrictedStockMember 2015-03-12 2015-03-12 0001133416 galt:MarketSaleAgreementMember 2014-12-31 0001133416 galt:SeriesBOnePreferredStockMember 2014-12-31 0001133416 galt:SeriesBTwoPreferredStockMember 2014-12-31 0001133416 us-gaap:SeriesCPreferredStockMember 2014-12-31 0001133416 us-gaap:WarrantMember 2014-12-31 0001133416 us-gaap:RestrictedStockMember 2014-12-31 0001133416 2014-12-31 0001133416 2013-12-31 0001133416 galt:SeriesBOnePreferredStockMember 2015-06-30 0001133416 galt:SeriesBTwoPreferredStockMember 2015-06-30 0001133416 us-gaap:SeriesCPreferredStockMember 2015-06-30 0001133416 galt:VestingPeriodOneMember 2015-06-30 0001133416 us-gaap:WarrantMember 2015-06-30 0001133416 us-gaap:RestrictedStockMember 2015-06-30 0001133416 2015-06-30 0001133416 2014-06-30 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsFourMember 2015-05-31 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsThreeMember 2015-04-08 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsFourMember 2015-04-08 0001133416 us-gaap:RestrictedStockMember 2015-04-08 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsTwoMember 2015-03-12 0001133416 us-gaap:RestrictedStockMembergalt:NonEmployeeBoardOfDirectorsOneMember 2015-03-12 0001133416 galt:MarketSaleAgreementMember 2014-03-30 0001133416 2015-08-07 0001133416 galt:GalectinSciencesLlcMember 2014-01-31 0001133416 galt:SbhSciencesIncMemberus-gaap:InProcessResearchAndDevelopmentMembergalt:GalectinSciencesLlcMember 2014-01-31 iso4217:USD pure shares galt:Director iso4217:USD shares galt:LegalMatter

EX-101.SCH 7 galt-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Common Stock Warrants link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Loss Per Share link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Galectin Sciences LLC link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Common Stock Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Restricted Stock Grant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Galectin Science LLC - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 galt-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 galt-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 galt-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accrued Clinical Trial Costs Accrued Clinical Trial Costs Accrued clinical trial costs Accrued Liabilities, Current Accrued expenses Total Accrued Professional Fees, Current Legal and accounting fees Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Aggregate Offering Price Aggregate Offering Price Aggregate offering price Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Dilutive shares not included in calculation Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Basis of Accounting [Text Block] Basis of Presentation Basis of Presentation [Line Items] Basis of Presentation [Line Items] Basis of Presentation [Line Items] Basis of Presentation [Table] Basis of Presentation [Table] Basis of Presentation [Table] Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and cash equivalents Unrestricted cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] NONCASH FINANCING ACTIVITIES: Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Commissions as Percentage of Gross Offering Proceeds Commissions as Percentage of Gross Offering Proceeds Commission to sales agent as a percentage of gross proceeds Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies Commitments and contingencies (Note 8) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Options Granted, Shares Common Stock Options Granted, Shares Common stock options granted, shares Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, issued Common Stock, Shares, Outstanding Common stock, outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2015 and December 31, 2014, 23,788,913 and 22,277,283 issued and outstanding at June 30, 2015 and December 31, 2014, respectively Consultant [Member] Consultant [Member] Consultant Counterparty Name [Axis] Counterparty Name [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Dividends Payable, Current Accrued dividends payable Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per common share - basic and diluted Earnings Per Share [Text Block] Loss Per Share Employee-related Liabilities, Current Accrued compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, recognition period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Non-cash stock-based compensation expense to be recognized Employee Stock Option [Member] Stock Options Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Investment, Name [Domain] Investment, Name [Domain] Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Fair Market Value Of Shares Fair Market Value Of Shares Fair market value of shares Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Of Asset Contributed To Joint Venture Fair Value Of Asset Contributed To Joint Venture Estimated fair value of the IPR&D Contributed by SBH Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Galectin Sciences, LLC [Member] Galectin Sciences, LLC [Member] Galectin Sciences, LLC General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative Gross Proceeds From Issuance Of Common Stock Gross Proceeds From Issuance Of Common Stock Gross proceeds from sale of common stock Income (Loss) from Equity Method Investments Loss from equity method investment in Galectin Sciences, LLC Loss from equity method investment in Galectin Sciences LLC Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses (Notes 2 and 8) Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets In Process Research and Development [Member] In Process Research and Development Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Investment Income, Interest Interest income Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Galectin Sciences LLC Investments in and Advances to Affiliates [Table] Investments in and Advances to Affiliates [Table] Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities and Equity Total liabilities, redeemable convertible preferred stock and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Loss Contingency, New Claims Filed, Number Number of putative class action complaints filed Market Sale Agreement [Member] Market Sale Agreement [Member] At Market Agreement Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss applicable to common stockholders Non Employee Board Of Directors Four [Member] Non Employee Board Of Directors Four [Member] Non Employee Board Of Directors Four Non Employee Board Of Directors One [Member] Non Employee Board Of Directors One [Member] Non Employees Seven Board Of Directors Non Employee Board Of Directors Three [Member] Non Employee Board Of Directors Three [Member] Non Employee Board Of Directors Three Non Employee Board Of Directors Two [Member] Non Employee Board Of Directors Two [Member] Non Employees Two Board Of Directors Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) [Abstract] Other income (expense): Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Total operating loss Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Accrued Liabilities, Current Other Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payments for Commissions Commissions Payments to Acquire Businesses and Interest in Affiliates Subsequent capital contribution Payments to Acquire Equity Method Investments Equity method investment in Galectin Sciences LLC Equity method investment in Galectin Sciences LLC Preferred Stock, Accretion of Redemption Discount Preferred stock accretion Preferred Stock Dividends, Income Statement Impact Preferred stock dividends Preferred Stock, Liquidation Preference, Value Series A 12% convertible preferred stock, liquidation value Preferred Stock, Shares Authorized Series A 12% convertible preferred stock, shares authorized Preferred Stock, Shares Issued Series A 12% convertible preferred stock, issued Preferred Stock, Shares Outstanding Series A 12% convertible preferred stock, outstanding Preferred Stock, Value, Issued Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,402,500 issued and outstanding at June 30, 2015 and December 31, 2014, liquidation value $1,402,500 at June 30, 2015 Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Proceeds from Issuance of Common Stock Net proceeds from issuance of common stock and warrants Proceeds from issuance of common stock The cash inflow associated with the amount received from holders exercising their stock options and warrants. Proceeds from exercise of stock options and warrants Proceeds from exercise of common stock warrants and options Property, Plant and Equipment, Net Property and equipment, net Counterparty Name [Domain] Counterparty Name [Domain] Research and Development Expense Research and development Research and Development Expense [Member] Research and development Research and Development in Process Non-cash charge for in-process research and development Restricted Stock [Member] Restricted Stock Retained Earnings (Accumulated Deficit) Retained deficit Sale of Stock, Price Per Share Price of common stock per share SBH Sciences, Inc [Member] SBH Sciences, Inc [Member] SBH Sciences, Inc Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table Text Block] Accrued Expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants Investment, Name [Axis] Investment, Name [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Summary of Restricted Stock Grant Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Weighted Average Assumptions Used to Determine Fair Value of Options Granted Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock Warrant Activity Series B-1 Preferred Stock Series B1 Preferred Stock [Member] Series B-1 12% redeemable convertible preferred stock Series B2 Preferred Stock Series B2 Preferred Stock [Member] Series B-2 12% redeemable convertible preferred stock Series C Preferred Stock [Member] Series C super dividend convertible preferred stock Share-based Compensation Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Options vesting period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Options forfeited/cancelled Restricted stock awards cancelled Forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Restricted stock awards granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending Balance Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price Outstanding, March 31, 2015 Outstanding, December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Exercised Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of the options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility of the underlying stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Exercised Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employee Directors Granted Shares. Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employee Directors Granted Shares Number of non-employee directors Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Number of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair values of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Unvested option Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Ending Balance Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending Balance Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Number of options vested Equity Award [Domain] Equity Award [Domain] Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited/cancelled Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted EX-101.PRE 11 galt-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`'=!"D=V;+^IJ@$``/`4```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CT]*'@$WIMD5J?\!-)L0B?L@V`?Z^=H"JC6@% M+9%FDP=W//M`=?;R$JY25)Z;QX(<5D)DKM4&U!!*;25W(=;NR"& M9TN^`,(&@Q')M/*@?-_''LET_%*#M2*'WN-.B+TG"3>F$AGW0BM2J[S5M:^+ M0F20ZVPEPY+4!VNX"GK2FW/KG[D,+W M%;AC_COEX#R#@J\J?Y;Q_MVE%JJFQI7"[*V>-J&+"[]-DJ"ZDQS:"W]+)F0< MFE&+;ROB_1^?I?42:UG-+%^+ED'=V9CB.952@PZP!,%" M5(H%J10+4RD6J%(L5*58L$JQ<)5B`2O%0E:&A:P,"UD9%K(R+&1E6,C*L)"5 M82$KPT)6AH6L#`M9AUC(.OPD*VG^Z)Q^`%!+`P04````"`!W00I'2'4%[L4` M```K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR` M.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/ MZ'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%``` M``@`=T$*1V2&T#=T`0``RA,``!H```!X;"]?0#@3VR1^(*FTN7U=+XK[T-!% MX-O8V(+1'PP_A'=MR+=/ MVF'UW/G&Q>'1EZ9WQ<658CC/E\9/YV2'W<_9L^-IG_GCB;+9B_.EQ'WVUOE+ MJ$1B,..-'H8-AN5;+__9OCN?ZT(>N^*UD3;^46&^-LA,.HC300P)LND@"PF: MIX/FD*!%.F@!"5JF@Y:0H%4Z:`4)6J>#UI"@33IH`PFB7)$QQR1I6&.T)H5K MPGA-"MB$$9L4L@EC-BEH$T9M4M@FC-NDP$T8N4FAFS!VDX(W8?1F16_&Z,V* MW@PZ:VN';8S>K.C-&+U9T9LQ>K.B-V/T9D5OQNC-BMZ,T9L5O1FC-RMZ,T9O MJ^AM,7I;16^+T=M.]`Z5\W)ZCKYNRW#OFF_#U:()WB'>KG+_E'&JVC#1.@X[ MB1FO=_]$X]3/$//KM]WA`U!+`P04````"`!W00I'-8O_*[@"```M"0``$``` M`&1O8U!R;W!S+V%P<"YX;6R]5DUSVC`0_2L:G]H#,4G:'ACB&0(D[0R=,(6$ MLR(O6!-9U)H"K).`;),KC3TR M7D69Q62ZE@)$190[:Q1?=[K<8-@YT"FFG MV`>-DK[/,B@*)05WTNCDIQ36H%DZ-MX(4/WX)2!X4.09B-)*MTVZ%:9N"IB9 MX`J&E"M95%%S[B%E)(VHN^- M`?-]2SR5]QUF7*\@K6-?7^ZT>`"+GNGYQ5F7/GL)=O8J-O!4ZM642XM)?^UZ M:Q#.V.+Z(J;64-9U6@ ML\G"V"?,`!SVX[TQ'.O8^EE^22[/`X).362\9Y8\R];@[2USZ13@W7+*K?M/ M4@1..R$NSZ,:^UT(QG7*QMK1.+(?NDI%S:M+LC\-#>V%1D@9G=`HF=*8I>R: M*ZX%L`_X7)[B,W/T135_P.=KJ\\U1XG,+-G4`I(6AYD/A+`EA1MO"I\$6T$S M9\13AX*&(G*/?$O+/#>:!1^VX-;2&+6'O:$18@]!+O9&:A)-<4;?HMLQ; M?28&D4W!LK#I[Q9P$""=GQ$,0T*Z.IIHH.P'!+BEWRQ!C"'47V60R;)>J M?$3X7?KY&Z_A$/.7JK-/<_Y(._3Y)/F?O8[OPMMIFM*^C6T=,-9A@S25=#R2 M]`@O:WJKYT7+YFX^>!V.7=#:Y,@&Y$1!503%L'WR?W#XC&KQ@6]R8MI M3HM%,664LNO)QV&R,W^#8=T-\6\=GPRF[:+"&B[<;=+(M-STF4`2@O#*H;+F M(ES"?!,G6-@M/T'@Y:!.F"[;%MK&>AFJ=+^&Z/!RXLK6UK?'U(_H[%557U!+ M`P04````"`!W00I'F5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H96UE,2YX M;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_ M1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB= MAIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQS MYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^ M!?F<-0HACA*FNVB<5@$ M_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W M-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2 M';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(Y MV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1 MDN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=? M]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K M8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/ M%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1 M!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`'=!"D>9951W3`(` M`'H*```-````>&PO>A;D6W9%NCBR7+F]-=/%U^20)8V34OSHJ-/1]_Y='2<,63-4@%0U7$;P8(.#VWXD,1_#I[.N?1JC;+\"-DV^3B?]T?KN+G]F%);\RY%Z7H#C,!1_S-(,.B,/Z&:P0 MU?Z!<4\%%1(H?1%:A44X8MAYW"%*$DD,F"-&Z-K!,P/8N^O\&.%"VM@NPFZ< MJ3]&DD420;_[O3Q<,K+;P1R/4+I]/`W$8864PI(O]`1T]G)=Z<-QP;$3:?T. M>!<2K8/9Y<8&.^BXB9`9ED/D`/90'%*<*[U!DJ(THQ*5D2Z4$DP;&4&%X(@: MRGY'9VC:%%/Z8+Z4QWR+N\V!\S%W[$-@5/2F3D1GCF5@D^IMLCGN3=KC>$&; M#P'T;E15=/V=DH(S[,0Z:"&ZV2'Z8`]]'**>%91"DF?M;PHAU0"6$*RP5"3= M1/Y*5"UQJ[H*]MI\G\)CC_R>FDZ?M5&-+L&/3L_1P2UTW[`$RX7]:WR]I(NK MPU=FOTZX(_-CJ^8("2=(CFELGU;:_/-*>Y^:.D6U7[]1F=R.;;K6%L>]HSJP=6XY=52C1#\&M*)HLPSEJJ/I-5D+9Q0B. M]D\C/Y@/7LN!(H*C_0MGI&'75L'XVHS_`5!+`P04````"`!W00I'**+)OI(# M``#^"@``#P```'AL+W=OXHJ M@#N6`9K^_#9.OQA39!J63JK5&<5 M/W1&M(/_]89\#%AN+0QR]2V>Q#R;#DGP'CVN4&%XFF?=6$&,9+`32I?^EY$P M77(V1RRDJ<2)":0BSDU_>)2:Z`,M/J^ZC=T,:>#.J[Q/%1E+JSWXA*<6-;2`;?<(C2)Z$L,W(X#F2>)U!I#O"6^NR9$ M0:"K#A3"UB'D',@\0>295$`UA%P@2X+9BXN+(R[`0P M?0(YAR]/T+>+CWA#A4:!?\M%.()Y@L'72'H6XU*T2`"ZG^=C"!(5]Z?@K!8)5E_-X2`#\JE=]HK@41[E(H'P#>%O',KJX M!R=O02R\;W7GF1?_;07(P2X28+,`OU&/X+#LRW.,] M)#C_;2T3!_SORCD?)3C?K6:QF#'ON!2G?90_=R, M/1P]^@H]GL0;'.=?J*^;9['YHCZK5>J(WGTU%U9V+4JOO.G:/OT$4$L#!!0` M```(`'=!"D&PO=V]R:W-H965T&UL?57+;J,P%/T5Q`<4;)Z)"%*24=59C%1U,;-VB!-0`3.V$SI_/[8AE.)+ M-_C!.?=1]8R_BY)2Z7PT=2MV;BEEM_4\492T(>*)=;15?RZ,-T2J);]Z MHN.4G`VIJ3WL^['7D*IU\\SLO?(\8S=95RU]Y8ZX-0WA_PZT9OW.1>YCXZVZ MEE)O>'GF3;QSU=!65*QU.+WLW#W:'E&H(0;QNZ*]F,T=[?R)L7>]^'G>N;[V M@=:TD-H$4<.='FE=:TM*^>]H]%-3$^?SA_5GF3UG^HL2^6M[SIG M>B&W6KZQ_H6.9XBTP8+5PGR=XB8D:QX4UVG(QS!6K1G[X4^(1AI,P",!3P0< M?TL(1D(P$8:K\P;/S+E^$$GRC+/>X<-C=$2_.=H&ZN8*O:DO2IU)J'\:D6?W MW,^\NS8S(@YS!#8(-"$\97L2P)#``5MT_%7@:","6"``3Q#,Z(&AAS`]!.GA MC!X:>K2X`!L1PP(1*!!9]&0A8"-26"`&!6*+OED(V`CDPPH)J)#8?+20&""M M@43#,_LH@D524"2U11:1;-BFQ#^=4T'^$4[-;*H9I.NU.#VV-3 MI#_A>=:1*_U%^+5JA7-B4I5Z4ZPOC$FJ'/*?5'TH50N>%C6]2#U-U)P/36E8 M2-8]>NS4Z//_4$L#!!0````(`'=!"D&PO=V]R M:W-H965T&ULC9=-<]HP$(;_BH=[8VDE2W8&F&GH=-I#9S(] MM&<'!'AB6]0V(?WWE6V@1KM*2_.3;9[;O3%=]%J5=;N8[;ON MN+&KSV$3ML:KRYN^#*>UI,>.SRXN?Q6[?]2_BY3R^QFV*RM1M8>NH,=O% M[#._7XE!,BA^%>;43NZCWOR3M<_]P_?-8L9Z#Z8TZZYO(G>7%[,R9=FWY#+_ M.3?Z/V_IFSGU(^@;7 MMFR'WVA];#M;74)F496_CM>B'JZG\9^4G`'QZ&SH MUY>\RY?SQIZB9AR,0]Z/.;\7KG+K_F5?*->GUOW7*Y;SER7(>?S2MW.6/$PE M,$IN%2M"D5PELT?&"C!>3>#G&:Z\3HZ0>)/J<0BB_(X0J MXY#27B3I16(OJ>=%3K(D@T2PQ'."-8D0M(^$])%@'YGG(T$Y0"GE56Y%J#*E M..U%D5X4\B*8ET6A+($,FLR@<0;N]5;C#/[P$Y+`/$Y)%REVX:5X2*F::V]D M5H0J4UK37C+22X;65&C^])BCR,!P;Q`:&#*JM3^5"5'&`NN;!RC%L9?$]\+Q MZ#&%S&"5GBR,6S,TK3A@,\HW`RB-2GTK;VING=#")5F MH0E#DX]C](E0?VAF\01/VM#8T*3A>!5J@2<(Q2J2/$JY1M1+$S7=$MUYH MGG`,%.D#A1.L$+X50@,!)S1->(:="-])AA>@5,!180B=R!(1`#[0>`*,)^GC M"3!Y/KG/>8:^/J20IUEP&T-C"C"FI(\I(#"E4^T7B9`!YUG(3V!?A4DE?5(! MIA#U1:)DX4\2T+P"S"L9:H%F#$A,B`"E@&8,X(V1]#=H@/<\7$LT:2A5;.<.?L/1;6MM9UR+ M[,[-NKT[D%\?2K/M^EOM[IOQB#H^=/9P.7%?C_W+?U!+`P04````"`!W00I' MD`?C\UX#``!7$0``&````'AL+W=O=":3B_9ZHZLR`=;"&M.W+PMJV3U',;F(@+^S MYT..WX"SHV[>VIU2)OBHRKJ=ASMC]H]1U*YVJI+M@]ZKNGMGHYM*FFZWV4;M MOE%RW1=59<0($5$EBSI%KH-&;>;A%_JXY,1&^L2O0AW;T79@X5^U?K,[/];S MD%@&5:J5L4O([N5=+559VI6ZSG].B_[O:0O'V^?5O_6GV^&_RE8M=?F[6)M= M1TO"8*TV\E":%WW\KD[GD-@%5[IL^__!ZM`:79U+PJ"2'\-K4?>OQ^$=$9_* M\`)V*F"7`GJ[@)\*N%<0#63]>7V51BYFC3X&S7`Q]M)><_K(NT]N90_:#ZH[ MI[9[SR86L_=%0F?1NUWG%'D:1U@?86YBB2222R3J^E\@&`K!1O7Q`.&U>!HB M=1_)^@AY(![I#P)Z).@']!TSN$1*(^`/,+C$:`/C0E+`,]TSN%)49X4 M\J0>3WHGSW3.X)IE.>4^%9)D+$U9QJ]0X?*E MT+["MR]E=U,AR=M4N(@I-'&<7ED!%R>%YA2^RRE48HY.P&3.)<+52:$[A>]R M"J6($TWF7"):(8["F::#+A/N,@9=!F::<3!H,;O5"I<>0Z3GSS2+/]D*MQE# M[@2OK8#;AR'V`3.-W)0A%VHBY=+@YF&(><`T([=DJ?!A;H=<%EQ-#%$3F.+L M'I;;(9<%=Q>#[H+3FX.12H2X/E(WFAM5+>AF>:?D^K)3JHVQFVFWW0S/_<..T?OSSQB7WU(6 M_P!02P,$%`````@`=T$*1YW8H+6``P``A@\``!@```!X;"]W;W)KB2W;3`"Y M@./TVU<"0O#NDO020/[MXZ_79I<77;\T1Z5:YZTLJN9^<6S;TYWK-MNC*K/F M5I]497[9Z[K,6O-9']SF5*MLUQF5A!]XR@_'U@ZXJZ4[VNWR4E5-KBNG5OO[Q0.[V[#0(AWQ M*U>79O+NV.2?M7ZQ'S]V]PO/YJ`*M6VMB\P\7E6JBL)Z,I'_#$X_8EK#Z?N[ M]V^=7)/^<]:H5!>_\UU[--EZ"V>G]MFY:)_TY;L:-$CK<*N+IOOK;,]-J\MW MDX539F_],Z^ZYZ7_)?(&,]J`#P9\-!CCT`9B,!`?!OZG!OY@X/]O!#D82!#! M[;5W,[?.VFRUK/7%J?OE/F5V5[$[:=9F:P?M4IA9:\QOEE@M7U=!M'1?K9\! M2:8([Y'X&EECA(V$:^*/27`JB80C] M_8Q,G[3W)_9^;P]23'JDZI"P%Q%X0&F*(29C'TP'AF0H`C`C&/)%$-":)*E) M8DT":)*3(++7Y,D0:,(0"R,&-&%(A`&`-@0424%K"DA-`=8$9C<)4!`_0)HP M)$0H@28,Q7X,/&TP%'$6TYI"4E.(-8%,DA`%N2%$$12ABJ`(600UKRLB=47X M3,[LWYBTC_&\@"R3&&]-L!U2`@&G8(T1#B[:#>$EI+78VD==YAY6`X*D`W,U MZ0%<&`HRJSR3S$QE83@94#>2@?ET;@GF1L+;CH#0]%*.!)^I`(RL5`^,(U&1 M!T5QZB#Y`NHB,.%S5%H)+/9A!=Y0F+GV9LX2HPL<$U@=@^H$#L0%+%$DY<-; M@J)\#B]TDHKDC#*Z]#)<>R-8>YE/;#1T?"@HA+H(B#$)=7U!7>NBRR_#]3>" M]9=-*V(XS%\L&%1&8"*$V)K"F.=Y2!W!Q6QV0]*5F.%2',%2S*;%,>H#>;=P M%Z4TQM#2D1@\O)L9C,^HHVLRPT4Y@D69X1K)\:JD%,9BN!76I#<1HYN2\B;1 M/\ONI,DH57WHVKO&V>ISU?;5>!P=6\@';IL4,)ZPNY01XVO;,\Z]:T1EUSL]>Z529[[];LO*-IBL>/0NU;^QJ:][IO$_N/5I_> MN]ZQ]5[]`U!+`P04````"`!W00I'P%^WK#`#```^#0``&````'AL+W=O6?GG<7[,.07W;WT1Z4&[ZVIVW[E'X?A]!`$ M_?:HFK*_UR?5FCM[W37E8"Z[0]"?.E7NQJ"F#E"(.&C*JO6+?!Q[ZHIZ M:M53Y_7GIBF[WVM5Z\O*!_]]X'MU.`YV("CR8([;58UJ^TJW7J?V*_\1'C88 M6LFH^%&I2W]S[EGSSUJ_V(NONY4OK`=5J^U@IRC-X55M5%W;F4SF7]=)/W+: MP-OS]]D_C^4:^\]EKS:Z_EGMAJ-Q*WQOI_;EN1Z^Z\L7=:TALA-N==V/O][V MW`^Z>0_QO:9\FXY5.QXOTYTDOH;Q`7@-P#E@SL,'R&N`_`@8ERZ8G(UU?2J' MLL@[??&ZZ6&<2OO,X4&:E=O:0;M0IJ;>W+.*(G\MTC@/7NT\5\GZ5H*C!&9% M8":?,R"788TD'/].L*&*1/`9)%N#O(F74PT)'Q^R\>%-?#C%"V<-)DD[2I)1 M%<>84PJC22&:\EXCU$M%:4CX^9N-C6HOCC40141[R%A/23$ M0^:N9T(R0")=&U2$,@MY)RGK)*5.P$F2DB12+OQ[,C9'1IY8AGR\Y0FW!05U M*=T]*.A:8.J4PH@`%O8J+.``J)?0]0+4BXA<+U1T)Y>V`K#D>`2D9B+7#-(\ M"69D:1A9+.32XO"<`0J:+%Z8@2<-4-1DB6LUI%9#L0!$X"D"$/9/A5.5%#)>8#;R%$)*(1`NAI`2Y@Z3V.D8-HS,D%LNH!MY%"%% M$0B715#?RNY0M;WWK`?3-(]M[U[K01F/XMX@[V@^9N:+ M6NT'>YJ8\VYJ[Z>+09_>OU;F3Z;B#U!+`P04````"`!W00I'*YM2=I4!``!P M`P``&````'AL+W=OH7F7EVR`VHZ2"6O3*O^#P&Z86KF/"$I5+7U+VSJ.^4"C1XF,\ MI4GG,-YP/M'6"7PB\)EPFR7A8Z$D\Y?PHL@M#L2.H^U$W.!FQ\,@RAB,?0>) M+MQ%1)&?BTUVF[-S3#1ACDL,'S$S@H7L%V0?_Q'X5K MF+MO1=AB)!ILDS;O2(F]\6/OT`_8%+_).-/`D;".-(R?T83%IM#6B MAR`EN[JFI`W/?W84U#Z:-\&VXXL8'8_=Y7W//UGQ%U!+`P04````"`!W00I' M;V.;9),!``!P`P``&````'AL+W=O<`0-1DY@F86C_?I/`4-32"[&=]^QG MQQ0CVA?7`7CRII5Q!]IYW^\9:TTO@6;:=CP%6%FSAU5*#<1(- ML=`@5$P4"K_. M.3]*1N+:OF3_E;H-ZD_"P3VJ?[+V71";45)#(P;EGW'\#7,+-S%AAE(7%D=AIM+V(+YCO M>1A$%8.Q[R#1A;N(*(MSF>=9P3`0``<`,``!@```!X;"]W;W)KUBIZJ$]9\!`U"2F21C:O]\D#!1U MV0NQG??L9\<4(]HWUP%X\J&5<0?:>=_O&7-5!UJX*^S!A)L&K18^N+9EKK<@ MZD32BO$L^\&TD(:618H]V;+`P2MIX,D2-V@M[.<1%(X'FM,Y\"S;SL<`*PNV M\&JIP3B)AEAH#O0NWQ]W$9$`+Q)&M[))U'Y"?(O.[_I`LR@!%%0^9A#A.,,] M*!43A<+OEYQ?)2-Q;<_9'U.W0?U).+A']2IKWP6Q&24U-&)0_AG'7W!IX28F MK%"Y]"75X#SJF4*)%A_3*4TZQ^F&S[1M`K\0^$+XF27A4Z$D\T%X41861V*G MT?8BOF"^YV$050S&OH-$%^XBHBS.99[S@IUCH@OFN,;P";,@6,B^E.!;)8[\ M'SK?IN\V%>Y6].O_*-S"[+X58:N1:+!M>GE'*AR,GWI?HLMRW?$TTB]X6?2B MA3_"MM(X4=&']%T=!XZ-Y&VP[;<3D>.SG_5Y^LO(O M4$L#!!0````(`'=!"D=;IY_]E0$``'`#```8````>&PO=V]R:W-H965T&UL=5/!;IPP$/T5RQ\0@S?;1BL6*9LJ:@Z1HAS:LQ<&L&)[B&V6 M].]C&Y:@EE[PS/B]F320,OEKA!:V'_G$#A>*0YO09> M9=OY&&!EP19>+348)]$0"\V1WN>'TRXB$N"7A-&M;!*UGQ'?HO-4'VD6)8"" MRL<,(AP7>`"E8J)0^'W.^54R$M?V-?MCZC:H/PL'#ZA^R]IW06Q&20V-&)1_ MQ?$GS"WL8$*E4M?4@W.H[Y2*-'B8SJE2>%3H23S MA_"B+"R.Q$ZC[47<8'[@81!5#,:^@T07[B*B+"YEGM\6[!(3S9C3&L,GS()@ M(?M2@F^5./%_Z'R;OMM4N%O1;_^C<`NS_ZL(6XU$@VW3YAVI<#!^ZGV)+H_K M/NV`?<'+HATE0$``'`#```9````>&PO=V]R M:W-H965TZAMEO3O:QN6H(1<\,SXO9DWXZ$8T;ZZ#L"3-ZV,.]+.^_[`F*LZ MT,+=8`\FW#1HM?#!M2USO051)Y)6C&?9GFDA#2V+%'NV98]+`LR5NT%K8 M?R=0.!YI3J^!%]EV/@986;"%5TL-QDDTQ$)SI/?YX;2+B`3X+6%T*YM$[6?$ MU^@\U4>:10F@H/(Q@PC'!1Y`J9@H%/X[YWPO&8EK^YK]9^HVJ#\+!P^H_LC: M=T%L1DD-C1B4?\'Q$>86;F/""I5+7U(-SJ.^4BC1XFTZI4GG.-WL]C-MF\!G M`E\(W[,D?"J49/X07I2%Q9'8:;2]B"^8'W@81!6#L>\@T86[B"B+2YGG^X)= M8J(9YY&ND[O"QZT<(O85MI'#FC#P^31ML@>@A2LIM;2KJP_HNC MH/'1O`NVG39B?K+R/U!+`P04````"`!W00I'SY#PII0!``!P`P`` M&0```'AL+W=OBG??]D3%7=:"%N\$>3+AIT&KA@VM;YGH+HDXDK1C/LL],"VEH6:38DRT+ M'+R2!IXL<8/6POXY@\+Q1'.Z!)YEV_D88&7!5EXM-1@GT1`+S8G>Y\?S(2(2 MX)>$T6UL$K5?$%^B\Z,^T2Q*``65CQE$.*[P`$K%1*'PZYSSO60D;NTE^V/J M-JB_"`)M.J5) MYSC?++1]`I$?"7<94GX5"C)_":\*`N+(['3:'L17S`_\C"(*@9CWT&B"W<1 M41;7,L_O"G:-B6;,>8OA$V9%L)!]+<'W2ISY/W2^3S_L*CQLZ)_^HW`/\_5# M$;89B0;;II=WI,+!^*GW-;HNUSU/(WV'ET4O6O@I;"N-(Q?TX6'2:!M$#T%* M=G-+21?6?W44-#Z:7X)MIXV8'(_]LM_K3U;^!5!+`P04````"`!W00I'"CZD M,I(!``!P`P``&0```'AL+W=O6B4:<2PVH%#TB(!WC.M&X;D<3=))W"WY.DG5)!>6ELYQS[V''S M`>V;:P$\>=?*N#UMO>]VC+FR!2W++$]5H+^W$`A<.>;N@Y\"R;UL<`*W(V\RJIP3B)AEBH M]_1VLSML(R(!7B0,;F&3J/V(^!:=AVI/LR@!%)0^9A#A.,$=*!43A<+_IYQ? M)2-Q:9^S_TO=!O5'X>`.U:NL?!O$9I144(M>^6<<[F%JX3(F+%&Y]"5E[SSJ M,X42+=['4YIT#M/-=J*M$_A$X#/A)DO"QT))YE_A19%;'(@=1]N)^(*;'0^# M*&,P]ATDNG`7$45^*C8\R]DI)IHPAR6&CY@9P4+VN01?*W'@/^A\G;Y=5;A= MT/_\HG`-\UTC6XQ$@VW2RSM28F_\V/L1?L&+O!,-/`K;2./($7UX MF#3:&M%#D))=7%+2AO6?'06UC^9UL.VX$:/CL3OO]_R3%9]02P,$%`````@` M=T$*1W]T,_.4`0``<`,``!D```!X;"]W;W)K&UL M=5/!;J0P#/V5*!_0,*'=KD8,4J=5M7M8J>JA/6?`0-0DIDD8VK_?)#`4==D+ ML9WW[&?'%"/:-]/*AE7$'VGG?[QES50=:N"OLP82;!JT6/KBV9:ZW(.I$ MTHKQ+/O!M)"&ED6*/=FRP,$K:>#)$C=H+>SG$12.![JCE\"S;#L?`ZPLV,*K MI0;C)!IBH3G0N]W^F$=$`KQ(&-W*)E'["?$M.K_K`\VB!%!0^9A!A.,,]Z!4 M3!0*O\\YOTI&XMJ^9'],W0;U)^'@'M6KK'T7Q&:4U-"(0?EG''_!W,)-3%BA M&UL=5/!;MLP#/T501]0.4JS#H%C(.E0;(+7&]UL)^G$#A<*`;>@T\ MR:;U,<"*G,V\2FHP3J(A%NH#/6[VIVU$),"SA,$M;!*UGQ%?H_.G.M`L2@`% MI8\91#@N<`]*Q42A\-N4\[-D)"[M:_:'U&U0?Q8.[E&]R,JW06Q&206UZ)5_ MPN$W3"WL8L(2E4M?4O;.H[Y2*-'B?3RE2>AT&4,1C[#A)=N(N((K\4&WZ;LTM,-&%.2PP?,3." MA>QS";Y6XL2_T?DZ?;NJ<+N@W_Y'X1IF]Z4(6XQ$@VW2YATIL3=^['V.SH_K MF';`/N%%WHD&_@K;2./(&7U83!IMC>@A2,EN=I2TX?G/CH+:1_,NV'9\$:/C ML;N^[_DG*_X!4$L#!!0````(`'=!"D<#B$-AE`$``'`#```9````>&PO=V]R M:W-H965T,5>V MH(6[P0Y,N*G1:N&#:QOF.@NB2B2M&,^R6Z:%-+3(4^S)%CGV7DD#3Y:X7FMA MWX^@<#C0#;T&GF73^AA@1E"%N,1(-MTLL[ M4F)O_-C[')V7ZX&GD7["B[P3#?P1MI'&D3/Z\#!IM#6BAR`EN]E1TH;UGQT% MM8_F7;#MN!&CX[&[[O?\DQ4?4$L#!!0````(`'=!"D?.#\SXF`$``'`#```9 M````>&PO=V]R:W-H965T%/9APTZ#5P@?7MLSU%D2=2%HQGF4W3`MI:%FDV+,M"QR\ MD@:>+7&#UL+^.X+"\4!S>@F\R+;S,<#*@BV\6FHP3J(A%IH#O^I!J<1WVA4*+%QW1*D\YQ MNN$W,VV;P&<"7PBW61(^%4HR'X0796%Q)'8:;2_B"^9['@91Q6#L.TATX2XB MRN)8:,8D0H'XZ?>E^BR7'<\C?0+7A:]:.&/L*TTCIS0AX=)HVT0 M/00IV=4U)5U8_\51T/AH_@RVG39B?K+R$U!+`P04````"`!W00I' M"'1NA;P!``"?!```&0```'AL+W=O,3=6!H.9.]2#=3J.TH-8M=8M-KX'6@20X)FF: M8T&93,HBU%YU6:C!D7S_4I27T$X%!9KT#=<(4GX-P+.>/? ML^:WI2>NYS?UG^&T+OV%&GA2_(/5MG-ATP35T-"!VS4AG6IQ`9@+9$/!D%&+^H):6A58CTM.G[:G_![,C M<1^B\D5_;A?1N#V/*(MKF>W2`E^]T(PYKS%DPBP([-07"Q*S.)-_Z"1.WT43 M[E;T_9PPVR2,8?YCLH^:[","NXU)#+./FQRB)H>(P&%C$L/D<9,\:I)'!.XW M)C',P\8$KSI(@&[#13&H4H.T4ZLLU>4N/I+0@=_PLNAI"R]4MTP:=%'6]7'H MQ$8I"RY*>N<.W+G78EEP:*R?WKNYGB[0M+"JOST'RYM4_@502P,$%`````@` M=T$*1SPD1427`0``<`,``!D```!X;"]W;W)K&UL M;5/;;J0P#/V5*!_00&CW,F*0.JU6NP\K57W8?Q2=1^1GR)SJ_F2+,H`134/F80X;C``R@5 M$X7"KTO.]Y*1N+6OV7^D;H/ZLW#P@.JO;'P?Q&:4--"*4?EGG'["TL)=3%BC M%SH23S47A1E18G8N?1 M#B*^8'[@81!U#,:^@T07[B*B*B]57GPOV24F6C"G+8;/F!7!0O:U!-\K<>*? MZ'R?7NPJ+#;TV[GZ;?9!X1[FHT:V&8D&VZ67=Z3&T?BY]S6Z+M<]3R-]AU?E M(#KX+6PGC2-G].%ATFA;1`]!2G9S1TD?UG]U%+0^FE^#;>>-F!V/PW6_UY^L M^@]02P,$%`````@`=T$*1[:QS!>4`0``<`,``!D```!X;"]W;W)K&UL;5/!;MLP#/T501]0.4JZ%8%C(&DQK(<"10_;6;%I6Z@D M>I(<=W]?279<(_7%(JGWR$>*S@>T[ZX%\.1#*^,.M/6^VS/FRA:T<'?8@0DW M-5HM?'!MPUQG052)I!7C6?:#:2$-+?(4>[5%CKU7TL"K):[76MC_)U`X'.B& M7@-OLFE]#+`B9S.ODAJ,DVB(A?I`CYO]:1L1"?!'PN`6-HG:SXCOT7FN#C2+ M$D!!Z6,&$8X+/()2,5$H_&_*^54R$I?V-?NOU&U0?Q8.'E']E95O@]B,D@IJ MT2O_AL-OF%JXCPE+5"Y]2=D[C_I*H42+C_&4)IW#>/.03;1U`I\(_(;`QD)) MYI/PHL@M#L2.H^U$?,'-GH=!E#$8^PX27;B+B"*_%)L=S]DE)IHPIR6&CY@9 MP4+VN01?*W'BW^A\G;Y=5;A=T'>3PNV-PC7,[J8(6XQ$@VW2RSM28F_\V/L< MG9?KR--(O^!%WHD&7H1MI''DC#X\3!IMC>@A2,GN[BEIP_K/CH+:1_-GL.VX M$:/CL;ON]_R3%9]02P,$%`````@`=T$*1]'%Z8'+`0``J`0``!D```!X;"]W M;W)K&ULC93=;J,P$(5?!?$`-6"3I!%!VB9=[5Y4 MJGK17CLP!%0;L[83NF]?VS@L)6C5&_SWG6//C''6"_FN:@`=?'#6JEU8:]UM M$5)%#9RJ.]%!:U8J(3G59BA/2'42:.E$G*$DBE:(TZ8-\\S-/ M9:#.G%/Y]P&8Z'=A'%XG7II3K>T$RC,TZLJ&0ZL:T082JEWX(]X^8DLXX+6! M7DWZ@3W[48AW._A=[L+('@$8%-HZ4--<8`^,62.S\1_O^6]+*YSVK^X_7;3F M]$>J8"_86U/JVAPV"H,2*GIF^D7TO\"'D%K#0C#EOD%Q5EKPJR0,./T8VJ9U M;3^L;"(O6Q8D7I",@IC\5X"]`']70+R`?%>0>D$Z$Z`A=I>Y`]4TSZ3H`SE4 MNZ/V4L7;U-2FL).V%"9KRJQ9(L\N>4S2#%VLD6<>IDSBF.0KL5\@9B:'6V0= M?44>;Y&8K$8&F3C&8)+%8)*)`?8&ZV4#O&B`)P;$&VQFV1B8UC'K(=857LTS MLD#=Q\G,ZW!+84(2/,O++15'9',_"PQ-2M[1$SQ1>6I:%1R%-K?'U;\20H-Q MC.[,K:G-LS$.&%3:=M>F+X<_:1AHT5W?A?%QRC\!4$L#!!0````(`'=!"D>_ M,Q3E[0$``*P%```9````>&PO=V]R:W-H965T MX6)D_$VT`-+[H*07>[^5G32,4RS5DI^1&#C@VI@H05$0 M9(CBKO?+PNR]\+)@%TFZ'EZX)RZ48OYY`,+&O1_ZMXW7[MQ*O8'*`BV^NJ/0 MBX[U'H=F[S^$NV.N%4;PMX-1K.:>9C\Q]J87O^N]'V@$(%!)'0&KX0I'($0' M4HG?YYC_4VKC>GZ+_F2J5?0G+.#(R+^NEJV"#7ROA@9?B'QEXS/,):0Z8,6( M,%^ON@C)Z,WB>Q1_3&/7FW&<3M)PMKD-T6R(%D.8_&B(9T-L&=!$9NIZQ!*7 M!6>CQZ=>#%BW/-S%ZN8JO:DO2M4DU)E6E,6U#)/[`EUUH%ES6&LBHXF^*XX. M1;I(D`)8*"(G1;3RQQ-%&K@#Q,X`\2I`,@<(K3(F36\T^0R96H5L-6'XRPV2 M.$$2!XAU6X=DE20UFCC/+9"M)@L2-TCJ!$D=(+$%DFZ2)%'F3I(YDV2.)(F5 M)-LDL6O]2?$-(G="Y`X(JZ^'?-O7(+.;OQ7ET;U%@E8_UH#/\`?S<]<+[\2D M^D?-7]8P)D'%"^[4_;;JZ5P6!!JII[F:\^DUF1:2#;>W<7F@RR]02P,$%``` M``@`=T$*1R[?6WAA`@``%P@``!D```!X;"]W;W)K&ULC5;1DIL@%/T5QP]8!463C'%F8])I'SJSLP_M,S$D.JMB@<3MWQ?0&(-T MDY<`UW,.]Q[QDJ2C[(,7A`CGLZX:OG8+(=J5Y_&\(#7F+[0EC7QRI*S&0B[9 MR>,M(_B@277E0=^/O!J7C9LF.O;&TH2>154VY(TY_%S7F/W=D(IV:Q>XU\![ M>2J$"GAIXHV\0UF3AI>T<1@YKMU7L-H!7T$TXE=).CZ9.RKY/:4?:O'CL'9] ME0.I2"Z4!);#A62DJI22W/G/('K;4Q&G\ZOZ-UVN3'^/.3 MJZ!Z%=(U+I\I1)I<4H"BQ+LHH0&SF6*@QD3+>\AV#@$CPI,)C%E`6Q8;.*/# M^PVR.2+VC1P>BNR^%+E+,[":%4SXP6!6;!<(K0+A1"#4`DNCBDT/:30DUI"% M;V"R.28.D>'&'`/B(#0,F8-@L`SM%2%K16A640SM_,C*CYZW-+8*Q(\MC2=5 MHKY*:)SQS(8!AJ5S#`H#P]$Y9A']YXPMK/4LYH8&=O[2RE\^;ZCJH+:6X#^V M=,!,3PZ*C=.5V4`P-#O''`3`TK!^9T.AP#RIWJ3KU82=]'W#G9R>&]&[,4;' M.^T5JJYIQ#=@E0%+?*ON0-UE;_)ITN(3^8G9J6RXLZ="]FK=;8^4"B*3]U_D M1U+(6WI<5.0HU#26<];?6_U"T/9Z#8__!=)_4$L#!!0````(`'=!"D>;!]QZ M,@(``"P'```9````>&PO=V]R:W-H965T8OGUM0S(,.4C9@&W^\W_'YM@N M!B%?5<6Y]M[;IE-;O]*ZWX2A.E2\92H0/>_,EY.0+=.F*\^AZB5G1Q?4-B%! M*`E;5G=^6;BQ9UD6XJ*;NN//TE.7MF7RWXXW8MCZV+\.O-3G2MN!L"S"6]RQ M;GFG:M%YDI^V_E>\V6%J)4[QN^:#FK4]F_Q>B%?;^7G<^LCFP!M^T-:"F=<; M?^)-8YT,^>]D^L&T@?/VU?V[FZY)?\\4?Q+-G_JH*Y,M\KTC/[%+HU_$\(-/ M(@7:E8N^>AC84>**5)-((P M&MV,'Z@F";1)Q(.5GXQAKZTYY>Z'-F>J.Q9,0FAM'%)@M5YFKZ]9I^$G;9FK: M&ULE5G;DMHX$/T5B@\86RW)DJ88JG8@ M)$S55J7RD'WV@!BHV)C8GB'Y^_5MP):ZN;R`;4Y?)/4Y+9G),@Z!8;6T:%P_9P>ZK7S99GL9E=9N_!<4AM_&Z,4J3`,(P"M)X MMQ]/)\VS[_ETDKV7R6YOO^>CXCU-X_SOLTVRX].8C3\?_-B];[ M]2ZU^V*7[4>YW3R-_V&/+S*L(0WBY\X>B][UJ$[^-E%GZ:3(>I?&?]GNW;[Z/[2_*=&:X`70& M<#+@\J(![PSXK0:B,Q"W&LC.0)X,(+QH$'4&T=E`7310G8$Z&["+!KHST+<: MF,[`G`=].:5ZS=N5"\\F;0FU2]X4S#PNX^DDSXZCO*WR0UR3B3VRNB97]=.Z M!*MJ*:H?:\AT\C%E430)/FI/'>:YCX$.HX:8&8;10\P$0L\`P M;(CYBF%@B/F&8?@0L\0P8HAYP3#RA`FJ!3BM`N"K`#T/O/,0X1XX[H'W/(C. M@[-&BQ:S;S"JP7!A*JETYG=Y'3?(2.`9"20CIR(6HA=)-A@-6AJG`)=788-\ M))Z/1/)QJF^)8#0QZ@B/$B$>G-I<1KWAZ`8##^[4O/@@QAZXQI-1>#(*2<8A MP5)Y<\M#0:ZUQ@-I))#+).T%4A$9Q^!Q#!+'8>/">-6KP]`K\J\^3`GI<\&' M51HA/-R+CP-NZ'FL=1N5XQ`9(:$EC))T=KN:,$*0&-S`W@[47U(`[<_A==PP M)T+B&*)QFAH7(4I,W#$WA)`P3"6$VUND7Q"2'C*A)@R3$T?6O[`(H3`9B9`* MAFF%=@>E[AH4(18,4PM#^""$@)G;UQ$(K@'"->/6+@IB1"""D,"N%\RR`SE* M0TXN4#L)A+@&"!\$T8#?,;D$T0!I_\9I"<_@-_9JUQ(QI^YF"$XS+MU6AL`X M5X93>S&"WX#PVP@W=9_?U$H1W`:$VT:Z87QN`T#$I#MT'T>E0P@`(`)`[;"` M8#;H.PJ'8#8@/=XMG!D8;[A*J1ZGAEMF0@`XQFWW8-.!!J&(,`3].4)_MYYF MW*=_TR*)5>0$_3E&?Y=.*(@08$Z=-_QF#&2RA$;P.YHQ)\C*,;*ZY<*E+PPR M(O;2G.`KQ_CJ50O"5R(,P4..\="K%K\1,]""$#I.T)4CC=@O%A\$(=$`.<%I M[G,:0F)>!$%6$=Y>+()@HL"8Z#8EP7S",ZZ(:A$$$07&,>6&\C?&Q,P*@H8" MV1-[O4KX!WK@D:'>40CJ0(^U=.W&PD"$M@B"T\+G-(2<\$&P541WE`M!18%1 MT2L7_P"MI+M'GU]##?,A^"HPOGHUY9^SA9O,)<@P$X+0`FO27MEA9V+IG@[G M5V'#ESN$/$BLE[O%B8*<=T#S*Z`VFZ#W@O40O]E_X_QMMR]&KUE99FGSMG63 M9:6M'(8/53EO;;P^W21V4]:7JKK.V]?U[4V9'3[_?3C]!3+]'U!+`P04```` M"`!W00I'U.')..S:9]V*3IP^XSH]>/%,0%9NS^^P5T'.N0 MO@A9^,]O+@MTH->X1DV0(C\H$/T.N=F@M&E%Z*!LE! M`*DLB5&$@R!!C'2]GV"$L>=R$:"9$-T)L M*YVB2)Y)OCHB>DN!F*N/-Q'^N1*$S0'I6N2>L\@\NR2XR#.T,4(S9CC M&H,M)EP02*LO*;`KQ1'?T?'7!,4](@W<&2)G$=&*'TT&T\0M$#L%XI5`/)_" M;G,*+DRR*<2%2=U&=DXC.X?`X\:("_-C8^1[S!+" M8+>1U&DD=0A$&R,NS.8G+K['3$;0ZM4P$(WM)M(K^;E7TY^Y1)>&]83-J]O$ MC[J137WG)I-G`VG@%Q%-UTOOQ)5^T_95UIPKT!:#!WUKK6ZURX)"KM45YR9Z;T2K=W%E3+<% M0)<5;YA^D!UO[J&][J6K:1XN==_`BW!^H0'O"S MYKV>]2.7_2CEJQM\/^WBQ$7@@I?&*3#;W/B>"^&$K/';J/G7TA'G_;OZ5[]; MF_[(--]+\:L^F+HQ,_L*LR+[+_Q<0N9$RRET/X;E5=M9'.GQ%'#WH>V M;GW;#RN;9*2%"6@DH(D`\3\)Z4A(_Y>`1P)>$,"P%5^(`S.LR)7L(S7\O(ZY M,P*WV):Z=).NLK8(VJXY1)'?"@2S'-RHU*4_HES<*ALV#H+!!ZZ9.M?#ZI"PE:D(!%NJ@+ M65D@A,CR2![6L$^2T&`2&DB"%Q9T94$S3))E4<'LIG7LPG\P=:E;'1VEL9?6 M7[NSE(9;R>3!%K"RC^\T$/QL7)?:OAK>HV%@9'=_7:&PO=V]R:W-H965TWEK(_>IXH:M)B<6`]Z=2;BO$62]7E5T_T MG.#2!+740P!$7HN;SLTS,_;*\XS=)&TZ\LH=<6M;S/^<"67#R87N8^"MN=92 M#WAYYLUQ9=.23C2L#Q#7TN,XF=#!K%H.SKY"V/ONO.]/+E`YT`H M*:2VP.IQ)R^$4NVDR+\GTW],';AL/]R_FNFJ]"]8D!=&?S6EK%6VP'5*4N$; ME6]L^$:F.83:L&!4F'^GN`G)VD>(Z[3X8WPVG7D.XYL$3&'V`#0%H#D@-7F/ M')/E%RQQGG$V.'Q\I\AR`I!"P-_,DCM!K[5P%\8!*-!!%99CIK.:$*C"8,8I.F33`,K M*+"`X`H4;$#`C@BMB-""0"M$N!<161'1!H%@ND)$&\0G"/3/#HJMH-@REV`% MBK?[XO]G7Q(K*-F>H.B)06HU2+=+@M8G*%UDFAB-?XAB.T57NJVD*RES? MXN+K\97\P/S:=,*Y,*FN4',+5HQ)HAS!0959K;Y422NIFK-I\O+O'CF3] MXU,T?P_SOU!+`P04````"`!W00I'$A^<-FH"``"""```&0```'AL+W=OO(DOY155EPUZ% M(R]U3<6_':MXMW&1>SMX*\^%,@=>EGICW+&L62-+WCB"G3;N%JWW*#(0B_A= MLDY.UHX1?^#\W6Q^'C>N;S2PBN7*4%!]N;(]JRK#I#/_'4@_OOK/PA#`[`0P`>`\8\<``9`LAG0&"=]LJLKV]4T2P5O'-$_S!::IXY M6A-=N=P%I]C$%AE+L\$/X+,'^ M$1'[<`8"FB"3>#*8(#!!`!($$X)@(`AF5>@QC<6$?150@%$%1X@>O(8G])`EG-0%P07B'NQ.T`@6M'@2A M50(3)"!!LKPDIO>A=O$7%&4`3=T2E&""YU6!@`0A'S]QA9[T,`)$14\HP![= M(OR%TL!-B,B2TA#`<9R0)_\#!+BWY$]AO%V]O$ M'S\[LO]02P,$%`````@`=T$*1WIR!X"Q`@``TPD``!D```!X;"]W;W)K&ULC5;;[$RG%[O7J49E M"L1-8NV^_28A(H;?5B\DA.^4A/RD.#'^+O:42N^SJ5LQ\_=2'J9!(-9[VA#Q MP`ZT54^VC#=$JEN^"\2!4[(QI*8.@-5U++4'4Y8,N:5UK)>7\UXI>/#5QV#ZKK\QP5?PW M(NB2U7^JC=RKM*'O;>B6'&OYRDX_J!U#H@77K!;FWUL?A63-F>)[#?GLKE5K MKJ?N21I:&DS`EH![0N\#$R)+B"Z$^$M";`GQO0Z))23W.J26D%X(Z9>$S!(R MQR'H9M>LS2.1I"PX.WF\>Z$.1+^W:)JIU5_K3KW8:EV$>J819?%18CPI@@\M M9#&+(08;3)I?0Q['$'2-6(T1&%]4`A6R3XJAI`L\%KBV6`*(*'2"?JOR-$9D MCL@*$$FN(<]0%@0/-P(7)AH(1%8`PP(Q*!`/!&(K$#FST6%:@\D,)DXB5::< M`3^-<7B"LLD0>)4H`1,E0*(8%DA!@?3^.93X83M+M3)SE,7+"K,8XC+(4WYA>7=ZA:A("B7*W M$H0#JXD!)0_QC5J`;I0M-#:*W6UJ0<.E1"A/;ZXD`@O/'&'`:U3>\&C^HB^< MX#V/HN_W[,*"AJ-R!KX$(."^7@%`A))\G#L8?$\:RG?FK""\-3NVLMN+?6]_ M'IEC_3UR^A=HND1`_R.:/G6GC8M\61S(COXB?%>UPGMC4GT%S7=LRYBD*G_X MH$K*7IVP^IN:;J5N9JK-NS-'=R/9X7R$ZL]QY7]02P,$%`````@`=T$*1W?J M-#*#`0``-P,``!D```!X;"]W;W)K&UL;5-!;L,@ M$/P*X@'%P4DK18ZEIE75'BI%/;1G8J]C%&!=(''Z^P)V7*O*Q>PN,[/#@HL> M[=&U`)Y''9BPTZ#5PH?4'ICK+(@ZD;1B/,ONF1;2 MT+)(M9TM"SQY)0WL+'$GK87]V8+"?D,7]%KXD(?6QP(K"S;Q:JG!.(F&6&@V M]'&QWN81D0"?$GHWBTGTOD<\QN2MWM`L6@`%E8\*(BQG>`*EHE!H_#UJ_K6, MQ'E\57])IPWN]\+!$ZHO6?LVF,THJ:$1)^4_L'^%\0BK*%BAV'G?OE2+M-X".!3P2>^K"A4;+Y++PH"XL]L<-H.Q%O<+'F81!5 M+,9S!XLN[$5$69Q+ON0%.T>A$;.=8_B(R2<,"_I3$WZS"9\)Y*/`\K9`?E,@ MGPDL1X'5/Y<#QB3,*F'^>V2SH73B`._"'J1Q9(\^S#=-J$'T$-2RNQ4E;7C% M4Z*@\3%\"+$=+G9(/';79SK]*^4O4$L#!!0````(`'=!"D>C6=?[T`(``&`+ M```9````>&PO=V]R:W-H965T<>Y+>%7QJ'H0X3BR+;PXT)_R)'6DAO^Q8F1,A7\N]Q8\E)=N*E&<6MFW?RDE: MF$E<];V720"O$KI6=^TS:4^35CG^IEM9V:MO)`,[H12H+(QQ>=TRQ3 M2C+R'RUZC:F(M^V+^J(:KK2_)IS.6?8[W8J#=&N;QI;NR"D3'^R\I'H,GA+< ML(Q7_\;FQ`7++Q33R,EW_4R+ZGFNOX2VIL$$K`FX(31Q8(*C"J_$$&2N&1GHZQ3 M]DC4SD"32.;71G6J=)(KS^4WA4CBKP2[?FQ]*2&-F=UBL,8$;`(1CMS&O`,9K0Q9]2-!1>7OH M9?E89'772FO2'#`%G!N^HR=M8-9=4,"]$7`K@:B3'LL:4E20H(*XMOK!83PP MC-<+$W36=N'UPOSP@]LPM1L`YCC!H!T?M./W[&!O0"``!8+Q\QZ"`N'#>9^% M_S7O$1@F`@;:V;GSJ!<'!;@W\2\`S(MZL-<^+'(&3:NS#"IL-F`;=RL;!'(& MX@P44`1(N-W2!X$&-BD"2]LSP@_3?Z4QK<2^M]X(+@C(`=SZW5A.+Q:^%PHN M':A?.[`7#$C`90%YX_<1@KLFZ.WIR6^^KBQHT-.Q6B-MCT M-I?#9ZR.[D[_'$T6".A_0Y-E??6[RB?QD>SI3U+NTX(;:R;DA:$Z\G>,"2KM MVT]RF@[RNMN\9'0G5#.0[;*^`-8O@ATO]]GF4IW\`U!+`P04````"`!W00I' M83*Y/8PG```JDP``%````'AL+W-H87)E9%-T&UL[7U9;R-7EN9S MW5]Q8<@]2B#$Y"I*MLN`5EM5:4E.9=H8-/HA1`;)L(,1K%BDI%$/]1^F7QJ8 M^7/U2^8L=XV%HFP/IAMMH"HMB7<]]RS?.???/AI/3S[[^JHB__JK\^C*;5>LH+668SN556L;E5MZD/&:3^H=GU;(G M^]/V#\UZW$7\Z[LXC>1-&:V+?^OL\&&[B>H?#OI'WS>FA]9SZG&=A,OZIXLP M*1K#F#GNHSS.D$YS>1F6C79ZV^)/?]JYM^NXF(6)_)]1F,MK^&.#NO66:M[6 MMM\/ZW_YD(?S.%W*A^WZ,4OJGWYS]NY#_6_JX-]'R[@H\Q`FO@W7C>U!SZN+ M#S>W\L.W5^_/[J\^?KBY>)`WMQ<=PUW`#G)8_0VPR"?YUVA;;W=1Y7F='EVT M/3H:#(]&@XZIKN,DRN4%]%MF>6.>L]DL@L_ATSFW[%IPMEX#NSV4V>SG0#X0 MX\N[JBQ*D`Z@:&/]&>PL+6!4^*G(DGA.4YR'29C.(A@`Y+``$?KX<"D/#][( M`QFG\L,JJPH8KWGHT0RX9T!R,>XB55@4,.87C8_#8D4B/,,?HK]5\5.80/O& M)/=YM`GCN8P^;7#E!77*RA50;^9-T6"JK(0CVMWF/@>=E`,A<5! M198:79_/XZ<83GK>.1`OU%E*DU76Z[A$%M5D;RY$V] M%W'B*DOF45[\#Z)HN6UL\B,P81$O4^*]@GGWH-_K#V"QN00^J*(O@:>"?I_^ MKQ2Z#*MRE>7Q+]$\D"?PP8`^=(8*2PD*+3)ZG-8-3!JM'X%;NACU`505C'XF M!\//<9=/P!!TS&":%A$ZXN@#,! MJLW9CA`MY($=NSY(VZE!/X>H/E4G.ZBZ]PJ'HV!Z2/';Q"&]QG!L5\YT<#8K_]1F_1ZEU-`S[XSFF'OV%: M-]BCP_L0%>TZ4KCV6\G+O MK@6^W//7+AL%?KW9=2R_[5!;I?JAA/\PH,@6\FZ#^!;&>`S<+Y.D[)+4%+ MUFY3LL;4+[5+LJ+1YHY@<)S.LG4D#]5(;QJ;`.@:`5E+U;+^\3L862[R;*UL ME%Q'P,US:/T$G]C8J6W=U M7[.E!LN^U#`$\!LA2W7-),/-)@$;@FQ=9J"ZK`I0=KJS)UHXW1Z9%)CV,2SB M&3-&G%0M>O_'*%ZN")B",(7+R!O`$]Y]1MM+JLBMNDZRY_V]N(NSAV_E];N[ M'Q_D]?N[[^3=/?C*X#1_(\_`=_[AYL/-U4/33YG_5!7*.P!*YA&8@1DXJN@3 M,<'@K_@SN7<5KAK68+DY1)37[@)=1J!Q9C'K%Y*G=0:JZ)>P[63)WS@"VD6( M.];(:-Q1,=WOQ.MMK'ZQ`G^0E96S+_+\:-F[W+P=3FV[[UCW"YDP-6>0O;)" M#NG3IG-VN\]YO,0>-[<_7#V\Q!Y7OY6XC:7R&*];ZO7-[=GMQ0M+Q9DV>3:+ MHKGB##3'!#]!GEP5051]#G,,-[5%$IPAHD]1/HN+YA"Z.Q\X6>!6G4-[AV6A MYIO+QZU7K^A]!7_M['=[=\N'M\^)W8=; MXB6@;=WMLF$/=`\=PM?'.`=M2PH3)+&`P5J5RZ`G6]L)P\(?0&+#352!8U+( MFW36DX<@Q/*?__C?`"\W8;K]YS_^SQM@*!F*60*@8$:.)YJ"QSC;@!E8AS/J MC9$J[B'+%;C+,=NJ+1YX7!8BB4(T3ZMX@SM;ZOD+%B$V&WFU="$*6;@\`NL` MBOA9E+14Q.V++`=V>LPSF![@K^,L,31/:&%A*'@G6L4!/ MW*#9W7^`H@_S9422"60R*P/>+:,8P-WS*IZM!%K,GR/4"'/0[%E.-`4:)-E2 M6;U-"+J"?UU4Z0SIK%8BD#*@_>!4PZ3(Y#K@*FDE4:5O`'LB7:V,Y<8ZNDD$]1F]VP M$*#.P4:QIBI7<'C?5R'\GB<8HL:/D'#76;Z6&.`'<[E`,L%V$A$ZEI1HA=0. M>"#0'QO@&N@+U%J'*3".CD^"WBS"'+@E$QMF3;D(8YP0N]EU;K*"=H@C."<' MBX:_B&94!MO`>%7">"+&_UBDCE3&%N4JCR)!08[XDUPS`(\0@+<$>A!ZTP\X M&"FV!0(4H0?;/*N1:PTR0<<-@\2(<>-U^PD!$DTJ:(OT!BYCO1S*%.]K M&+,#XJCR')D8//@JCXCU#+&0!V*4/P'B14@+5@YZO`AG3!>2V6P&8\AP`0NA M)3VJ*`;=;DED(/E8E>(Q@HU'M6-RV0D^5'$TV)NR`>!4Z/`7K`%UW`S/*2$7 M@R0=W+40F`:-Y)J$%M>826Q:Q@N0O+"$A?%2@5_!0.?NJ*@(9@#<:.\/U6,! M+9"IU(9)WAZC*(79P>4C80`FR*KEBG9"NRM);W1N*GP*XP3!BX!U/>I-,J4U MRR%/Z*/K>+#^H'V!X1$4S$EH8$T]1>R4T MNN#1D4J:#Q=5DL@MN'N\I)>4@6C=:$W,"D#=R1R7@_><;)72GY1^$\\Q*"&4 MBK,TK6"!9OB,&(Z7%H^/DY!M'B*X(JLA3-4#5% M!%@7%J%+W7/*;3G'5='`G#7\CW8$/F M:DY'@?F;>8R2&':I=H*'@5:2!X:95X2QVY9+$BJ+:H'Q9902Z@*JF&955TZ@ MBC>@`#`0[6A0+30/<`+J$'GD8^\0R;*R_[`UVW&&82U#"I5G$[0$H%-6Y3,V MV2`!JQ"4)47"-X2*8%?8QQDX>T2U(1Q%8)$FRLULA21"-;2(2R*N746`5@3& M8!,/_`.^2Y6'A.F!AY#KER"A8,?1?B](YT!T:M1Y1OK#GHNQ!\C1UJ`(XH,U.NVX=FMD8U^H8UR>#2(H MI@\1Y2TS7`\ZPU&>^F+Y'*)ZJ\C"@1[X2P4+&>)E#'V"P9( MR+70L1O18DHR6A?E<'L*V[SYL5QUQ MNR%QN]=$U&]M&5`4I;86BRP!1`2T^L(B,E?)BT/B"!7`>2/>`7T3'0+`W2'3 M+2(8^$`.)Q/X=S`X,;-Z<9'1="J/^V/[H79+0+^2$X*B.!X>`U/\N^#XXE1. M!G[:&8\Y`C5';*1L"V)[N:BFM-")0Q8HH7XCN,@1@JL;\G MV!-4OG7@>8%TPV@,2=VU]_IK1_T+D&'`NEZ063X`8G7_(`BH$LXU/]7/K"N2 MC$+/AG(]%1\ M@T<)_4?],5U]CWKCB;A2,1K0!*>3`$GZ1@YZ)WUQMS'.SB)"`/B6'&-0'M!T M-#X)IH,3:#ONC8?^2GR_902'`W0=3F@5)R-Q1NBP%4V@]CH8!6/H@.M3F&>6 M`1S[!=C+.TF'XT^&)\'D]!@:8W`LFENN9R0,0J11L,+<=E"9/6&T43XKXO[S M'_]+AZDU-%X(\+#S[!.99+!6@][QE'"HPE&ZZY'NN*1,+/(%T!D5G+Z`:%`M MC%L@(*ER;=H[W3_A>Y!$HV%O>D)_.@`S-#KQ4P8\=">6M4/W]()O2_$@@.9, MM.DQ-A>ZH:)LM0'2\_X(M;.?C+F*N(_A\(0/CCL)':LD&H\TSM,,U'%?PS\.2@ZG.B!A9T]T_]K1GS/`& M#UKEJ:!3G>C;G\8,>$,.9GA-J1E5H=8MSI,0-OPP6V4).JW4ZPA,/B'0=3:/ M$CY6JYB>:]KF@%CFOD$?YQF,G6E, MV@2MI/\Y_&\?1>P8,AZ:ST6K9!$W`W4[5'+3I90[5?)+&G@\.`Z.IWVK>$?3 MX'3DZ%R&%]V*EC]W)V'PIV:8R.ED'!SW)\(@402$1J4:6*BY[V00C"9#<_.V M$`WZX7T5<%ZTWB39%CAD'H.44:02@3W)8I:JL#/,`-K-%4\0;AB![CX7T>G!CK#],3[0D%4L-26%WN`A-T[&UXH)U%E742QC+%*?DF^9Q"H&0R MK\\>SN79PX4$_'0T[,-2S*@8%@#HO0?%IB#(4X=@SFD(0S`0U':B^2QU,!P= M!Z?3"=)]Y[84,G#Y*I^_R%4N1V4=4B;V829YEA0970DP@1#_\'#(EVU4"AUE M%$Q.IJWT,@PF%EF5=W$9"F41Y4_QC$(<,TH++J$)\$^<4Y@9+Z2F'%8'[WC4%GM0NUNYT=;%;FKOI=/$C0<-QSX?1@0.&_%Q3[:VVP?=M-V96VS3[D3N M1BRO=B(GP7C:#TY/T7T;@>.CL0PA$_R_CV7P_]=M#N-`I5NCPS@\WHEI)J#: MG"D;^6K7>*8_Z#.]-J'.FQ2XFI[?-`YATI,=O833JW%]H&^3;#BU/;'%"*<( M2X?EU*3TLP?['[?R'88^Y``$:`.DD!4BYE\BD3VBDB%>`!D&.:\P5%+(OU49 M'AHZ!)QK0UP`[$KAPX)G$CMF&M9FXN$W64RW->2J@)RFXH6)6)@QJNZL%`Y[ M19G/J.Z2K:#+*_W;RT08U8E0I74RJ'7"GBM1,F&_&P(5)>*0/$%[W/J^E"L>V8@=>2YA&O./%*7UC8\[5V&>9>= M;#7J%S2!CE:V9C$)FPMEW>2"H;9=#&NT>:7O?>&S8@6;.T+J"N?N%K$+(TPP M3\P'9*F8[HJ;5U%"-SR68!HCL0CZB5M?02W`RHWO?U9++B#U+)TQC_.6THMTXN4G-A$3'/G`X MJ"L4IWC@<0;]H6PLXNENP/_18AIB_5!CA[HB7E39,.)(*S;5*Z_3VBH4$SBFBQ MP"06:-N@Z//J$--Y4.HQF855$2E^$O.QG6HG):_#W1AE/=%^',*7XHI8HX_XV M%AK84+I&!18=\ZGJL$[MPIIXP!<3^LF$0?;H;F/*HV`T&`3]X:GXJ(._K1C? M[Z[",`A6'MIG\/G<9[X:X\EA,!E.@T%_A#^-Z"FR6LPZV@D`B_#@-\Z!P97>6[!P&<2=8770R8 M<X#WXM`A,*X:Q1$>MW2OKG)_=38C/C`C]P5OF\.2)F380A?,>F-A0:_V M%$S"1A][#SWQ@.E9C#CIV;\.7M`CU:+0N8+V-A@7!"!#J19WU1S+4[TXZ`H8 M!2]`,P#=_<\U-98Y*325UBM,G`B'HD@W9?>TRA"@(C\[BJ87+G?@7VN<;?B* M8C0PIG<#W.1H3)51$;;A8!H<#X<[V,D$^_"#KHDI62@U]M8PV<&D-SX5UH)P MNA7=TJ8U.A%E:M< M83L=>^`QM7B]-7?,IS936H!*FYX&X\%QU]DC\-VY/G$P!F7)]WS[\(*/9<\^ M?">\S$.%Q5MVXYFL5A?>?=Y]X3[OKC<^89WLM!=>>S8FC-_D10+`0I[-+.RY M!-E^XIOK=^%S46%"\WE4/J/9I308J[*Q^5FUK``>'%LUCGMC=`.P8T;C\_X) M]B0A^4A$HD6<6`?E8QJ;%S(%P%8L)H@AI$6*V9`:09)5F"STC1F(5D&75RL+`2@UD6#M,V`B M$<[(GYLW-#6SW:,FIPI<*>+1Q)QI=*)<%WF^E>BRY\8D*GH/AX[=%+6]2R:: MEPQM^6Z&"=88A*)\.OI$@!H'/@Q53B3E7SXF\9(1&3T9*@!A.##7'"2C]53@ M63)'F!@:61-G9$SU=`8*?9\T7+,DF+$E7X(SD]@0%,@GNMGZ44'(`4WN$B\6 MA\6;!E:])XX&S&`-TSOXC]K>>TSQ78LSYJH!@#R'[$P\?5`35]DPT46-Z#JH MBRWLWN'P0=XU-4DG+%0&DW=*2E#4NMM%0GHB(6[!H0:^2SW9^";*\F4<.@\< ME#!@-I@*&`['ONK$015Q8=)ODFTJO\W*7RAM$!KX9*:$K'O]&X]L?E5GMHH+ MX;U^^(C"X=I@/E]Q1G[*$^\$6='/0/']\HW.1"-0/3C"",QF8R]T,Z'5S3P]6% M?%\!P!KT'X\F!D/Q'N=`!:IVA`0&R(#LP_ZASO1$<*"WC$,!TT`#T$P8'"?/ MVCX%41&#"I323-@AZN1=5"0++61&8@G%>:W$XFG2J`5?B\(:3/`R0\!9.JJZ M-99)[;I&9CQ6AT1\&&1J71VE^PS[AZ$Y&I?D]7T64?1SH9@;24AIX'0-*ZH4 M4VS@#[`6C&R4J+?FX1HP(N77%13:HUQI8*5Q@:*BPFPLM M1F#Y#I5*PVPE:(ZXT)".UYFE#&R&QTJ*Z::5+=B`DX4FVHYIZ22)IC@4J7^= MZUH[!%J`$7/G,U"Z!K\X9@H&L#J[IDH#HB=.B0%RP--;W^@[V7(&2SBR6E<5 M3BX"G+Z68DK#M7GD`\_O;<4NQN0#RF=C9$V%N0UZSGQ[KA-U7FG08[`T*KBE M*!8(:\MYT-<8\W8CKIQ$8T28*-:XBKIQK=L\;5POVPVK<`VK#W\,JSCLD5@, MH#S/?0RN;#.X0AE2/ M,HQS)[NODT.%]AJ`#ZV-J`,!)Y^]#0D(3]?O*Y;&N`IMX1RW9Y>9(./WF$?A M;&4VLH!&LYCT;$6F5`F5!_P=[25`#C#&J5YM;/"JJ30BK8^YQ)NBGZ.&.<7C M=^PIVT3W`85ZS]#R&,-Y!(4T>,0E1!P/H+S,ACVE%YR*P,(8TSU)9:$''NLB MFE."=&$11P+N)06@S`YAPY0L%A*L1Q-F**+TP2C$&";*^P6!A2W.,N1_I>9`4&1<+N,5YOJ(Z= MBD(B6#U5H+GW#Z/E-MUO6(]/,J'D_4#05)G>E-BR%<2]3R8GQM+H-A/&0\;L#7Y5>4_C509(^W46-A7SODM[% MHR?T!$31/3VF$G1[%V#N"R(JA6PYEI"']&@(1+5@+L/+N=SD.:@8GEF:"M*J MQ`,.Y]/K7<\K,MHA`OSP2ELV@'>3!H1A9967\A M#^,WVO$1.P3/3N0'&PWMOA2',0S%*EI%*%\LHS7;>5=#M-!3-$G#YE MR1/J"9W#1[#'6-26F!CE0C&Q(AQ54,T?0R5G"TK)LJW\"?-2,/*QV41AXJ-V MH9-8UOCB(:$'P"XIU+TLKE0][:--(P.J.AKXD!RS`0(G34I1NS:_BA)REIVG M!(56@FGT[#YB19MARZ'QZNBU:K3FH[5"\3+*'L"/,F$S![Q#91Y4^1KPF52-$ILSA4GZ4;HL5\ATSU'X M,SFI^B4/Q;N,O:\PJ92!'[TO#C&&&(#P$IEL$0%;`F`#\HJ@$/>)7+NF)'0. M.>)=`&\=Z!\0S].(T'=KBK4P5]1$`*LO&`$1NP4D<#D6*]'.\O@1S<@CL`)5 ML0)-C\4?G.\HL#LQ&7E^5,A`(U4G@P$8YZ.;+=37!9:HT*MR*V$PZA;,&GJA M-F]$^=XM80Y;C$@X]2^HA)6./)@R3CWY;?8,*\WIL41"A1P4`V@]`<>F?&[2 MBDJX"8)2RK%:6D!Z:H[)3X9W\7:!'%X4^5P[OH6E.R>WZL'/]0+NK;KP,C$XA[O@1-PP44\^ M*LK6J MEI!00"N=^\#U?_2%C7+?B)&$JP'92Y#T8*DTO-\HU+I/]<'37GN5PN;3$-`* M7&-MWE$@U;B'\#-E.N5H^F\X9R]"[S"@6&X"`IBIY_T(^$J!4`C5VBP[RIY5 M0M3#^;?.\%QP#H:#/_-(`&GRECH#LEC3P]Q\&6+ULW4&*\4K)!"*^#%6Y=B$ MKMUV-.(GVZ23G<(#.LD*=\4E2V+EV:E"[/1`127$'8S5NP=B6*<"9*TVCUZN MJ)=%L&4.=4H[SNF61/3".X1%V)^:81HN<0;=^;6771!(MYO[]_\2KC=?7E)4 M&+D=U*;.7@:B\GZUEIZ+YJ,:,T)+[T`#)GJ41.ZS:D(B3N_9%970UBMB-B+S M=.A8H"F4D_[G^A4OLH2N!VBJ^U)7.)Z`3R%5[Q-00VR%2BBD160)8P35OE:@ MAZM@ZB)1PLUDPY=B,/+?N+P=/3-L)*:I+'_UY"FF:UFW`*B:U+X!K]5BQ?MV M4]:D)S^:)*EZ,Z?ZB5=%BM2J,Z?'K/8]&89?$4Q1X2<;?G$K`IGL%/_]@:IX M2T^RW-))=DXN"XM/0PISY,YC4RW_6$$)D$62%`VSP*EVFLV,OL!WW"&%X@&3 M:)N;SM^B:;`(3`EDC7^;C\)$._^J71M!M\5X].,S+@C@<;3*ZG`>C28EQB=( MI2EI1P!K\_]#CO>1_\/Q1%R$Q*B..4:H$*UO`SUQA:O46F@`Z1_`R.W'@7&R2KE6AITH]]2*H M0]GFZL4-2Z]0#R=2M"*JU"T&\]&,VZP=?LRIW";WH,@Y,I*J\AJ[I=1N#8\6 M=0H=YURYBD9G$P<5JX!4SQR4*K9`HC:H*3PVK=.2,EE#!6:".EK0NR`F.#@= M\4O&`Y.\254^IIPIF8*5=]Y0-C:H\F,Y8NKOV]:U5(YY_6/]\$BH79`"]>N* M=&V#KL"L*@9NQ=H*F#SKZ#D`/L?3WNCS1BTYXG%14YNVR&:+8M>U".P5+"B! MB.(.(3X1RU#!,5I`A0;L"%#%"]'Q599B+Z";&IC^;)YQ-&L.MGQ;BZW+11J2 M?4;U[%N5I,*:DE51T+.ZZ"G.J@+-"Z@'H5G-5*JQV+%QZZ96BU1MEK*PAN'IJ>U(YZ'L%,KE1XP6E+9.) MVN#%LJ&<(%:KIYDYK_[:*]LY918"KB8)>C?&KYU3('C!-DA5]F3W4UGZUF=\ M'05N&X6+7BR+)@\_H(XO&D7(_UO70NND2F<'14_YWKX*\UY5W^F*3^Y?`VAN M7@!YS3G5>X_7VW]48OO_6(FMJ9/P=3R5%7)/G<*K3VW?6[7ZHY#;_[M";IU? M\Z%V!6C!UJ/Z6+!(7.KWW[7W^'J-:F>M)_E'A:W?N\+6#@%S-"?+&IU,EZCA M-]U^46S"6?3GSZ@"1_X4?;:/_/U1OXOJ=\F]2HMTFLVVUK]%*WJ6Z(^Z(ZW5 M#3H/P[SXUCLG['I!0?$K>O%][V2H7SG/YIW%J;.\J;WV_M%_[7WCO/:^L"^] M.U?TQQOT/]Z@[_,-,/+(*4KF?:/WX25^JZC[Y9.O^'+D!F1HGWS7MX9_W*L& M_LM>V6NW\8"IJ!4_>=:CO7,*`.U:U9)'<'.WBJET+JKQE_/HV6<4J:Y^A+8Q@5>.U`V5K'Y)8^=(*4Q!NOZ MCHD;,-]8L'M\*+\W9[VH8AJL*.-FTS6@[/A_E[=H\57MTT(^8+A>?4O(W4(:/=C-=1VU4_]N^K:J M$=G<>8#X9K'PZK_294"+PL8"I^)/?\(2IZ_>XH?G;(\-J@+(/,GDE9.TC"\I M@OL[C'.=50V2_IYAN$Y;W!'?:GYSY/&X$62BZ%<3MW0'PQIU!-NE\Q7AL>9= MUKC7;X;#!H/6/[='U.JM^FU=]P^PN=BRT?2H0U-Z$&DG&GI5!.D5.%=WW85X M6^(T#36],SBTL[4?U/G/%YQQB=EQBN`AFNB'7T>"!Z0`W(5?Z?!*9<,X`:I= M"*L>$JK';6;=T21UQ)T(K-VA,862,`WV1DI=@N)-TN M+1H.-Q:HBY_P$G<1^GZO[U1NL$"S!%:CB2Z')_UR>*T5KKC*&[Y]<"O`81*% MDZL!:_*KF#6_LJI-I74'KYHDO]>UU+RVIJ1:T\GUBJH1"77AN5WDLWMNY:W. M@E^_PBFMEJ!Q59DI"O1\1UG0W=/*L\:LN_C'@JM:Z9UFY2]Z,O52HB^ES_P6 MF=HI4IXW7/_PQD\+I!IG\R?^GD1@S;,%/BJG]Z>["-*>7[PC?46EK7EI=0V3 MSG=*WW%*I5UH(.],5M.]D91Z[TFKK=^G)R9$-7O>UC)Z^-M@7\SEW8]2`"L; MZ=/PMYN4$^-A?"\QX+)[_*ONA$HG(?BBD1!LQWE;%.77_Q=02P$"%`,4```` M"`!W00I'=FR_J:H!``#P%```$P``````````````@`$`````6T-O;G1E;G1? M5'EP97-=+GAM;%!+`0(4`Q0````(`'=!"D=(=07NQ0```"L"```+```````` M``````"``=L!``!?&UL4$L!`A0#%`````@`=T$*1]N$Y_$^`0`` M:0,``!$``````````````(`!6P<``&1O8U!R;W!S+V-O&UL4$L!`A0# M%`````@`=T$*1YE&PO&PO=V]R:W-H965T&UL4$L!`A0#%`````@`=T$*1RT/$CUD M`P```A```!@``````````````(`!Q!<``'AL+W=O0!^/S7@,``%<1```8``````````````"` M`5X;``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`=T$*1\!?MZPP`P``/@T``!@````````` M`````(`!J"(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0# M%`````@`=T$*1Z\Q<;>3`0``<`,``!@``````````````(`!HBD``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`=T$*1PH^I#*2`0``<`,``!D````````````` M`(`!S3```'AL+W=O&PO=V]R:W-H965T MJYX@5E0$``'`#```9```` M``````````"``6$T``!X;"]W;W)K&UL4$L!`A0# M%`````@`=T$*1P.(0V&4`0``<`,``!D``````````````(`!+38``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`=T$*1SPD M1427`0``<`,``!D``````````````(`!NCL``'AL+W=O&PO=V]R:W-H965TF!RP$``*@$```9``````````````"``5,_``!X;"]W;W)K&UL4$L!`A0#%`````@`=T$*1[\S%.7M`0``K`4``!D` M`````````````(`!54$``'AL+W=O&$"```7"```&0``````````````@`%Y0P``>&PO M=V]R:W-H965T;!]QZ,@(` M`"P'```9``````````````"``1%&``!X;"]W;W)K&UL4$L!`A0#%`````@`=T$*1_69:M^?!```#AD``!D``````````````(`! M>D@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`=T$*1R#PN>HB`@``&P<``!D``````````````(`!M%$``'AL+W=O&PO=V]R:W-H965T`L0(``-,)```9``````````````"``:Y6``!X M;"]W;W)K&UL4$L!`A0#%`````@`=T$*1W?J-#*# M`0``-P,``!D``````````````(`!EED``'AL+W=O&PO=V]R:W-H965T``!X;"]S:&%R9613=')I =;F=S+GAM;%!+!08`````*``H`,H*```5A@`````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free interest rate 1.64% 1.58%

Expected life of the options 6 years 6 years

Expected volatility of the underlying stock 104.00% 114.00%

Expected dividend rate 0.00% 0.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 15 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Common Stock Warrants
6 Months Ended

Jun. 30, 2015

Common Stock Warrants

4. Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2014 through June 30, 2015:

 Shares Weighted Average
Exercise Price

Outstanding, December 31, 2014
 5,470,995 $ 3.67

Granted
 — —

Exercised
 — —

Forfeited/cancelled
 (100,000 ) 4.26





Outstanding, March 31, 2015
 5,370,995 $ 3.64





X

- Definition
Stock Warrants
+ References
No definition available.
+ Details

Name: galt_StockWarrantsTextBlock

Namespace Prefix: galt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Common Stock - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Mar. 30, 2014

Class of Stock [Line Items]

Proceeds from issuance of common stock $ 4,532,000 $ 28,178,000

At Market Agreement

Class of Stock [Line Items]

Aggregate offering price $ 30,000,000

Commission to sales agent as a percentage of gross proceeds 3.00%

Shares of common stock issued 1,279,416 217,622

Price of common stock per share $ 5.49

Gross proceeds from sale of common stock $ 1,196,000

Commissions 36,000

Proceeds from issuance of common stock $ 0 $ 4,532,000 $ 1,159,000

X

- Definition
Aggregate Offering Price
+ References
No definition available.
+ Details

Name: galt_AggregateOfferingPrice

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Commissions as Percentage of Gross Offering Proceeds
+ References
No definition available.
+ Details

Name: galt_CommissionsAsPercentageOfGrossOfferingProceeds

Namespace Prefix: galt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross Proceeds From Issuance Of Common Stock
+ References
No definition available.
+ Details

Name: galt_GrossProceedsFromIssuanceOfCommonStock

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid for commissions during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForCommissions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=galt_MarketSaleAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) - shares
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 11,428,358 11,299,127

Warrant

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 5,370,995 5,450,995

Stock Options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 3,192,325 3,311,029

Unvested Shares

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 337,935

Contingently Issuable Shares

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 2,527,103 2,537,103

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=galt_UnvestedSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies - Additional Information (Detail)

Aug. 06, 2014

LegalMatter

Commitment And Contingencies [Line Items]

Number of putative class action complaints filed 3

X

- Definition
Commitment And Contingencies [Line Items]
+ References
No definition available.
+ Details

Name: galt_CommitmentAndContingenciesLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total number of new claims filed pertaining to a loss contingency during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name: us-gaap_LossContingencyNewClaimsFiledNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

XML 19 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Galectin Science LLC - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Jan. 31, 2014

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Investments in and Advances to Affiliates [Line Items]

Equity method investment in Galectin Sciences LLC $ 400,000

Loss from equity method investment in Galectin Sciences, LLC $ (67,000) $ (337,000)

Galectin Sciences, LLC

Investments in and Advances to Affiliates [Line Items]

Equity method investment in Galectin Sciences LLC $ 400,000

Subsequent capital contribution $ 172,000 $ 159,000 $ 93,000

Equity Method Investment, Ownership Percentage 50.00%

Ownership Percentage 67.30%

Loss from equity method investment in Galectin Sciences, LLC $ (400,000)

Non-cash charge for in-process research and development $ 200,000

Galectin Sciences, LLC | SBH Sciences, Inc | In Process Research and Development

Investments in and Advances to Affiliates [Line Items]

Estimated fair value of the IPR&D Contributed by SBH $ 400,000

X

- Definition
Fair Value Of Asset Contributed To Joint Venture
+ References
No definition available.
+ Details

Name: galt_FairValueOfAssetContributedToJointVenture

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.12)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 11

-Article 7

+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=galt_GalectinSciencesLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=galt_SbhSciencesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation
6 Months Ended

Jun. 30, 2015

Stock-Based Compensation

3. Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:

 Three Months Ended
June 30, Six Months Ended
June 30,

 2015 2014 2015 2014

 (in thousands)

Research and development
 $ 226 $ 221 $ 543 $ 860

General and administrative
 574 524 1,191 1,534









Total stock-based compensation expense
 $ 800 $ 745 $ 1,734 $ 2,394









The following table summarizes the stock option activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:

 Shares Weighted Average
Exercise Price

Outstanding, December 31, 2014
 3,332,617 $ 5.79

Granted
 304,000 3.45

Exercised
 (95,574 ) 1.80

Options forfeited/cancelled
 (348,718 ) 4.42





Outstanding, June 30, 2015
 3,192,325 $ 5.83





As of June 30, 2015, there was $3,492,000 of unrecognized compensation related to 828,596 unvested options, which is expected to be recognized over a weighted–average period of approximately 1.67 years. The weighted-average grant date fair value for options granted during the six months ended June 30, 2015 and 2014 was $2.78 and $11.38, respectively. The Company granted 304,000 stock options in January 2015, of which 76,000 options vested upon grant with the remaining 228,000 options vesting over 3 years. Approximately $173,000 of non-cash, stock-based compensation expense was recorded during the six months ended June 30, 2015 related to the options granted in January 2015 that were vested upon the grant date.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:

 Six
Months Ended
June 30, Six
Months Ended
June 30,

 2015 2014

Risk-free interest rate
 1.64% 1.58%

Expected life of the options
 6.0 years 6.0 years

Expected volatility of the underlying stock
 104% 114%

Expected dividend rate
 0% 0%

The following table summarizes the restricted stock grant activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:

 Shares

Outstanding, December 31, 2014
 416,670

Granted
 337,935

Exercised
 —

Options forfeited/cancelled
 —



Outstanding, March 31, 2015
 754,605

On March 12, 2015, the Company granted 81,352 shares of restricted stock to non-employee directors as a component of their compensation. A total of 77,784 shares were issued to seven directors representing non-cash compensation cost of $280,000 which will be recognized on a straight-line basis from the grant date through May 20, 2016, when the restricted shares will vest in full. A total of 3,568 shares were issued to two directors, who were not nominated for reelection, representing non-cash compensation cost of $12,845 that will be recognized on a straight-line basis from the grant date through May 21, 2015, when the restricted shares will vest in full.

On April 8, 2015, the Company granted 177,618 shares of restricted stock to non-employee directors in exchange for cancelation of 222,615 stock options. As the exchange was made at fair value, there was no additional non-cash compensation expense recorded in accordance with FASB ASC 718-20. Additionally, on April 8, 2015, the Company granted 71,378 shares of restricted stock to one non-employee director representing $236,975 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full. Also, in April and May 2015, the Company granted a total of 7,587 shares of restricted stock to four non-employee directors for service as committee chairs or lead independent director representing $23,500 of non-cash compensation expense which will be recorded on a straight-line basis from grant date to May 20, 2016, when the restricted shares will vest in full.

In January 2014, the Company entered into an agreement with a consultant that provided for the grant of 3,000 shares of common stock. The Company recognized an expense of $25,000, representing the fair value of the common stock, during the three months ended March 31, 2014.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 26,362 $ 29,128

Prepaid expenses and other current assets 305 533

Total current assets 26,667 29,661

Property and equipment, net 1

Intangible assets, net 12 15

Total assets 26,679 29,677

Current liabilities:

Accounts payable 775 906

Accrued expenses 1,065 729

Accrued dividends payable 68 68

Total liabilities $ 1,908 $ 1,703

Commitments and contingencies (Note 8)

Stockholders' equity:

Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at June 30, 2015 and December 31, 2014

Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,402,500 issued and outstanding at June 30, 2015 and December 31, 2014, liquidation value $1,402,500 at June 30, 2015 $ 567 $ 567

Common stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2015 and December 31, 2014, 23,788,913 and 22,277,283 issued and outstanding at June 30, 2015 and December 31, 2014, respectively 23 22

Additional paid-in capital 146,217 139,531

Retained deficit (128,930) (118,925)

Total stockholders' equity 17,877 21,195

Total liabilities, redeemable convertible preferred stock and stockholders' equity 26,679 29,677

Series B-1 12% redeemable convertible preferred stock

Current liabilities:

Convertible preferred stock, value 1,740 1,731

Series B-2 12% redeemable convertible preferred stock

Current liabilities:

Convertible preferred stock, value 3,431 3,325

Series C super dividend convertible preferred stock

Current liabilities:

Convertible preferred stock, value $ 1,723 $ 1,723

X

- Definition
Undesignated Capital Stock, Value
+ References
No definition available.
+ Details

Name: galt_UndesignatedCapitalStockValue

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=galt_SeriesBOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=galt_SeriesBTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation
6 Months Ended

Jun. 30, 2015

Basis of Presentation

1. Basis of Presentation

Galectin Therapeutics Inc. (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.

The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of June 30, 2015 and the results of its operations for the three and six months ended June 30, 2015 and 2014 and its cash flows for the six months ended June 30, 2015 and 2014. All adjustments made to the interim financial statements include all those of a normal and recurring nature. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2014.

The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At June 30, 2015, the Company had $26.4 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes that with the cash on hand at June 30, 2015, there is sufficient cash to fund currently planned operations through September 30, 2016. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Immediately prior to March 23, 2012, the Company was traded on the Over-the Counter Bulletin Board (“OTCBB”) under the symbol GALT.OB.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 800 $ 745 $ 1,734 $ 2,394

Research and development

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 226 221 543 860

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 574 $ 524 $ 1,191 $ 1,534

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended

Apr. 08, 2015

USD ($)

Director

shares

Mar. 12, 2015

USD ($)

Director

shares

May. 31, 2015

USD ($)

Director

shares

Jan. 31, 2014

shares

Jun. 30, 2015

USD ($)

shares

Jun. 30, 2014

USD ($)

Mar. 31, 2014

USD ($)

Jun. 30, 2015

USD ($)

$ / shares

shares

Jun. 30, 2014

USD ($)

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost | $ $ 3,492,000 $ 3,492,000

Unvested option 828,596 828,596

Unrecognized compensation cost, recognition period 1 year 8 months 1 day

Weighted-average grant-date fair values of options granted | $ / shares $ 2.78 $ 11.38

Number of options granted 304,000

Number of options vested 76,000

Stock-based compensation expense | $ $ 800,000 $ 745,000 $ 1,734,000 $ 2,394,000

Options vesting over 3 years

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unvested option 228,000 228,000

Consultant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense | $ $ 25,000

Common stock options granted, shares 3,000

Fair market value of shares | $ $ 25,000

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options vesting period 3 years

Stock-based compensation expense | $ $ 173,000

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 177,618 81,352 337,935

Non-cash stock-based compensation expense to be recognized | $ $ 0

Restricted stock awards cancelled 222,615 0

Restricted Stock | Non Employees Seven Board Of Directors

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 77,784

Number of non-employee directors | Director 7

Non-cash stock-based compensation expense to be recognized | $ $ 280,000

Share based compensation, cliff vest in full date May 20, 2016

Restricted Stock | Non Employees Two Board Of Directors

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 3,568

Number of non-employee directors | Director 2

Non-cash stock-based compensation expense to be recognized | $ $ 12,845

Share based compensation, cliff vest in full date May 21, 2015

Restricted Stock | Non Employee Board Of Directors Three

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 71,378

Number of non-employee directors | Director 1

Non-cash stock-based compensation expense to be recognized | $ $ 236,975

Share based compensation, cliff vest in full date May 20, 2016

Restricted Stock | Non Employee Board Of Directors Four

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 7,587 7,587

Number of non-employee directors | Director 4 4

Non-cash stock-based compensation expense to be recognized | $ $ 23,500 $ 23,500

Share based compensation, cliff vest in full date May 20, 2016 May 20, 2016

X

- Definition
Common Stock Options Granted, Shares
+ References
No definition available.
+ Details

Name: galt_CommonStockOptionsGrantedShares

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair Market Value Of Shares
+ References
No definition available.
+ Details

Name: galt_FairMarketValueOfShares

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employee Directors Granted Shares.
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployeeDirectorsGrantedShares

Namespace Prefix: galt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation, Cost Recognition Date Latest.
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationCostRecognitionDateLatest

Namespace Prefix: galt_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_VestingAxis=galt_VestingPeriodOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=galt_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=galt_NonEmployeeBoardOfDirectorsOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=galt_NonEmployeeBoardOfDirectorsTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=galt_NonEmployeeBoardOfDirectorsThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=galt_NonEmployeeBoardOfDirectorsFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 26 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued Expenses
6 Months Ended

Jun. 30, 2015

Accrued Expenses

2. Accrued Expenses

Accrued expenses consist of the following:

 June 30,
2015 December 31,
2014

 (in thousands)

Legal and accounting fees
 $ 255 $ 118

Accrued compensation
 377 604

Accrued clinical trial costs
 426 —

Other
 7 7





Total
 $ 1,065 $ 729





X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Undesignated stock, par value $ 0.01 $ 0.01

Undesignated stock, shares authorized 20,000,000 20,000,000

Undesignated stock, shares designated 8,001,000 8,001,000

Series A 12% convertible preferred stock, shares authorized 5,000,000 5,000,000

Series A 12% convertible preferred stock, issued 1,402,500 1,402,500

Series A 12% convertible preferred stock, outstanding 1,402,500 1,402,500

Series A 12% convertible preferred stock, liquidation value $ 1,402,500

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 50,000,000 50,000,000

Common stock, issued 23,788,913 22,277,283

Common stock, outstanding 23,788,913 22,277,283

Series B-1 12% redeemable convertible preferred stock

Convertible preferred stock, shares authorized 900,000 900,000

Convertible preferred stock, shares issued 900,000 900,000

Convertible preferred stock, shares outstanding 900,000 900,000

Convertible preferred stock, redemption value $ 1,800,000

Convertible preferred stock, liquidation value $ 1,800,000

Series B-2 12% redeemable convertible preferred stock

Convertible preferred stock, shares authorized 2,100,000 2,100,000

Convertible preferred stock, shares issued 2,100,000 2,100,000

Convertible preferred stock, shares outstanding 2,100,000 2,100,000

Convertible preferred stock, redemption value $ 4,200,000

Convertible preferred stock, liquidation value $ 4,200,000

Series C super dividend convertible preferred stock

Convertible preferred stock, shares authorized 1,000 1,000

Convertible preferred stock, shares issued 176 176

Convertible preferred stock, shares outstanding 176 176

Convertible preferred stock, redemption value $ 5,660,000

Convertible preferred stock, liquidation value $ 1,760,000

X

- Definition
Undesignated Capital Stock, No Par Value
+ References
No definition available.
+ Details

Name: galt_UndesignatedCapitalStockNoParValue

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Undesignated Capital Stock, Shares Authorized
+ References
No definition available.
+ Details

Name: galt_UndesignatedCapitalStockSharesAuthorized

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Undesignated Capital Stock, Shares, Outstanding
+ References
No definition available.
+ Details

Name: galt_UndesignatedCapitalStockSharesOutstanding

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=galt_SeriesBOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=galt_SeriesBTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2015

Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:

 Three Months Ended
June 30, Six Months Ended
June 30,

 2015 2014 2015 2014

 (in thousands)

Research and development
 $ 226 $ 221 $ 543 $ 860

General and administrative
 574 524 1,191 1,534









Total stock-based compensation expense
 $ 800 $ 745 $ 1,734 $ 2,394









Summary of Stock Option Activity

The following table summarizes the stock option activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:

 Shares Weighted Average
Exercise Price

Outstanding, December 31, 2014
 3,332,617 $ 5.79

Granted
 304,000 3.45

Exercised
 (95,574 ) 1.80

Options forfeited/cancelled
 (348,718 ) 4.42





Outstanding, June 30, 2015
 3,192,325 $ 5.83





Weighted Average Assumptions Used to Determine Fair Value of Options Granted

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:

 Six
Months Ended
June 30, Six
Months Ended
June 30,

 2015 2014

Risk-free interest rate
 1.64% 1.58%

Expected life of the options
 6.0 years 6.0 years

Expected volatility of the underlying stock
 104% 114%

Expected dividend rate
 0% 0%

Summary of Restricted Stock Grant Activity

The following table summarizes the restricted stock grant activity in the Company’s equity incentive plans from December 31, 2014 through June 30, 2015:

 Shares

Outstanding, December 31, 2014
 416,670

Granted
 337,935

Exercised
 —

Options forfeited/cancelled
 —



Outstanding, March 31, 2015
 754,605

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Aug. 07, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol GALT

Entity Registrant Name GALECTIN THERAPEUTICS INC

Entity Central Index Key 0001133416

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 22,788,913

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Common Stock Warrants (Tables)
6 Months Ended

Jun. 30, 2015

Common Stock Warrant Activity

The following table summarizes the common stock warrant activity from December 31, 2014 through June 30, 2015:

 Shares Weighted Average
Exercise Price

Outstanding, December 31, 2014
 5,470,995 $ 3.67

Granted
 — —

Exercised
 — —

Forfeited/cancelled
 (100,000 ) 4.26





Outstanding, March 31, 2015
 5,370,995 $ 3.64





X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Operating expenses:

Research and development $ 2,600 $ 1,594 $ 5,736 $ 4,366

General and administrative 2,057 1,781 3,761 3,853

Total operating expenses 4,657 3,375 9,497 8,219

Total operating loss (4,657) (3,375) (9,497) (8,219)

Other income (expense):

Interest income 14 13 28 17

Loss from equity method investment in Galectin Sciences, LLC (67) (337)

Total other income (expense) 14 (54) 28 (320)

Net loss (4,643) (3,429) (9,469) (8,539)

Preferred stock dividends (230) (245) (421) (485)

Preferred stock accretion (58) (57) (115) (115)

Net loss applicable to common stockholders $ (4,931) $ (3,731) $ (10,005) $ (9,139)

Net loss per common share - basic and diluted $ (0.21) $ (0.17) $ (0.43) $ (0.42)

Weighted average common shares outstanding - basic and diluted 23,731 21,983 23,398 21,570

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.12)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 11

-Article 7

+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of accretion of the preferred stock redemption discount during the period.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockAccretionOfRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Common Stock
6 Months Ended

Jun. 30, 2015

Common Stock

7. Common Stock

2014 At Market Issuance of Common Stock

On March 30, 2014, the Company entered into an At Market Issuance Sales Agreement (the “2014 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2014 At Market Agreement. As of December 31, 2014, the Company had issued 217,622 shares of its common stock through its 2014 At Market Agreement at an average price of $5.49 per share resulting in gross proceeds of approximately $1,196,000. The Company incurred commissions of approximately $36,000 resulting in net proceeds of approximately $1,159,000 as of December 31, 2014. In three months ended March 31, 2015, the Company issued 1,279,416 shares of common stock for net proceeds of approximately $4,532,000 under the 2014 At Market Agreement. There were no ATM transactions in the three months ended June 30, 2015.

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Loss Per Share
6 Months Ended

Jun. 30, 2015

Loss Per Share

6. Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:

 June 30, 2015
(shares) June 30, 2014
(shares)

Warrants to purchase shares of common stock
 5,370,995 5,450,995

Options to purchase shares of common stock
 3,192,325 3,311,029

Unvested shares of restricted common stock
 337,935 —

Shares of common stock issuable upon conversion of preferred stock
 2,527,103 2,537,103





 11,428,358 11,299,127





X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Stock Option Activity (Detail) - 6 months ended Jun. 30, 2015 - $ / shares

Total

Shares

Beginning Balance 3,332,617

Granted 304,000

Exercised (95,574)

Options forfeited/cancelled (348,718)

Ending Balance 3,192,325

Weighted Average Exercise Price

Beginning Balance $ 5.79

Granted 3.45

Exercised 1.80

Options forfeited/cancelled 4.42

Ending Balance $ 5.83

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Loss Per Share (Tables)
6 Months Ended

Jun. 30, 2015

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:

 June 30, 2015
(shares) June 30, 2014
(shares)

Warrants to purchase shares of common stock
 5,370,995 5,450,995

Options to purchase shares of common stock
 3,192,325 3,311,029

Unvested shares of restricted common stock
 337,935 —

Shares of common stock issuable upon conversion of preferred stock
 2,527,103 2,537,103





 11,428,358 11,299,127





X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events
6 Months Ended

Jun. 30, 2015

Subsequent Events

10. Subsequent Events

The Company has evaluated all events or transactions that occurred through the date on which the financial statements were issued, with no items noted for disclosure or recording in the consolidated financial statements as of June 30, 2015.

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 37 0001193125-15-283901-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-283901-xbrl.zip M4$L#!!0````(`-T]"D>MN;OU^5D``&6A`P`1`!P`9V%L="TR,#$U,#8S,"YX M;6Q55`D``S&/R%4QC\A5=7@+``$$)0X```0Y`0``[%UM9-TCOCQ[\_C2'IB:18F\8-__]>/_R/+TM65Y"9QS**(O4B_^BQBJ9GIUZ]?3](TF#_FQ$_& MIY(LSU_Q2]&[,TFB)QB?J`N7KI)I')Q)9.$G)V5>#K=+`?3C3,(*TF1%EPFZ M0?0,Z6?8_-?BWND[B#.X>3[SX M1;*B2+KBK3+IBF4L?6+!R>RASW=I)`&GC__H73_5R+N1J9IGHJK\UO#+%$QTC=UIKCC]=E9N.K) M<"LZ_?6GS]?^(QM[6]Y[V9UH-[MP6HP#@G&8-PG8VXM$CS+F MGSPD3Z=P@=^NEF]_\**\U#'X@?EY&.>/('(3-LU#/Q.BPU^E4*(L]"U_F;!L M9>?$E16]XST*\G('9SQHI\7%TJWAREMI<6LXOS7+)^EJT/P*[P8J=\,'`<_3 ME]5M9A=Y,U)I-DU34.-U[6975[#,GOW'U8WXE14\Q1[0OKJ%N+0"4Q@_L2Q? MW::XM@)1%OIKB`O]%>^(V0.H?[!6[,W3-(G8Z>RVUU;3\>H609Z>RC*6.PD(%_0R/T#/^8&C'$WX:I M/_-_*:(#:1J'Q3MF%O'VYVMW(`7,#\=>!#(.!B4$B0J#6ZJ96#'U6UUWZ5#5 MAM`/79%5:VC)AJ:#*+HCK"++IJZ);KGEO$6#CZK"__?CZ6[@"\)F5O1L^.]I MF+_\Q/+')#@7JL)]Z\77&%SD8SBY9*D/?WL/!W"VR-$")Q/HRR(9YU]&^]%! M.!UD\%$YT8",G8$5?("+.!O&.30!ESQ.XNL\\7^_?O12EEU,'5!CQMWM"?W?QWP9]C4F0M0,H4`8?B:(L6H758"HF M`*Q^\L+8-82=<%&(B\U#:QZ^71.@0"ZRO7AID-TGN18O7G23+OR3Y M;PS0^?-1GFM`^/W]0K<*:INI:BUJE\9'2!Q\1-E3MFU(U/%J- M*I48*@H&\)M2;1DF53&6AVD_)5)=2FVJ4)G"T,JJ-G)D"PU-63%CF3%;\%=$T4R]Q3$4VF6"=A'M6W31^&C5-83UA\J`*?@W0WC8 M,&%507J;AI'RD>*39$)-_5MXT?1P-:I58JQ4B`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`:'2N&9)5NYIO^KI_Q7+.*AUN?0 MNPLC:,8R1^2TY1W"=50>)[A(UC3#@/F(AF33M&Q950U'HZ9%\,@JP@2BEZ%N M15$96=]/I^\#+%\-4JA6'MAUW2^C7+C>/YE%!("9BE$"MM#CM99UG^ER%SK( MTR+(NN!^Q9S8#9_"@,5!!M['NXM8]Q)8=Z3PX",MC].:OB^/62B2SC*^7`"P MP,*RV&]<')^S\"P.HP^#'+1B;Y3J:RYE1B40J+QJQ'IL*"".QMM)2 MK(&PR;OW5,T(N#J-ZAOF!"M432R6OB.;#Z:DC'`S@$W#^#G\]S0,1/!;7``% M9*V.[7).;UT+BK<&;.O1E#FX8KD7QBP8>FD,1B<#ZJ;CJ0@-7'8?^F$/S:P* MTUT98<,DY1GO=BR5"2$GZC&)`I9F10YP_[!J?,:K&Y4@;KGG:^,9<"CO`B>$ MJIA2W5P7Y:S$L>2%>%%*_\,$&%-=7W(_*_I>QG<>P^3K(83+(FT_^\+RX;,? M3?E\[%.2!%_#J(=3+LK3]4I8Z^"HC*RXK[<#J@K9K?C:4I\[VCSNSE/57*?F M:>:JB5?.0!M'W_YFXB&R9-F$$,5$,J((\\U$0[85E\BZI3L:!*.CH>[.0E-* M:)FR/382"_'KGZ[HJ^Q\T=FEZ&SBA<'PF8\Y`_1%:-=O2T!X6856C;FWX5A( M2?@Y#E@6/L0\:)FM0KV'#0B^4EHN)ZD+I`;V+\FEES:NKLWOTA)-[-*B+0R\ MP5DL)2JF+$X4QJ'O13=IR.U=UJD&UYQSP>1#Q72A<&A=UVN+=6]7Q@E8*T-1 M4%VQ7ETYMZY-"QZHD04>LKS`L_3\Z-F3/UY,' M94@M3%4B:Q1K,N@!!M%W+%E#R`6G;5(;N47B/.BX#J]0FLA>V96<=SG&W8%'L]SB,2!PI@DQ\H0(FATIV5J=9\;9X@@'%Y$Z.3U*(;-IXDJ9>^ M%,-Y>%H`YXSH*J^H5L`GH):"!%%-9?)5NH5DK`U@:J`^.![J$#I1ZD!?FSFP M\NY#ISE=CCQ/*"@IRQ9$&^'/Y_/6F"\&GL>S1;'+)!4*EQ?'=/`%PIL$E(J3 MDR81!-X/YT`3O&??^<(&QAK>O!`R@_C6%%4V\=8`%1NI7KE!TA5Y!ZH<%BJW MD;Z5\':0O3+!,&'=>[EE=W;V7GX1"LG+P_5*?L'.4+MS302;6&_'0(G#?S#/ MMD#*1F$YHGMJ';Y:%_[17%3K%."Z%+PC+U4EK5DO5?"F\86NS;R]3R]5D[P# MQ8YNIZ^77JHF._MZJ8(8=)'5:VT]=+%U63G7U=5"%; M&I](J3O(UG87U49.!D&8U\RW5^"-YR8:YJ]&.6_A'19XJTMT-5C@C69'2Q%" M,$7Z.R[P7J:IQ=0!W+,"[WUEI"[8PPJ\&ZQ!;ALH3W;B=@0;QZ]!;AEK?VJ0 MVQ[4/UX-\C[&;L\:Y+F'T$YT\P]1@]RVM-%:)J3]&N2V)RH4OGY;<=8.7EMQ@ALXRTX_+; M+G#R\EN35LJ,CU!^VX6+5/A>$ZV:WF.4WW:`EI??EJ5W]_);\$@3EN8OEY$' M\^Y8)%Q/>*P`3?N'6*MF9&[J?G-UQEU87J&DM#)O7%]GW,IYNNW#Y/E*)JKD MH'=5`ML!/GV5K>VF!+:+H(\7XY!JS'?\$MBVU[_[60+;\3[6(26P;=6(MCWP MO:L1[6(&_HYJ1&=T=%,C.O^^I(KX>2#?:D2WCTG[-:)XON>D?JL1W7=O\!@U MHJ_9)"?TX$\SME,CVES*[1O-W52NX?[4+'8/O5T.J6Q^]-A2M%N[ M@7M5NW,$]#VKW3D"`ZW6[K1B)MJOG\"S^HEF2_RNO8A=W!$ M8LP)H411UWQ:=8=%PI&M8@N9FJQ3K,BJ;9JR@368VNG4<8GK$'>H%#:4+Q*? MJ(L9H&N0=;6<(;Y*F)W'\-XPV4'GT.WZ3ZWOK'.U/JPN9L4P@3$0T7`7:QEE M:M[S@"Q\1Y-_JE%M9X#P;`E0UW5#/=8`;5@MX6FT-# M2*LFI'7S9ZF/+JVC)+UG8_=Q;06E\EGF^I8(PIZF3U?HF>=V)% MNAX4L8RJ4W0TN_$^1V3#Y[P;'"'A075^6JW11"%N?^UZ38[WYI#G"_Y)PI`M M5&)507I+!D6X4)Y+#7/T/W8<4I/DO4FDK8CK/L>_CKRPR/*QLFPZ+FCG26`^ MN-8;EH[1#MP9@CUU?OQY]7A;A]HC>T1E6S$<626.(MO\H%MC:!HN1I9N#&E1 MBW9)?VO@8-NMR"J9B'$>!F$TS<,G=LW\:2IRJHNL6Q:,TF3,WS_-Q>LO[N<9 M]/-%D&)Y:'^R=M175\=#W1VILJ:Y7-1T*ELC,I)M=TB=(1Y231D5V:@(8=-$ M>,&_-(*T(6NY:I"NPNSW4FA"I%_IS6A`FL MB[],]Q>6\R3;RS3A96.!_?)SQ@/ABPE+/5X49ODPMD5%BZ@2F\)OLXOP_`:X M;/KXEEM>KT*5RDKL83`K5;D5*8:1"'TK#ERN"+NLX-?AI':.C6G8R*7#D:Q: M0QO8(8BK,94QO)VXEFH.5>-6%;6=LG*B+JPE;L'3[)$&93]I7E M(Y%9[_QT'L`@=$*:T-[]Z"F/3>7VTO'K"_M1SN@(JM>$TO[S#M M!ZU%SS)W_[\D$3PF@N"S)=^R0CCK^19^;/0):F))NC[^#@B?US?WC6Y2'.G4 M,MV+Z)<<^7GL)V/V.SFD.@PI(57(-%9&YLX.$%A93M;'^8#W0+?!P/=Q]/G$R]`V M6>]*O6/A\[*;Q/)!%5+6!^VN.K'/+NX7''TO18%/6`RD&Q4. MMD!9$Z?,#$$O%1Q"W/5!RKSCFZ3[]6RBPB2(,TY%`#">>'X_Q5L!/3#8H40C5JD;_`)R5L[C8)(6.BDOPWY$P)>`GK3$_TOP_ MXO<^,D.*`U(7#N:J`:0,_1.+@9.(WQ.,PSC,7[=!M\ MI:<:/Q\&LWK26L:\U.&TX^GR"T?$S51A`+*0R+L::(28K- M!&CV3X\O-^;SFN9^RH+&%_P-_>U$C?IX%O,XIA/PJ9P@+WJ-R2YBAY?F@W\% MVUJ.V_I(!:\U4PWCC8E=0?4H#X&7FV!--T1!KZ;M_@WC6GD):%9>@C6B(X6T MFIG0&SHU7=\]B[!>FH(%C^(#U'\..OV34'FA3,TE[H#$'S:NZ*I_UW80Y8.&9F_@B MO?'F9;)[%*.MR:93C9'AZJHC8X*X*"-5MBS#D)$ZLHTA"#/1>#8C3_^&I_YX M6NU(;],'UP&NM:.+.D\?Y+S>I![/8[A^&=\E.QPON@4PV+FYN+G\XD99+_((TNOMS( MU^?_&IY)Z.V'D?73^>??SJ2;<`R!]!?V5;I*QE[\@S1[Q,W%Y9E$)_E@]IJ; M1R;=)U&4?.6%[:+,5X+A'WN\)CJ3\D>NP7PY&+K":?E:$"9YQ33G!1YQ#XY` M@EDOX]DNWWOCR0_?/5O*#P3]3>)6"YZ1)M.'1^D?TY@M7%;$9>V,`SV=[(,: M\Q\6<2EON-Y>M/3\&;Z)DW]?K17GY9Y2E<,K+%M7`<; MH8CWEL5I"_A*B\UM9_V=2=9IY,8`];KS72:3&V?V;CX%M-2R MN$N3.E*RX_WKKZJ[^9(H60_J09G`3M:2R.ZNZNKJKJY?5?4'@Q5".`NG^5^F M.RHNKB:_]`??X07R^%GXWO_?[]+MUU[_*WPCP5=)-SFDHKA&KR_IU4JE9F\9 M340F0C&A[QNB;LDB6#@;O1Z$SY$[_?6:_?^A%TG)N^]WHQ(3$QZ"P&JD_G@R MKJV5<0I2!N5Q3!G>7Z066UB>_>SD@TOTA$-M&'6A>\?Z=97LMLW*:E96'5?6 MN:RC--O#+T/$9/G^D5=4%>>MCXHLBW#&WW6V_U8'(O66:IY(G/.W':OI.P(/ M%Y<%-_7HE4QFY_WD=EX)Y=M*]4$[//Y)__#/;:(XJ[R]GO*::L#C1)U3M8C;9K2)U>%TBP33X9S]*5>(]_J"VZSNY?7<:TQ97-\*D4DN"5=8V^LN8/ MZ%%>..OH'Q)6)L,GN:"AV(MG0CBF_N74_=RX@K=T!=O;NX*MT[F"#]YUXPHN M=Y4N`2^H9LEYKGMS5O\7\N#Z`K!+<-F)#5%78\+W]&.:^CO:OJIQV;:]HM@G,NW/RCNQ M7HJ3$]TPAS`]N@#O>U>E60?!29P?H:9\JMNJ6JOJ5,A]+_"&H+5GD> M'5];[^VFJL1+U?BIJV399>T)-"-0[=;%&]D"3H4(U.ODKFAF`\B[YP@@7,JNE]-'$A.E]TQ_$Q[:P7$R\ ME*'Z$'&\JM&3[8XN66UM(.F*J4J.WC$DM:,[EJ%82M]TWIZ'6ZO&PTWA)A*= M0:&[>*E8'T_W(`VD]ECH-(V9EFBH?>&R-/&%"Q&38F$6\C!K:(4%6HCKPAJXB0B\M&E\)""SQ4.SX?M_JKOJ\JQ+VM[NE5U[?WJFNG\ZHW M73=8@K)W]_>FE[I\OT\BD@,3_`:[ZR3./O>#$8M4R3G72^$'M<<:E'+GSOMY M!KQI9+<<"7+9.)>J,"QG2UTS=Y>_\E>R3='/!X!T9E>_S<7R/A?+2?I::D&- ML@2V2T;-F=[$JO7R[.]%J?)&*#5T[8U0:IL[AX=7![)H]'EM42>\:@-#U!;J M-AQ=?^^+T3"L*F!ZM8*E&.J;(UD1E7;MMK']B3:T`\_TI<5.7PZ8IN%?P[^& M?_7E7W."OK@;D?6YQRC4[E77]='/U[M:F+LG(*N9+6WI56`.ZT"I(EJ'/D^> M#:VJJ+6;L_.;Q0PV'&PXV'"P[AP\$5:1X?=6@!4WJ/R21R*F%5\$ZG,ET`(B M-=W@A1.NRDK[H16$)I64?9/U>EH+^G47) M@2%[`?52--T6K=WSS]5"K/66KIY(K&MUAWTY_N,#R.#!GZNAS[O^IY4MS,WR M4M*UT_B:J+1545,O.U>,T;*K@+-?O,J_)(='_97^>3AIG!BK))2K.Q'=,!$1 MGMU8>*^).J@2G%1X?AY$9!@^!-Z_R`@:*X3>_1=!:9F6\$+<*&Y13U32BI2\^H!7+\((*[",72^"!F`2Y^BR MBI)QLF=@)*-Y1'U8Z++R?@J/-/!:(!AOO3?ODU2S%C!_K'_M,-YF[TPJ<)9H0QU#+Q<6@@ M>93S?3Z%B6$$/WNS"24D(H^N%R!9*DP3G5CV$G("7L-?Z`QH"1N=`H/?*Y:6 MR$,0!M+0C2=(^ZLI29`=.,O1:!5GH945O&6D:>2A5Q"8/")^:\$_FZP/@:\/7%!Q/'_D75+FS6%.&S_IEGY2 M=7L_J;F]L[*RIMZN'[/$=^G]Q$9S7KQCI=RH`8E"*66-^.R=4N*8XRNYXKYT M._\/+_ZG-(X(@7,"<`+.`P(F#3RJ;5\R&7!>U3^\SZT, MP??&)"D+QT]3IYYXLR5G;="3]ID.XM(50RHD3R&8%YC]]"41E3GL@9'_@N=D M:MZ<6F84^32Z0BGK]D)5Q3R?CCF7-)4=E7#KA421#,TPC#-6R.:X.0]DT._! MXLPI:@X7E%QEI&`$6Q$U0Q5B:I@Q1,[2M<@LI%`1\CCUPQ="A)$7D>$LC&+! MA?]1N$@8@)''[UTI*B>/(6D)#K2!V8/@`$@!*T6$"I9>QI;?J[9,H2T450.M/'N^OPA."F#`F`L4Y4/R MO8`(]V[L\4#T(K3D*@T^!Y:^9`Q5V4V-B7@H$BS=)''"L&^$K0@>$C2>^WZ! M#9IHF/8*+LR>PXP#V$N(Q.`S03B#_QZ]@`)I$/,4$>(C'BD,Q')>+18 MO/Q*H#2_M@[R:R!\35$L2,0J\1<"ZT$;Y>51?GJCE>IE[UHHL%IYT M@*B1Y\_1Y7-'AC!J++?9_SGTYS#0`4@D=C&?T1Y^'_?="-&Z\3<2T2Z<1RS= MN7OYR7G@L;?85%T+(S+T'ET__O7Z]NM@J3QESU+[5F^@2X;1LR3=L$S)&6@# MJ=/KF]V^VC<->8#5.*]O%$57;QT5A7H/$6Q2,Z89%G%=`U[ M<7*XSGR:;\U1N#>DU][>4;C&MUC5]R?KNO%1EOLH2X'`.13M99<<*W4U+G.@ M*4M6MG375X$\356R.E](?B$/21$75O(<3XAC0HZ+_L0?=\W2:UQV#*^R>UJ* M2_+;K9?BY$0W7*Q@7J=K=,VJ2>*S?0DUY2K2:K\Y59T*N>\%WA"T]BSRX%^\ M;3Z^MMX;I%2OXHF7XY!_,WO"[W@77[MU\4:V@(.0N8'\Z@VTY#(R4;TM_IT# M-*=!\BS7:JJ+D:R(LGG99K*EGBJIW6C$`=D#AL>>1R2^#;ZQU%;'\N_V>RJ\:)K0 M;->0]('1EYR!Y4AV=]#6;-G1.[+RPY#QG^L;3;?@/0#AC+,CXGWJSJ,( MGA]X\=#U_R)NU`]&/81H5.785;JJJ2JZ*?7:=E?2+5N5.JK2D]1N6]<&M@K$ M*^C:1C'5KF^@>572E'_[9=W@BH)Q2Q.@43#`;>`$(V?TA,"G^'OHC,<@6/!" MG`E=[NGJO=AZ#[X?*(XT,&Q%T@T@V[9M6=+[MJ/+FMVV[>XJ+W;!;;OHATW^ M^"R,8:C2V'WT_)=/2V?F7[]1,][*!J21\%3G_0/BUQ>.R4K$4+/L,(B M0O&A2Z2)2)OPD0'1LNN<[F@!Y0"O"K%#YCCK/[%^&N\Q^Y8=P&PY;P,=\%_+[0.@6I(8H(@3_4 M"30B3\0/@<&/-+E:].`&WE!X#(%*6(&"%TR\>X_BURC<[X&3+VDL.V"$OJ31 MHQ=XB"5CP&2$-2%/$!0)/\P\A"U>(?1RZL$1FF*<&)I*>`^:A(*D*(+-2U<[ M8L[&>$ZI3H8,K>0&39_DD>4>27,I8K\I*`O8E,-WB?@Z-(+Y!KTQ$.IA M+K@0^!>7L@5[@,<+7+W]]@?]B/_U"OREFBGR[N>S='Y:V6Z,;,%D@I@T$,>P M#-XJM%S2&$(_Z8,4ED?G(WV(@I5I>D7.TES/M\DD%+%N2">*T(2"#EW!D#\D M`?@H8E$\\:999B`>M@\3*[+9"V";PE1\4S>BMR%R<%WW@SS)>:D M*!MSEA(P(?&1S"9IOLS4$YH;Z9^8Z:3TC=SSXKKZ;+F1%-9"AL)T9PP[C@Q% ML9S?Q]`9%>O1/^9\YTN2.P[=***)5YC0P+'RY&*2 MPYHG.@B6!7+N&7>9UH`IBG1%+*\'U,0K5P3G2:IG'A_)R&/I.#G*BZ6V7%@CB+PM0K9]$*Z`Z5JN M;.8Q$=PGU_/I'D\1W]C5%#4Q@W%F[2VL[W!*4`O"'&7`4:Z*8MH,3+@W%O(K M!T[Z)*9!"/",%]%YS0A%F4;YPRK1R'YH!$:`JA$[B5`R$:[JCF=<5KF09PP]+2;P3.3V>,)/=*EW\(]=]VBSPC$&6<:B\XSKB+\.MU)J(#%$Y&J M-CSHXQ/(WB6^IE04J4ZY2L,`7-P7YOZLJ'=RM'#I>-_6&$SWO6*TZ4!8AEN+ M90H.",E#A)?(O'K'"1U[$>B#(OTL@2Y-#`L+'OY<_#G!-3+I2-5T,:_N*F(* M*QA;2'4_"#-";3!%<$Z3>K%@6BWM`RJO\JRT=&5G2C%1EW%*?LFFDH0]!?0Z M%14"U2&X,<.J"3!@!S4G._N@G@2AA0-:`41=U$6)+%+F\EZ*3P1D1K54.BY, M]\7S[:Y.#X'CFH)=%J5ZF<6(\$`.CJ@!C3N,]6SB:RF MR9\#"O^EFBGKKYRH=(VQ8*J"`&>A`/#M`T89Q.'0H\HUS75;BF6XPS,7J_S0_VA M7M]\4_ZR?U-Z&0>/2W%VC]`+A_/'U%9/'@9YK+,6O7+#0'"#IW4I2LY)7JDRR1=#* ME!5<.'EQJ*N*]>//N]X/T*8_EB^@U&5P?=?I][I=6](,HR?IO7Y'ZAAV1^K9 M]D"QE+[1=FQV_:1=WV!!MBTNGZIC3G%6!G!V^SL>W;*PD`-I]1Y/Z MP`E)UP:RY-BF`>PQNHK65Q5-4][8A8U1S84-SI_P]^3L/?`"4.1PBJ1W(6`Y MT(49U^<")Q]8-<%8.Q+-7`P$3`C#K9',J'$B^-F-=FJ8H3TURUDD+6&0_EW( M-`^&^1>\*A`4V,6G_!,&Q?JZ>K>N-W6A-]8!M5!B?K['4Q,T\DIGS"2A9XALM-P\8:&' M].H&C>L@^?PZ,[1E9LR#17;PT7H!/P4QLPQ.ES`7,W@HQ$A*/LXK&HKH)@(F)UTI^X+LQX9SAH])U?OLOBC7(&.F(7W M+UKW(V;AL]_B"9`H(9^A$3CY@7JE5*`9RT+8X:3,Y()&D;(YX#(^(?ZH*,U, MNE=4E(`&5I]]-SD6KMT+*O(2I7TXV;QB-NL!&-VWW+CX8R_'2+J%3V'\^0U; M7SX`=LW.H`-GOXZ,3A.M*TL=/`K:_;;=4Q7'LOLFVY;DEJR8>@7.HDWI7Q4I M2%N]7^SXCS2*]P[C1^%(O_#-G\"4V.&I/`\46ZC:CM6S-4.R@'&2WK4=R9'[ MJC30'5WI]67=5%=N\DU.5*?)B=KD1*U1M%>3$_74H.DF)^JE1U(U.5'?7%Q1 MDQ/UW%)F#U5'VR&TCWZC0-U]FQVQU!P]N2< M0"O]/N9K?I_-W$=?$/T`%*`.O'2T#QMS$#!M]!;."$2O$E>%JI_ MXTB?W8CZK#FP=]60%^ID#Q%3$<4\"2R=FXB,211E&5&YFRC+QH=/CK*9R^:- M35@"XTO)8$@GI!+=1DOT4\<;A=9AFDD8LY3D!41'T7A,AC.$^R[WM$T:S?J6 M&NMQ9J3Y1*GC;QC.?10/E*CI/$+>SI(YS0D->BQS2Y!)C9=YLIGD,+!XD@*: M@[`2]Q\N"]9SH:.H?WA"S,HL#0FF[,O0/Q6[MP M/T6Y:K(6J6++;;-4D:L#^YNG$P;3EPC M=Z5[QL(]4/%B9NE2IG9+2Q4-U1(567L;.PR0JQV,W,9I>JY.TX9_]7DKNG/L M$*BU)14WB('*>^[3R*?,U[IMY-.:4(6K=TWD4[6.6'E[1VS[=([8@W?=.&(/ M'71UGO0EZ3"RWGEB#.PVYU)-PBL$FBBC"GY<^MWZI0:A::*F87WQFM3XV#$3 MN]&RSMBC=#P9O]`X.UG'A&#UD."]B6WI9XP(:"(*JY_QCVU#-*R=R]/M@ILZ M_@U=RVX"H6L3]EB)5&NZ+5J[%Q*MA5CK+5T]D5C7ZLKY1!".:2MEW'XZ= MT5FYOAF[?DQ84N?"4"I.Y%Q2*:O6V9R-ZQL\T5:8S7E+#E4\/TG;ES$[^O4- MFM$5SLY6_%F8&]0&MW$\)Z,>#2]G#3`'3%Y5I/>D]3@".:*:G0N]9S]'9?MW]H/Q2L MIR>W=&TUV&.!GFHK+JY-_4Y__/_VKK9'<21)?U^I_@-JS4F]$J[VN_'L7$N\ MSM9>=U??5,^<[E/+@*GRC+$Y&ZJ:_?47$9FVT\:`J0+*4$BKG2[`Z8R7C(R( MC(P'P?S2QK.OQ,R*8`O`2_7:VB,LXX[KW>MW M):77`[I569;:6LN2NBVYTY)MNVOV]3>&B&#M!Q&AR^ZHW*6W3M8,N$?@@V<` M'>`K//PW-7QNS[&;UE_NO'$CM!U9H<1+*2FM@3K,3&^#E4Y?+#L8:P% MP?ZED`3IQ*8.->I&[X3:A\2@S\)=0(0:R-UKXG"(V-SE'EY^S_":PLG$I7Y` M!,B`#RYF>+/V)TV^EAO`0!_KXQA`GS=E$`#TWPP8$481YGO-F<';V)36T>7F MM7:D)B+3$48FH;X-$2-B[&(#(2*?@1\R!#M$?7"Q40]!3(B,AV]Q&@RU0>1U M1KF#3T\2P`C\]>_7=]A"Z,X=@=='.!S(X/X/#JR%"@Q\3[%%$XG0-&?.DC>` MR5-#8&+)E%!P1!R.P1WA5^7UG M3'*/&2E7S)^-:MV&,K,D1@X]#*7I!@77$J@S6PE\V?E*: MBFT2FMA5'I/%"T8(%CT61%3VO$8/9R^]HD;YV!%I\TL3`+ZMK.6P@\"&!O!L M_A!S\+5^.C`Z#JP-WCY6/PZ(>@74ZI$,'%-C]KFU)?;T+\8UB6%+'A`$TT^@KBM7K MZYKZQARZUOX<.BY0WBLN)]1Z^WCIQ,AWHZ"$K<-&UW?`"+='64>\'FRSCPS0 M]I/S%,,RC0MNW_#%#J"(T=5Z'D97QYT_8=.T?RW\99E3B*2T%_>+>)Y]:V8> M(YHUUIF/&N:-B`W,^%'3/M\A="FRD!//SV"=L+4I_'4W)^REGL=:.)`Z+*)Y M"@6:?(&V^HO[Z(R=52^3?UX<(^]B.O<.=IY;0=Y.,,GXM@WN$>RZ4:*;#&N+ M8->Q^=R#XT]HUT"/!WZ%LGYZR!JRC!&VB9HV/GDQM9T;<63@]6C.M#4-$RDP MO/L55O/IY(6DMA(TJ/2CSK)!EB+UWXNB4U7!VX<1"[SCW!>1.8$>CADS<30N'L/B=!($8X6\1+3?M^9AJ!6M@B;XKJ@;3M10Q MGEQ<86QP_,6A\B"UR.HIVU?3\?%7PT3KLFLQL.,CXADY7#C?AN\2C#%[R)M, MWL=_7VEJ^)76LBOZQI_@/YQ(V&Y"P@1K,T55;-LH$PKCYXJ,#=&M80*Y^EM1 M)/>L;I7ASJ=<$74)W(L4]!E=D`GS7J[^EAGZGG/#E_.Y023^]5?!HU_AO-_<]3P%8DUWHMO M_YI\O&X&Z0^X;CQX,=N&,B:)YIS6+=.H$DKY5[EW88")<;8@XU;BWJ6?)(XX M&QE!XB(,&^#/:=[:H&ZG-I9;V,HV*+5`5W^K&)@FIN@6[%[.7U>9GFI5;5&! M0-]W[Y-^JP4CC"JZW@P+1GB5_X*<,#,14(->C"][)6L$]X%'+V0M:.]<>BJ; MKR*_'_X]P[P7EGH:`J?K6]-7YR+^JJ@.2,9=O]OX;0&NH2(/)2.-"!ECQA`S MT8$M2@]B,51QUC,5)DO>$HNZ$C[A8`CN'-S'"!Z/^-Q@EA$#/M`&6>(01 M>3K,6@%-%K3$2P2%/&;=#*8_9.P-W4_[CBL-D)RV1)PZ$MPGJYS+=\3D_ MULF'J8O`1R90C#B9^"K$[R&04QH1$B<"3X+!%@;O,66O<]%RW3!RX*,9>C#VG MXXPC3N99,JOE<'N/"SO$!S""3YG/YA\&A3!3-=>%F65N)[MG>1B_\S98\4T4 MHHZ;&=@1$NM&-I%NM-*&_JN#`*%>L*)/Q);44`K?P8:9^N*"^T%#9'MN8?=K MDO3QM8A&^^B"<',^8.[";.I>"G9LK;G-[!E3YL38Y39)4.#9O)`Q47*IVC5N M;^KZ.0%W.[+M/^E7+E'AQ/ M4J:;?H%=)5X5RRX9I=PJ>%5ENX7H425I'>Y3Y3VJ5.4$-?,S[S!-BU;QM4H] M+7B6^UH%1YQ=CD$+:C<='F539 M!!C'XJ))6B=AX;V_.2E>?/7(A=Y=_&5@.(]>_MV!W#%_(FH#RL%2PS#K5L8.-VM`:@YS-$ MJIZGUBA1J3G"3/_EKGA$3-4$IXBY-8)3@_H%Q`>%$8ONAX`[#AP;XGQIX\C6`XK"102'>,[Q$:)92"2"R2FL8!"VJ@]S@%/51Z*]*>6/"9KPFVJ@H*;YW;?%D\WZ'0^D*NL'[I:!OSH@I];]'*YVQQC#54ZV?+M MB%(3>&09.'10'>>=!FZKRATGT+PQ/^/,4E48F>_L0.52584=//EJP(UR6XP; M5W)'.:\KZYO#O4N>6XL7P]C]OP7HB[],\H]>%,]YP<((79L2EZ2X'/*_%.2: M6#>>+`+*T]VZS,@TN>WFEGM*108,M(>9?)I$T>@/62XIR(6?9$]1G$CBW"&( M'SHWC2%"\YTH\]A80BO+]Y>SN?'>_3&"0$?<5/.\3/!\.-%BN,^5D^^F.(G" M?DIV)'V>)D01#?$M=R)0'E.F2@NK+E7:S03]/0E_6.K@>>8[)X]S-]]KM3Q< M"414-8GI-L8KW++R@$6(%?*2HX`HIXSYQ`I.%!/0T2,P-7DVIYPP`A4H`0=! MN/<\Z39_8%FYR*&*;[`#,=-7K#Z*4O2P--&?3K!X,,11O7),AD4^@2GE8MIT M`'Z0DB?AS]#+/"6@M32`;F.ASH/K1,R]?'#]\6KR2%%6#RK8UO)S]J/WWM^S M/WAXS?>+-28@F]":TXQ4"+B3OO?$%[!-AQ^+;!T_"PES60;@3_(*?.`?^(ZU M+RGA>3IJ,F?+3FF0I,Q'I<+"6?S*$R&-O1Q:BUSVVD)_U8B\77+ M#749W7SP1`\X'G,/\2=L?%>G!IEFU+WM[`ESITE?+4`HOR26J!$ MM1*+\_YQK0!F3I1$G[`)0?""A8/`E`4N,+"9/->Q_AVP'TJFLVGP<;EY+M>O:LXE.HJKKN4,]@$)-^Z_I"':=O=GQW]REO&[RI4!AW1: M^V"WIHQ1E$,)%VB5HP85Z].V$\:QA\4NB(Q'Z'Y)61I6[\$(HC/'BJ[0-&+A MHA>@+2,':>RAKP@/TL81N71>%;.:1B`"]B^66\.J*WSKGXOQ/?-A2!40&RZ" M89ZH%&M.58\0A47LP.0Q]!_1>(_=.28=`O*&4[>I)&]/H(],&5PGDK8T/D7WC"/736'+;:!#Y>=8PJOZ<+9@>1_Q M!!])QR7*X"IC2A13%6I3@%?DG"_,@1]MC!=H@7*[$YEB-O<`Y#UV'UT_G%$F MHP.QVZN$MXNO&@(4',;+9P6.%)ED\XAQ509(N+H($Q',&E@R#!R0< ME1IS+,A]GL+BO""A-&E1T*CP]++AQLG/45T*:P1^ZJ0K"'FQ<0TU184&:<6C MR!OB!C\$';ENT#49=MKL!>@;,AYE]*2XI/GD;>H4#UDI1^)^XW<"(<6Y@7L0 M)S,37L+C-%SOI#7)=+/Z99Z>VI0P9'3''#4RZX$;1D+:#K.S+8A4<2360&9(JFCEQ=`X&0C3W8B2FB4XP>2%([8D M1X1:#"9Y2+8L2=*Z*?AN$G^BZ6.V"GZ7U#([K)29UP_P#`RM:S16PH[%`G<, MCL&0I":I0OGR;B6]V[M#B]<$Q=NI?R1[1AMQ@-EG!^H4K9BR.NC+LM1K==N2 M/M!TR;9T4U*-GMRV=;/;T;7Z=8IV0&D>Z1(I+R=B0D]@G9.S4;IFPKPG].#C M[*RXXSNCOR2024C)>GI.PFL+^)-I.';]ZT)/ZA+P;B>3#C]H`)E>>D,?'J37 MW+U!\]Z&>KN]FTOZ-7L_:(?+.A=_IGLBV0SZ&`<4?K,*+WN6)#9**;NH3\;; MM$U6?>=7TM;SW'N;_>;%?TD3S%A0H`QN%EU^?%;?I\I2VRX,Y=K4_^-5WFNT M2MY[:IU+-\N\_V/&TI2^-TGK![@W]=J"-Z_E;(REZT3/`0@XQB3.W3"D2O)( MYYA4^LQ5A2Z<^DM6]GULE,VR12N_CJU0REY[IJ:":I!07T/<92_= M2]^^Y^<%2CHZ#;?W+!JNZ5GT!^%5YSK9[`/:JUH?L(J-FHQW'RTSUXCG$%3O MJ5-6VMY)$&"RH/Y(K>IOK/#II6R>+2)W2R^LKMD9=("['1F[/VE=6>H@LUM] MN]53E;;5ZIO?873L7"?K>^B%59W^`L/3LJ0^'G7'^\^#R=UVNZ6U^I+:[0PD M798'4DNV%:G=DCM*K]>U#!CG;5V;5^3]W)O/A-=@TMLTZAYORN\Y!?[@Q,EI M'F8!?1_^8F7,4;YQ!B6V>4J;);"S]BYXC0#/O++N0-E9BE`93=E$UAZ$#ONP MR5`0-CSX/DE:8P)^G":=V3D>YNB%LL/"U872-[$6)R_HZ+%N9:[+?K>#N3?& MWF?>HYM=5.S_H%.!\2`*I\AP*A0-@]O)6KC*_75`DVW;Z+1:4K^OM26]KUN2 MW5?Z4E?5#461E8ZAV,?.@,L;$N`]SKRD5PQ3)7:FY_[P(%PO7@%W$S@Q=C27 M]:+C]V;QI#E:I(TM^(B\-0P6&3'99#6C(\?'LSM6F\>K`_C-$W9R^$2S><`Z MHB'>R,43=2F1.A[44/:<9]?C2\K\\"ES_?7@%`_^ZK>;4]T,-[B::!>N%+/4 MJY"S?L_LR7.`6\Z"'_H!^7'NJ:'_<2)J;TOE1[R;PYI>9D?-%.RNIR6($4W- MDIO@(U1Z_-5Q,5Y.KFX%]GJ/0G!@;SH/-TEX%F-6UM'XO@:,OAY8NQ.,(J6[+@"OVF0TWUS>PC M=^5-7S'_0W'J8D8M"0,LT.6%Y+/(G;@\OW2:2TMM&JK55.2#H''5DESM8.2> M&_C8!6_RPK_JAOZ"?7FDI?M2&P@NMJZVFIKQ;%3AT[+Y0*]JVTU%M2Y&?[L- MN2!.7CBX3KMWJJ/9UPGC(='1?B7DBYJ5TNCO/FJROEI+LU^JCU!*T^.E:74K MI-'>?92O]\+>JM2O.X7O3V=^N'1A?42/WLA=,P\?E@%?);^YH_`^\/X-TR!1 M=K'_ROX/XRVY)=NM;DNR+%.6]'X+--7JXIVT@=%O=\Q>UVH=^S#>W'`8/TCO MAWF\204&XQ+K0)3K88.=:((XN\J(=]TIVD\B^*3>NIG+`C37Y=(8!$!^A"=^ M#%.?`_6MYZ[[.$^WU1>>IV\XH5YWJ*V]WGGZY=67*H*R9U]^:FZ6G9I_0P"- M[-7'NN%W(MS!^X&OSYN+[I97?#SSAN'I4%=R/_&,J+O([OQ7_EJV*7H9W]Y3 M$6JXB,']/5YM5LU2S.>8P"X&*@>\X.S&+H(X\6Z?:1NQ9V7)7I+3^ZG2@E@] M2E3-2@_6I"#A190J;X120]_'P?`I4-HRY<-2>K'G9UTL\ZL;N$FW1F<\]0*/ M6CUZC\>]@[R[5U2RZ*U*+F"=%OV+25;?',F(87YRV]C+B3:T`TOZW,Z_SZ=H MY\*_"_\N_#M=_ET\Z+/+B&@;?>IOX9RZ`FP^NCZZ?_W<"%,^<(19&THM_:2N MIKR`4J5I'=J?K`VM:E.S+[[SFZU\O'#PPL$+!T^=@R^H7]YS;6:^!!0&\N+; M27LT0DPD+%S<5^FFI@\&LMZSI;:LMB1=[FA2JZ5U);DC=SNFT6^K[<%;ZZ"V MGP9J)#.\]?DUZ.X<1.,KE?QOE?@9A"2 M'(@GV#O?"[P1:U]V[S:&7CB#I3%U1C0B@=%P-&YLP(8/S6:L)ZU'\,B(0>U& M\8,WPTY6]RE4[<@CY!$Z#8X6]^*1,%7I1BZ6D0?NTQ6!D0`)B'0R(7B?813" MN[$1F^LPO._&"`$O(X*/@$]&V&EK3*BOK.U5"DZZ%EUG#E)P:6F"R--ISN!- MKA?P?E\P$,*=_.4N&PS)"M%KX>?`%#^\AQGA3&;._('_.5D$#/*-3>N*@0B" M"4!,%X0(GSI+UJ\+F>8QR\)ZS`%+&*X+\B$%PN(4LX9AHX(]PA>_H(/?(G`68X\54.-@+,#->N.MZXP'CS-PHJ3W&>C4?R\<^!M1VWY+ M(/L0H&O:0%.),*( M96`DR&@]NKS]"#W/%AV:MJ%+6:Q1TCD39Q4X5&/`H7H][+#82949&VRDBBBHB-(')H$`P-AZ=>DR#*U,_/F#@P0& M(?P(/-T)R!HT,D*57+AQ?JEBK\F1-R/=IS7)(0`1TX_V/71[%VXFY!!-K$L> MZ&3!EGY[OL8>-7D'S(R4<>,GU;S6&T"\STWQ(A#O[*#U8WX!_`-7&RP:5`LT M9LDJ(+1=V(SY!`13G*>-@QYRPE!1F$_"!H>W/S!`[$VS)\/2B!<(7>KAPJ9G M:;.A*0CHB&"[$#A+V!B2=7X'\BGJ&GN)>9V7=MZW<88,-R"A5QB:&4W:,-@, M4%@X-007742C!/;MQX.SH'9#8Q=!W@B,G'##LZ'#(=I`VBU2J\97)L/`=$8/ MR$>./DX2R&;2Q/T31DD<+=`Z1/J*T)#C;H8]3QOW8&K`F\(XBGKN^LMFWK5# MM8+IIX#FF4$6P!+6^H"L_9?"V"& M"F%LD[X!MB0(]4E+V\8=LO&*8&HY^#,^YX#YC>A1A0F-?ALX!+(I1BU?HU#Z MFHM%0(DPP&F*@0QWE?%J)W.,<"2V\,3!UH=+N<%`S3X[RVSYJ29'F%=R"//9 MOS]CS:OP>XV6JYJ'5QVZ]Z#?X-=P6-20IM'XTK[KM?^[T870!T^*8*B_W+G` MDW@Y'89^X]?VIV_7C9LI!]>EG7D&FRIY()7>CP+"MZ?K"$:X?70CB?UH@9MU MHP/;,@9(C4[H1./&>Y%[M]^ZG4X^?$RG"6.)$[WM5&EPO9(PR>=3OKAS$$TX M=3_!+M-.[/FWL$LW,PF\`6(P]!QQH-$>;B-[<:BKBO7]][N>>"E9TE8R,G:K MH_3,_D#2V_V.I/T?*\FRY M3>Q6-D0=2=>!_0F+)?W"0X636DT'SW46WER%LW^X)> MAT&8YT.?7V"N(9&M%2+73K\H2 M-GB2\^-JD4N]`TE%7A`H_=Q_=Z43'R3-0&*V%NZ26.$&?*U1/;5;!MFJR@;MWDS3BNWJ0@#YE27/ MQIWE[Q"?W02#)!)L@YO]2,V!&)3W`CZ[S0+2.NJ^6:+[+R,SS[*>.X.PU:.O MX-\^&1+8']K3,)I[_V;'`C5D#*R5?..B*H3D2><72_`WN6LE-?9[P''7+#._ M7+:0L'+^.;%'(+[3,/$+>+E15:==U7,H5JZ_V#5W2;PN1V,/"GEQT$U]@(@$-H6%I>P!N)8/3> M._[\9]I2$_"._7?SZK8[EM%IRU*O98&H>JV!!`-I("JK90^TKFY7+`DY.D03 ME8)4:R*5*P412D365H7HVZI"JA67,.>VP?ST1(;[J`K9?_LT,4D[23NF<0DO MIE,G\O[MQARS3FAQQON9-1SFP6`Z<0(._H:#KO2`HOP`I#Z-T4X$:4S>O3.: M_7H]P@[^ZI/OMG*@;C8,P>`9LST1^OZ'+@NYX^SM[4?PLN_I3HS0W*N?("U^ MC;R1NP]^G/[5HRT82AD:97.#77]6!?"K7G1OZJ>$&O;,JRK:M?E:O38?/!P;HPJC7747UO;::[+:7E7596:>XLNJRC@9A-'&QKO4# MW5WP_2.OJ'WX6^\566[*S[_Y_9Q6DD2^N_YZCS25T'/I]6'`?0P8/_ M[@3;AYR^I[1#E%THQ.0AMG%R)O_$@+F?'V+OHQG$V=O\<[H\?OI6?\.%]PT' MC^+)Y&(V\ZFRQ_'3FI_;H$LHN',/!L_7!=7Q\%U5LFJF9Q&U)Z@L/..?+V^" M>!XMZ`H(57M^>W`"CM*5!@`)4-=SN?E=461=M^4?\%]#-^V=D0=LMAJE07;=KZ7<*E%Y5<[5U^=R!YGZ2T3^=AJ::V= MEW"_I_?[/4N5.A96L?5E1;+;;5FR+;MMR(-NV^CVOINXA`U@(OF:I[S1?0GY M&U9FD.;O3T`4>W(W*C#C]#:T(XG@6/Y%V5[&W/=#K[T%\"MY;U)RP@M-$O6@ MPI(#"$O8`K[/W.C[JO!646_U5EONJ%U#`B]$E739[DB=?F\@V9K<5G55'\B] M+O-%P)!A[CH)@^K"QZ/(-J].M1/KZB9?7:QL1=:&?T<19_+&\Y2H?@R)[L3" M_';X0FSW]O0E]SI!*HIJ6"V4BFX8YLY['6QS?:LWT"7#Z%F2;E@F5O0/I$ZO M;W;[:A^\\@&ZS[2R5$.U%%G+=KR]T%Y3=AJ691V&G=B]`^](:*#[FFJ\#78^ MRQ.KQ$X-V2F_^VAHEFS;;X.=MF*H^F'8J:_)U!R`FWO/)BB:;6ML\;;4PUWE M`GM(EYQ0#GO*)^R#:-NPM<,1K2+1N,ST9^10%L,8E,>)EK<1VXL_N_,'O-F' MC3]*#7L@&5Z5OY=8_;XV#CL3+66(:Q!-%/39/5$PL M246F5"*ORJ5O[)<48F_$T^`%MOHJL&(+785M#=?4#;7A[2VB]%"*K:LO[A-] M]2)>F*J*OA,X!_KN)Y^#CJZV%=N0+%,%1G1L6VJI!OA-EMGM:;VNUNO+C!'@ M3P-KX67"/E2)MG+C,0@C-#I>'._F#%6FO[(N5&I M15:^(UC%!E&TQ?P:@>TX$U[H%#B9V?Y9C;B\7J`M9;V#[MU@M(3UTO4=;QH/ M/-\=?UG@E\+ MU#+UI4T4BTE':@.,GB;F+7.V)IFY;V'(W3$/AJ!&!QHA7Q!E8;8>TZ:'(U>;`!H6B]- MD.RA'?C1*(:M33+RC?\JM@-_9K/KHU&&O:XU77W=7M?'L\'4V7`_G:Y?T/#Y M:/1J=`R\QO(>L]_S\22,)QWZIF;FN[1[WEL#WZ/13SU*6R_HW_OB',6+*:UV MFHV46GKUE,2>F[$>3Z$I_,[O/15ZL1Y$G$>MT"#2#77W=KL'(_G@]1DJ)AC5 M0K/Z*B3O.6[>>)%UOW&SDL3-JE+KN'F5)?N+FQD`A;H2&YY`W'SP9M0*BYMA MX=0K;CX"X1@WZZ9Q="2IHQ&(<;/^C+AY;Y'C$6ALK=!XC,#Q"(39I)V%6L+7 M"1R/8830%VG5)'`\`KT(?K+6]!P_<#R&A-'UTN1Z!HY'H%\EM!/KM0/'@\-X M$*6M2E>@#Q@X'D.A0:!FI>*MPXOSJ(&CPO!+7BMP?(W"?H4%CN;.)!^T9J%B MX?[>:Q8,E@4KG$2_L&9AGV?T1<;L=D;_DIH%'?VVYY_/'U1=U%?,G_@K_1_YA[$\^-&O'H`;R/_WSW,)_/?O[PX>GI MZ3IV1]?WX>.'[LU_@9#!*BB:1K4IV6/94+%[CQ1^_.7',/+'WL_NCYGOC;SY M9X)+:(P]^!;K.?_S76I/X(WCA0_Z47Z^5W8MYHLS==L_O/C=1U8IR('([T:> M"YH6?_)'['V_?"B=QL=?/B3SY!SYD&/)+[/LJ@:C:NY$<[RS@-<==`E8+BLP M1OII^D/PXX2?J9*FX-!CX4>_?!`&_^4#E^RN8MZXU&LIYF_+&8A8N$\CR(_5 MP-V!%-OWD4O?'E!^AB3K%>0'/S,E33Z._"[+]$V(.>>YU5+,A2#T4SAB]^!( MBI7\_3D6V+R-R34@POQ-+FS[N#R=%7^M:R87DVD^FN(]&+%SD2H M];)B=>#.QAL,M53Y6H5,2K5=2#M8R+OQJE(MY7>*(5,]Q+SNT^7+IU2Z^,6@KPY#:?.LAY8\NJZUC*]Y*[/ M2:JYCM:UE.H+.U]WEN4#"`;[=V;'>9>?-ZH!K$7\V].`]+H>PQY]J](GO(6W M*WVA??!;U0`",'GC&B"6VG_UG;>F"WF(H5KJ0NK=L4`,!18&\.?%FJ_`>=92 M?FM2,TF2Y.W:X3P*\"G);K>TVEG)K5YGL/5ASZ6*\?@'`J\@TTLJZ)RD>DD$ M',EUK+7T+XF`(SB@M=:`2R+@J(F`VNE"O9S:.K"'>?RZW-I4$*'JLF*=<^1V MZ(*(;P^1>_@;<*T*X1'[V:MITJ6TIO:E-756I#-6G/.0FJ:H&S<2P]`MXXRE M>/"-Y"D\K!YIDJ)6NKV#/WLU/5)T59/K6M1Q"GIT&QS8':FS'IVQWIRXU.3+ M+:==Q.<%V&I[GKO4DGQV0*EHEHY2L2U@9#VEDF;'N[X3Q[<3U@DWD\P=,,6- M.V`%\YU4STD\FFJK-8VT*HH'G)WS%8\,&]'IK9[T)R2A[OF)YU(G5$>A7+RW MF@CCU1/HQZ19JQ_-VJ%I%F_%7-R\7<63UA\=3SP7-Z_6XKFX>?44CZS:X.:I MIM;2:UH1\`>X#EYP+ZP7_LE7XL;>,WBO(XB+OUU'H5S\[9H(HTZ^Y\%IKDN1 M3B[&.+B<+\U(3JUB(K\FC`/'8Y?:K).KS#4%N1B0FAN05]&/,]:' M6@OC4B!U8@52>?5@E0^OIAZ7NJ>ZU3T=4SVPI_4%K6M'J;">U0>-X%JR5:^H MU:!6U-8A-?'2X/:`"JL<]B@W$YYLRY@%!W.B:45ATM\MV_J!_S7KVM:VBS#F M;C1SHOFR(+2[X4,BKYM@F[PJOW#@!=[<_>0]NHBV"<;-&X(9BV-W'G>6GYT_ MPXB.4_*;X$U`>*9Q7'[7?E]S.W]-1[!5!JLC$"R2+ZM,)#`CN_`O>^% MB9&3))3SXG-?%E,WANVY03CU@G4#E[$F&W/UX5\^"',O M)?V3"\SZ[,S!"I2S4?C!&DXRW89__#]02P,$%`````@`W3T*1Z6/8FV6"@`` M088``!4`'`!G86QT+3(P,34P-C,P7V-A;"YX;6Q55`D``S&/R%4QC\A5=7@+ M``$$)0X```0Y`0``[5U;;^,V%GXOT/^@NL"B!=9VG,QE$TQ:.'8R,)!.#"?3 M&>S+0)&.8Z*4Z)*2$^^OWT-*MNS$E*A8BJ1T7A);YN7[CDB>&R5^^/W!H]8" MN"#,/VWU.@C4>OWWW[\X<-/[;8UF5A#YOM`*2RM MKPY0X'8`UHW]P'SF+:V!39V0V@&V9ET2_Z];6\"_+?G7M?#2U[/)I778Z5G6 M+`CF)]WN_?U]AW-WU63'85[7:K=7W?T9`3NQWG4.#SMO-GZ9L-!W3ZRCC4L# M#E''+D(ZL0X/>F_;!^_;1[V;WKN3WON3P^/_;I9F\R4G=[/`^L7Y%0L?O&UC MC2-KTIET-CC^R[IFOL#2WMSVEU:?4FLB:PEK`@+X`MQ.W"B-Z5HH45^!-FJ<'^T*M[K?OWC\MJ9@6>WB2\"VW>V M*LK&=E7M'1\?=]6O46E!3H1JY9(Y2DH&`"UM"?FMO2K6EI?:O4.4=.=!N*W? M9(R_L]#YH0> M^$C5/?<#$BQ'_I1Q3Z%N6;+=SY/1%GQL`YR`^,$,A^,$!]O%K'IF`DBNQA06P@R)>#NQ<*PBY?D,[8Y M['=KX0@7/@_Z-`#NXZ!80%&4GC9<./:!+687E-V+D>\2COB* MPOZTX;VQ#XEP*!,AAS-;$'$U'7-<2W%>RKO==UUUUVU:V+3/WUV!%/N.PT-P MSQ_FX`L0!3%YW&J!@*\#YOQU)C6V5'K8O!))W-,$4+F#>\/P-X_YJNS57!80 MJ`\#3IQ`U5O]UOI[-EU?3#2Q])+Q`35241-*Z M*'V,E#EU\_18(-$O((T]P4)Y\5AES-RREP+,[LIF!()5M(<,/2;_#M` M^QQ$V11S=5L@Y8\QV&OL#;WMR\M!F4Q->RO&8\!9`.*&K7VLM:$O8ML8#4L6 M*FGOQ2]//V4SB[L28WMIWU+`\11;SY?$OB4490TBN1\W\!"<49Q:)?%_+IJ: M2NE&%M[/H"\+4]D22WI&+WG#*(T]CP$3@5!:3)FMR$'5*GM\[8NJYE(K=;P5 M@ZUL"6XYJ&4/)TUGU7`L]>:G=EDVW[77E@S!TF]M>I]E,SZWN8_:7XR!JRE5 M-EM]?Y4Q+74X9_7Z(C-XQJ@+7)S_':)S*\N^G)UEWG_9DDCQ95Y.'#E!E"V3 MD;\`$<0?I5WG+F1F$POWIU.T[+"=N(QC=1SA>#IQA2E8!0D@H MNRT85*;D&=\>%C$*E7>?VN)6)=]#T;ZS[7E7#I"?AW!&=M$A1OG)+"I#KNF M="7(A0"9G]L--/JQ.EP98V"K3!4H9:Y<:E?\)TV.!:X>4M\&`_0JEJAOE;6M M06]6MQ)6>M-!QR6E1E4,XH!YZBUX7*P*K$.R("YJ);,E6U>Z"N0CJ9WOB`S4 MJ9GX"8+S!YEQP9O_D3'WGE#=$FA4M0I.&PI%`WVS1,4(<:X]]7JR8>^N5@67 M,;8%.(#=S*FZJV1%B.>HM.,])RC)*VDJFF@KDYK5,&)SX,%R3&5>&JUM'`YS MN93CG-122:E2!8<)!#;QP5W%0-`Z#+U0Q7"',"4.T3$QJ%@%'^-979-Y?`/> MG'&;+R,,*Q.F[TGWHA\$G-R&@517-RS:TJFAD[^=?&R?NM[RRK?/Z!,*K MF']DC&L7)(,*:TP;KFB?;\.SN;-J&#\^\4.W=U_');I"[HR1K;4)NI^K^E/. MO"`UDSRRLA_;9II!^ITDWNACY70K[WBL@;F1\)]&\M M7IJX5L+UW6OBJHN%)73?OQJZ6@MFG1IF6DL! M5^]7+85=I1+RS5S4C,D_PV](9-.@%3!=&B8^2$*[0>:,V2#8&01*^#;(AC%? M][:#TPG9!KEB9F2UF;&$:G3^96$"[[ M"#[BI6JWB4=\(@*NL,1NG28XEE6KFA20%.$5+1%.\"NR?($@$JP&\7:9RE/V%36ADY6WHQGB9E8^/ M."8\#%JIA"FN0W/YTA34!!'8]%FN+U\%^JL5E.1Q]IVHGY:K%&WF#-A5LOH$ MJ`S\@-2$\ME7%Z+G?>5N3>D.&25&TUNHGN$ZUA/)?:V81][<=LPH9C113?I1 M`)J1,BP]A`50IA(/Z?,\O4ZE5NY.%;)IX.Z<9XU,L61235F^&QF+?:;BW1+) MMLP:&:4M0`SY%C9-5+?]#Q-3AH;31'WK+J4L$V\[=:OS+1J9KLW)W&4@V%1N:LC8AG1CSVRUG7([;T],UIM=F2/@84(=IHI(MTS!'\1)U8_$S51I%CBV/\8#\+WY;QTYN1E6_1](*9+4U7$:^R2L> M]#2?TU@]>,<[=X:Q-;1S!X\Q;Z/&*HKKR65CS)DTA]VSI7Q9V M*[FE1>7[0[P6*Q#FIX0K]VFT1G*(IF/![V7S?I>_&;_%8O2/NL83SUJYD MR__Z-3.;+Z+1"%Q3N%(_X#F&YZ.PTEY+12/#<24)S5C/-'*S84E",S92&KDW MJ1C+[-$3%UG:HI&[.(N35&ZMU$89AG^T5,RB'HU\^*-X8>G,J48^ M]5:\>')'XM\T*1]3AKB>%<[1I'2^R\\P#+A?)JC"K,`SCB"I#^3'9XT4X;O' M;0ZPI-P2?,.)3=7K57>YZOK"WU]-]4ST.)FG((0:=1=@2$%7J0H>Y]Z7L[CL>,!5.R8;:?#GDH#!:&ZD(6\DA"R% MT$@;/=?MSYK^^^VEK(41\1)G==6(;=HY7#6"F>-0K?J@+N`HK/J0,3O=JCYX M4\ZNJ@_(%S]#JC[4,\^&JA?47&<\U0>ZZ:%-52/.!F&L_2LP/KZDOAYPGSM27 M2`%'PM27G/YP%RWF#UV)Y1;U''[Y/U!+`P04````"`#=/0I'*L;`AU`B```P MK0(`%0`<`&=A;'0M,C`Q-3`V,S!?9&5F+GAM;%54"0`#,8_(53&/R%5U>`L` M`00E#@``!#D!``#M/?UOW+J1OQ?H_[#G`H<><+9CY^6U+WAIL?X*]LZ)C;63 MM/=+($O4M"MI5Y0HB10IF07:.C8IS@S)^9[AKW__L?(F M3P@3-_`_')P[`(^N\)_5]G`K_Z MQ]G\>G)Z=#*9/(;A^OWQ\?/S\Q'&SN:+1W:P.IX<'FY6^YK`]7[R\]'IZ=%/ MN;_,@\AWWD_>YGYUCI$5+^P`1.\GIV].WAV^^DO_YN3T++MPL3ZXX^6,RFKCO2;SF=6#'-.5`9\(<0?]UN!EV2']U>'(*^W+T@S@'?Z,+_HH# M#\W18A)#_#Y\6:,/!\1=K3UTD/[N$:/%AX.EY85TG]Z]^?GM&SK_3Q>!':V0 M#X1Q+OW0#5]F_B+`JQCJ@PG][I?YK``^?`/9H>N'CW!VUR@*79O$!R],#_$Q MG75<^>'CKF#/8>;WNQ!.*EWC9G'E^K"UKN7=!B2^/N>>18B[<)'3"0O.)?K$ MY];"J-O6-%@'O@0?L3SQ&,Z`2Z[0U`L1]N%0/"%1*.U_6#CLYQ9YO/*"9S+S M'1<#?*)@W_]P9]@O7&)[`8DP.K.(2VX6MQ@X+]Q+NMM3QXEWW?*$7?OFRPE$ M<6K;.$+.Y8\U\@DB@C#9_:I`@._"P/[MC,IW*B+A\S%)TI7FR(.3X=P'\+=5 MX,=C;]9T``'I&6+7#N-YF[]-_?R_OED86WXHB@A]0"J2L-%J9>&7FT4.EBD@ M_`222!1%JI:0?D9D7MTF*PI$]!NBJB%RIJ!/6TLT)21:)8?H"Z&'ZP(!3U^Y M/KJR7/S5\B)TLTA/V4=Z@#K*>J&`R#C*V56*-RA>2M:9KEQ+('+[;$`P1A4+ M"$3CPO4BJFO1!Y(#-<$MY&F$2P\'UP^0-AVR7TN$0AM4:H MG1C#-@/C!,<*,P'F&'_@&\+HT!J1 M;#_NT8_PS(.K)0G_MM!H2J5[.KB;0B\+)MD4RU8&*SFGE*:6QWE`0A)+L5AM M!1SB6;+/5U>H-*>:U/,F!C;9%"P8J+*/$V,Q-3A*W?S*)67CN[7:LB,H?6NK MUY2-\:6%?9#^Y!;A^$K)QI:]GC),I1[GNE5[N<&/@><@3"Y_C\"XI6/[T[/X MUY=-B0I;IC]R-`1"-DUF_A,B8?HCU>N<)QH'A<'3Q0(T.QA':(S4B3Q$XR?; MT;+I)``PZ3B#H]PA^O'SJ@R3L]5),+6SS(LN(*&]BU324_"ZF@>5Y!Y/T MPWF,MK,`H6/'71VG8X[I!(GPP%*@#8(N>.B@A15Y83/H]J?W`VNPLER_-:C) M;)F0QBL&&8!:F2H3Q$3Z![>@!'6XITPS2L@^D\#K;W!J:6E.`&2X9 M\AT:/TA^2S\E/.DAA@+@@-M<6-RC22(!+J58C"=!]M$R>#IVD`M4._F)_D"9 MV$^';T[2/)`_P:^^3V%IARY_Y5G+S><\ZP%Y'P[V_WXL'9[S"-,4@BL0>9;W M3V3A2]^Y`$97`AISJ'PH-WN6K`T:G!LX5_`[4@(F>VS?<%(:\4&9C>P/QMRQ MA[N&9B#C=)A\Z*X1*#/)VM,?;AE;WATA M'Z9[;,4AY9?50^"50%3\^Q:>3*.;XB)DH`YN/I-JAGQ&33IG@8,5AXC:+!G4 M"(E)@!V$/QR3-3!V#)ORX>#T8!(10"E8)[%+6239,1E$$"<1$QN"'+TYH>08-&8[:G>& MVNG@46/H'AF*;T>#XIY:G2'YT\B0+-@X&9KO!H_FCAC)4/MY\*B5ZQ09AG\9 M"89[FGN&XE\'CR+;(9)A^9LR"MM<6VL,A#3/"( M'"XM:TW-MG?'R`O)YC>'267HUGY+?_U])W\LY74[QES-X/:69B>X=[+<:D%G MC%<"_39_]=9RXV3KM1M:NS9TW6@ED!."PEWWP\X?U<$U?:!ZELT\!,5!ZN"L M.:N%,@#?37([PW,+X!>1[G,G%P()OKA*L MJ'Q(R]5*_;@5`Y7`RTZC80%>,4,5!JF.6'ED=H>I@/7"?7(=T%'X!#AK]%CB M$.WI.*/A_Z5+4^AC?O89A9<_:"T4',6/0>`\NQY+/'--'5>$H#V=6:JP2A8(QR^W'JTPMAWZ+%>4T4$>#@3E8HI*G"8HQ"$ M)G(VV>Q@Z4:K**[&H7VI;)>%"\SBRPKP5D MR@F`MRQCCC%(#9R<6IE9CS4HS7>H>K=8!MO!+`LO&Z3%=47?O-`RQ^Q"% M]#3!* MOW@K/W+5ZEB&HW[15GX<^1P-6UQ/]0N\-CVL>6STRQOC+T,NNP`P44,2Y3+&.Q^J4(-D>3:=ME:.J7),B')I7V94Q?D6]B: M&4GTRW8609*JT1GN^J5#"[[XC'!;1@%]->GZ8%1!N60DW>F<;ML:4U::GO)< M6^'(,G,Q,E15">]*18S;%U^0827ZJ7(%;:\8L-Y17^3#1??X"`L`FQ%DU\63 M'61]A1$?9OPB*\-9D?BIK0FHCN[H6PT@`#$.UI6B>:JSUC,[ENNW0W$\ZU;E>MQV.S+('G:MVVZ'*DY6CE[-B[2* M#VR9>@"9\'X_59W_#[M]@^.#X<1<>=,JEH4"QTS%&"55K],H?(1K^._LUK`Q MV9NA!08S0B)^Z-/16D#.[AK%-64LM1H2H.G$+\959U'4FJ]=$,9.7"F>_(&^ MH\*?%2RM8H)NL!?S]SJ9IF<[<;3M8U MC;-94J[&(1V12;D:AW1$)N4JB^KL/].21W6`6;DBLXR_G^J%4=D6C2=?IY>\ M)"VVU&0FBN:?$'S=67UHK"F2O9:3QY_Y694,I3_>6AN<^7AJHU\>55*6\6TVMQ MPZ!K.*J*4[BK-G3(&@;#+5BAJ0H"?D!7$C MTFJ>6SW')`N/)UGX&W*7CV`839^`YRS1YXAZ,\`RI[93S@_!9WRU_-@0TFDT M\%!P.)RXM9-B(U^6P3$$AWA+E+DLQR$XQUOA7Z&##\%#7JL(%AL85,J_(22E M-L*WUK\SA/S41AB76#'*DU--FIS8($G%@1A/@ERIB3B>Q#@.436>S+@=M^-X MDMJ:VN".0X\EU:^L&4)X#ITM/21W"]O0EERLO M>`9>[+@8)JL(VT^=?T6I`7T?S!'HHK;KH0(7`>8!D-[B@(H.Y^SE"ZBP,W^K M_$P!ZZ>DH6G-@^TREE+266F<[[V70@;,U*5N%A"?%D$7*/G_1L@Q/J$*1WKE M:#$#_)AXC^C!\IVT]5[^D%']``RV"-=%"SM_5@4M+M`:F(X;YYG"SUZL'E$W MQ(J6?_P[_CT#7ZZI)G5GK`DOQ8L\\W>>%:`'8:_]/AO--A_3`^^M7$IK+&JX M1(,/Z(%?^OK:16I(E;["QHTKU\=,$M36BBM3A$J$2?*(3P2_2P]3X%=D377Y MZ/#H4)?C(^;C&M$E4SP$G@_>CPZ/#NW.1]./:T27$D.J^_G@_>CPZ-#N?#3] MN/+T56V3;$$%3+T%4QL48(R:J=#ZGH#:=K239*_4.(P?H1M70*EN7,=@D MU>F05,?J=QNMUTDTW?*V$:\;']CP$\(A?0.]&!TJ.\.-OZ$N9B#3AUMX9X[+ M8S2$6%I?%&-QFB$$W?JB4>/D/GV#=SV2C-L5I3SDQ]/>4)!;/NOYV%@`#.'I MY^8>R.I#P^??&T)'$=&4X?-HJ\^W?H4I\T(]@L6$H5J+;!`)YL()U-@@'$). MNKQSU-5W/X1F,&+]KH5;R.WS&4)'&7ETZAH!4-ZGICWU6GIO>;)]3P''DA7*(J#58_4I`="CL$&OI/`>TDTE MZ_/<=V?K`F0?ZQ%J]XW(TUILZUJ%Q\7&A$FLL<5%-)#`:;AJVV%#A%A+OWD. M(UW;\NZQ:WGGP?Y[LS6#50BV_>C=>80Q8C;"8X]7"#W8A0M$2'S2KA`G"JQ) M*O"X7*V]X`6A.?)HKW_NW:B?9]0*;K6BSQ::<1I!PZM7,TE,?J#]B)S(0S>+ M_84J;0>^B=)A9%H3]9/&*7%[4I<;G9LL&:E^)\>J0#X0?G)M5)ZX/_5B"-RD MC9@=+'WZ?E<2CHHY%4MYE+7*6.P>:<_C?"JPK6:/Y*1SU74.R4)GZ7DHL?5X M9FB$0>E!XILS"BR^GQKO0$JGRD;/E?>69Z:2>L>M/B"&SU>634I9:_#5N#TE MP4G2%@H9='(.TP@]#7UN2ET]IS)W1.9_0PLK\L)R$G'H%?NEF4SQI]Q+5^UU ME($TR&\-T.8JB*M77+B?7=A(8YT=3ZTQY[0@U+N@1N9BY\^7DZE6Z9O$H`]] MN!CI8!Y.SKFRHM7*PB_IP]9I06.29/K2W@>EEV=E7#9C=M099YLZ$)?QZ21G M+]F8M*IP^FQAA\^JZOI]?2RI',PLD.O7!MZ!_E MDRR_V,#IMO-TR*9MPRT&A5$^(2M7'S%EZ0%:]'5:>0'1DMY,O2K%<]MG9,/[ M91QHL4`,DLXE*HD*2C<%8Y"T+BHS*LC<``(UG43!0*=-F9!S$6%@<0F<,4HD MGV6R`97)99M_R+CS9+FK!-GP^KKPV$TTA%GJY2'#SI0=<9A0$NTE63;J(XLC MH"BW9CZ$`)=<&UK2#FQ\&^JC:&,B<*F[3>>,<04D;J$Y*D\_UXN",KSHRKNU M]$OBAJXA!6)P&'W[![(E(NW](3P5,))M:>A:',*+!"/9F<;.R*:O'NB0C5): M6"6@;Y:@)A2Q=P!6J2A"*8X14@:_7T@6,T^4:G`[@'!-$0273R(/KD986JI0 M/D9ETXW*G+#/0=QP#VX3W4%R'X2T]#;[.\T+^QR$_T1AEC'6I<2MU7JCHE[" MQ("OI;^BXT[Z)FDY$*.B<_:E9%)<;WW_:/DI:^B;Y+7P**5^QC,K"[#8XX=< MD,K@]%>6BS]9^#<4QNW;4N=ZJ>1A#1U^^B:#-G`#-F?A+*#JVN+"Q:#V!!A4 MM@BS12/?1-DPWOCEA8;\\V1#>`\3V\&8GRD=RN>@'8S;>8H*4-..!#$?JRLY M+1EK4J"'D0+=*&M"([@Y[/3X?[XFS;(3=8ZE10I=8E`T2IX0FOEPA:/XW.XJ M7:E[@3;;EY/FW0*"<5&XZ/'LG;P[RP^*MGM!%5=\/N&0AFE'^IQ?&#@N'6;;*Y@ MZ>V6O=H0*?>U/[*5+J7EO69:(5DTPG=N/JG&3K$8: M"?7*YOS=E)]>PW_);D/J5I]0L=OW;DC-]9GOT)?.(\NKB-"5C]4"ZF]N^!CW MCZ3LY]%=WP<5KMZV7WDUF'9J--<>U]1-4'$"\R,40EA)Z^*804`IBF<6_#R5 M_G'&2+4-KDJS%,2DHE2)1N65)GR=L)101X^66:;::O355FIIPKAC3=LBC90J M#!TUI<[;5TZ=@M:4TN0G4[5HJA9ETUYB'M,XPRZG+%'DF]5_TYPMI%J6RW/+@RZD)%.<>S-"4IH^-?#1W=8L_X$=9; MRCE9C=.,1ET\64KCWE)Q1EW]J$89K:]5:5K6.'RBMPOD9G1Z;992KTFR&9E? MBYG$5Y.:T>6UV#35E5(9/09LE'3(F2F5'ONU=AF9!JPC"R(3HSAG2Z)3]8'$ MJCAT94Y.96"D+CE$>9B-+]0LBP!Z1)/K[TG+I)^Z@JKRJL+H'ME-9V2]GP=&=E0=/T;E+?KL"O7L&T@Z# MY.^+GJ7K#HJ:>YY3B97\)GU>W[1?/=/G3=JOAH:79D%"?GE@TG]EJ'^O-P.X M%Z70I/U*M`";)OIJX`W:/A"_$XV,73W=7XK7MQFW<4OULX^F!:5QIG7*P!)K M1YHVA:9-H33D=LK:>B?N[OKCHFY2O:+LY.XL/RC:]NF6TXD>>CX6=4C1P M`AI'[_@=O7KTO-"M3XIQ?QMGEW@=]Y6[P?LM\C1.<6GFA/&,]UM0-^1F&#U5 M`'$V9-`@C)"K%_QF83&Q`[V\\AV>GHMO"3U)@0_GI-+,+!\[2*@[M><=5PQD MK-$$T<^DU,J3AL]7%XBE%6A:>LM><=2F]Y/<^+GO/L]R4^#&=9J''"'K_1Q7 M-L-3>(0;P#6NTVMBD+U@-P\\#]@DG:2.Q'D@-.<3-U%(0LMW7'^I#Y/@!4IS MVE;!/GV`:9;=X.6?WB`:%&=XK1%T9AN](-WKO;.PV6SA?)%G224T#*TP!GS' M#4(J,E>KYZC`(G7;5>9G%L>H\\]6^J;R#M8=I-2'JDSN@=(O>Z]>_4P>;-K<_ MFO@NM&X0_[JVK(FO7.?>\Z]KUQK&G'7N7_^Z-JYQB%5Y2WV3H*W191EJSF6Y MWOCZ,HBU8';JDXKYVM1R^;`+/?[+7;#*O6]\M6]BT&W3VE:#7-T+UX-!3\FK M/N3;HVL_G@>1YUP"[N%MA$D$:NI]L#G1-XN0_WE5FA8Y5>8,5,U0AD'Q42HV MW(5Q0K+`OJ3&6:)\E4+`'O>Z\T+X+)D>=)Q"C7^MH!B(2:09W;1X-H3ICQ.M M!I9[Y<2(HA&[YF1N@R`+4GW*65LR5I#:2L^O0W@QEGGUZ&)!S$>'M:[V)2?L9 M/<=_8A=D:?Z8U5,3;R\T2IP8UD*^!!J&/F1;+*IJ@H$C?>B66-[JR^_0%?,DNEZE_P MWS?5LY7O.%]6BBP"##1U/Q8MX0;)<$T9LEM81X>K&$?(->B5V6:]@(T`S-]=D2O7JVEWR3.S+R]!TSM5 MM!:KSOD(/09MB-7HN"AW)M1J/DUXG+X*GF*U7`/9_3&=<`>[!G;3]?6Y`)$M M*/I+1*T=0E!(>3QV'Z(0.??!_P3` M9[["++'A9!4[<45Y++IVGVA=<`@VF0L2*X:3G+U\LOX5X-B&KV`Z3;Z@ M&889=+77J.E77@VFC3D(*S.F*(')M6>S\SO8@U70?>:#:H&H1DM]K^6\B75[ M^.:JP2KV*!,R1P2!IO@(RNT%>D)>L&8FWS2;JP:K+55G/D`U=9ZHHYSR:UE52E#^^:/&3I%M42YRMA*) MB57U+#&OC#P\;C06D/ML]:9TG-J\P_+[R3(NJQY7Z/)))32('HCKN!9^N<%E MP)U'J[B7TA/*)0EM+-'I`N[%U//R02X6882OHS8\6N6W*KZSR\V/-'>42L-< MBWI[[J<_ZAQ462X2V^13GC_*>&=Z2#"-AI!W+D"&<04,AI">WID6M>X:Y4GKW.G/C;WN^F8$ MR<59C'M)>9YX/T0J]R:DR+\=.?*-#,F4)C]I:AP/K[R%@_\WCB9DKS^4.L/5 M/XC%^2:#`,]XM6I9=)VI/PM\;S?T2I9!%8I\#BBC"X"C`?MS+6_[S`4YLXA+ MP/:T;7IS7'^I(LUT'XCR,,7^N+$DF(XK(6%[O/:T;]9KY]=*4U:V8%1V-2D. M,F*\X\MES#-2^EKU^-VJ?`0I8979'BMRN//7Z);>,V&6J(;B-=TGBO M1J"W9KM&[(].[,?T(>V%OQ&!O3P$MK>5\;[5:40-/F!$O!'Q1L2/1L0W81U& MJNLKU3.)'?>VVSX2,T<>#''.`Q*2O4?#B5*COBO(Y6RUZU>-D:^EAF,T`*,! M&`U`A@;0F0T;M6"T:H$Q^C46B5E*R6KM!2$W2'\Y-HHV\_\CD^]&!:7OH0V M1W:P]-U_PX['[T<@]PYI)TJU^;`N]$A9ZO39PDX>;%I7D]P30J)5 M\KO6M.FPB%'FC3)OE/G1*/,2E0+E:KX$(K676T.H_FQ/C2Y2:PBEH*TH(UA' M5%X9:LQFIMD<[]ZW^#$&(4YR8P<;;5*(-MFIRU;YH2X"4#72Z+1&I^U1#%<> M6N7:J)&>#:6G\25K+$.+#Y0]!AX<0I(4&=)]WFSF#9Z[R\-DM@+$8":^OA-]V!LOBR^,SDSL\.%%)GG)^73W'*"I&5!M1;42U1%%= MP[2,.-97'%]:V'?]);E%.(Y4*$WK9@-3SOW8XTTJMA'!1@0;$?QJ1'`%ZS3B M=X#BU[B\-19C6>$C`.*X7D3[,=\A.$Q\>/E#]N+X-C03L0TZ2,*TSRIIOJ- MA(6,V#=BWXC]T8A]&:S(Z`OZZ@OEH1"AK=:,YF`D87\)9Z+@Y+T6+!1XYQLY M;^2\"CG/?\"-^-97?(,*MG*3AQNFOD,?Q0(=#,$@;=JE-H2PG)TV_(AQUAM= MQ5CM1IJ_&FG>E,D:D:ZO2.=YBRGSTN1&C\Y4;\^Z!="PG-T+^+!1!XPZ8-0! MHPY(5`=$L#^C(NBK(M`W?='O$?QX^31*R6\DW6`E79]P,J\!`V3F>".GC9Q6 MX81G'V`C?MGB]]=CN@1M@0/_^']02P,$%`````@`W3T*1_,7DO7F0```=ZX# M`!4`'`!G86QT+3(P,34P-C,P7VQA8BYX;6Q55`D``S&/R%4QC\A5=7@+``$$ M)0X```0Y`0``W%UM<^.XD?Z>JOP'Q+E*S51)M@B].SN;TLCR1#FO[;,]6YN; MNIJB25AFEB(5@O+8^?4'@*1$2@0(2B3`F0^[UDA`HY]F/PT0:``__>UUZ8(7 M%&#']SZ<&*>=$X`\R[<=;_'AY/-]>W(_G<]/_O;S'__PTY_:;7!W!RY\ST.N MB][`;Q9R46"&"#R8K[[G+]_`E?F(7`RN'._W1Q.C%J#_MX'O@=\^WET!>&H` M\!R&J_.SLV_?OIT&@9U(.[7\Y1EHMY.6?HUT.@>#4PA/>ZE?[ORU9Y^#;NJK M:8#,D)0&-M'F',".T6]WANVN\6`,SHWA.1S_;[JTOWH+G,5S"-Y9[TGA3K]- M:G3!W>G=:0K>7\"][V%2>KDRO3>T=)L.QX. M3<_*5*3"\JH:X_'XC/T:E<;..692KGR+64E"0<`M0?_53HJUZ5=M`Q)+G[YB M^^1GVN!/@>^B._0$F`[GX=L*?3C!SG+EHI/XN^<`/>5KX0;!&:U_YJ$%>98V M;6%,6S`&M(4_QU\S/SL!M.3GNSD7T#@C*ZIT%BGITG]0/\VHB5Y#Y-G(3A2E MU07F8M*9I9E0*M:W,@)=:G,_R`7.9#V9^)$)7./VPC179]1YSY`;XN2;=N3. M1FSD/\=??YU8%F%"2)AZZ[N.Y2`\><1A8%IATAK#^.%$HL+91G]:)8,@0-A? M!Q8J99+H\934XJO[2"LM75*%AA_DM3_?GP#'_G#BV%\'_3'LC(=?#J`96(FBY&,!PKC$ MF>638+,*VYD'^13X2REO2MKWI8URIH\_^-9\,Q]=-/%L\DVP)G'",1\=UPF) MDA<.MEP?KP/T0$+#1Z+-[^*G7EJ:>N:555'6:SN##LS2$H.X*6!Z-H@;`ZG6 MP+8Y\(4V"%B+>HE;KWT25C-3S%Y7R,,(-X#'A](@A^0'&;`!$6"Z#@+D%?2> MNX7U\3?60-;]8*=O#//IV0*QK$;P[B!<,(-K%4EJ$*UV?$O`FC3\KW^UVXZWB;"`),&F+A:?#Z/QE6B,K2@XC*Y2FB9#M)*H(4,FL6#5C>K MY8A$62UA"DU=W4Y'7-C;<YG3MZ0MI?,B6\,8=1(KMHH95M M.R'3YM9T[+DW-5<."52\A\LIK9)(^2K(1^1N=Q`S:",)4%'`\4`L3!-SJD`& M=Y"MB*@V06;QD2GCC-C5,F01F$(/2_ZUQB%]O<,/_AVB8!T77:-P[EG^$EWY MF'P_-?$SH?>+8R/[X]MGC(CB-RNZH$@BUL0*G1?6D18M:M31E%)^5J^_](QD M?]A/IH2V:H#0!QM%`-$$1*J`=U29]_1GJ@](%`*/;^`=U8E$A/=@HQ;8ZJ5_ M24:[D6&.D8.-D3UB9)JU^1"UC+G)F[[MN&O2XZ%[9*T#UN_-7BUW3;K&2P*% M9K*MH_[AYFEF!A[A%[Y%P?VS&:#)DLX5\,9/EH_I%8CA,Q6#@^2$9_\:& M8^_DKK5V6:M:A[]5$BTSWJW,[M]A_/GXEB]@\NKL+E2K:/'[B54B&-+]+>P/ M1^((]H7*T_7ZWA0+P<,L])U$)AD*5ABO"A_+=QC%KAP/S4.TK"ED;<5_/_%I MH[/\X+\SZE0ZG`)?J!*`:?%]AK`#C2B,5U4;\3N)=]-B M;NX82@OG@H`\&<06*B:>?>U[YO:;!_()TX4;W\._H.4C"GA^4%**2D:64TVZ MC^KVALDL9:H%EKM"VFBG&@'I5G03MDYKP&JMH8S/AU$@0^\#S*J%[1BCO=SY MG1]56=1SDRV MD')O+;T?MC/83$\Q`?H32H[`$87X^_O9P[U^%Q;F7^R#U.?2!8G+F3+*';KL MEC72UP_2_EQS#K)<.#X(1"HJ6U']QD1G47+Q'F#MCBT5LG?+ZG+TTCEPO>%F M2B_K\`V)Y$?A8@%]FO%^O?EY(K_BTD!_G/]F!O8#:46TY)DQ[6#I?TA]V1F,AX9DX_5P_`)6(YS6B M*DWQ`Z")Z,V'IHO9&1J)6+VUA(X1+=US-?%L^F?V[[7S8KILT2:C<:E*NK<.0KI9#TI!@L0\IT2U@AB"1#ICX6NBU0H'C MVS//SJ-8C>A[#/WD_N]@_SJYFET_W+?`C'Q[S[:PHJWH6F"^H.#15P[4 M8$@_>T3C,'"L$,5H96&K>DDL%:;3+X[R-FM.[W/+.#_WK`"9&%V@Z&\II^"( MT-X7Y>M5PF<[X\(N*6H#)(V`=TDS[_4L2=5G";9B=3U[`//KZ=ULZ]D`!+=_%[]J7CF9Z5V=&_ M/4BV8.GL:+&*`\`QNLKONC,R08&VV0)QJV#3+`L6FX;3)WJD#V[6O(*GUF:L M[[^^N6;1X7)^/;F>TN'<9/HP_W7^,)_=:UWZJXI"N['C:/MJB2>NBA,GS)1Z^; M`;SU&7%933PH.YEO='K=43^?"MI6*BH$ELL(S$*'MA:=+%V@FZ=/@4_;30Z4\2V$[-Q5RI(25"]AE%-/UL%&PT'/B!8V4@T` MDVW]BYN@3L<:21^1%#6C=KVC3A,8C3*!>'&D3CO`K!WHF728O"\2>RRB!#=@ M@E7&+@MFEY7`'$H65`X+`)MEE@-L6EW<8L?D<3KLJ6K:8E0 M8IUD?7'8-8;#5%AB4L&$3EZEY6K,LZ@&@Y%,V-"1K5$I1HEHH2UWHU*@$D%"J!QJB`;R57&PJ;<_&/M;KU@QN@GM"5V2SY-?DP$=!IU%44W%_7J"._"7VO>3>E#39 M6H`(!GX`(M'1KH;MV:'ZNNY*8>]1KP56!/8+;PN'RIY:TE%WNV<9^VCF7A0% M)NOPV0^<_R"[^&GOU=##M5TUI)UM!#LY'5K2@8&M1.V\.@YB#I_BJQ],(40- MO.(Y(8=/N79I!(_F&*_E.127ULF?2`7I%ZM^MSOD)J4QOG%')AZ^L>U1YX(B:OA&[VV0G#.96Y1I?WD?OLE5J\[&S_? MBHDO']%X^.7QH&!94.JZ'KYK9;L?C@GJOUTY/F;VTL&6Z?X3F<',LR_,<'>4 M*"RJZ,YE7OOR.X7[HR21)3X6.)(%J#`PH\,8(D[]9PX9?>2/F.\E9\NF MQ;;`1C![)4B+UM.S5`\:[H)F2,T"I*JZFS+^FNY^I.VDA82;E)2;)WK+'_(P M4^@.N71=;.KC$+/)ED<3(_O6?(L26\09G$<*54GR/XZ[QE2:E_\$ MTDV"N$W`&HVG(MNL79`TK#WS4Z6]8.WV4A8Y*B%9)J8<_QP:'6T^IM4NRBD] M5FH3XTV^JO*9&P-H5!-PM.>B*C49BSELHK+-Q&4,]EV$$#%S#HHA`L/J"2(O MCHT\&Q.5Z,XQ\259O-)*29^K@OR2Q2B96MI(`K&HFN_0*N9F!DN]VEVW$917-6G,5D$_*-(SA#I_BZ=WX>&`F M3OVT=47(X"'(5,Q;%[I9,G$M-H1J/M"9#B4N@-R\=B6.DQEI M7.DZEJI:A/!@A"H9(G*^79IP;:*%*WF'40F+ZN-(J7.*#/*&.A+Q0\=!3-4! M$]!"W\%+,BXF8$,5!RV59<)MS@<[Q`@'ECK2W:I M`!$LBTBEU^>ZTZ[+[X-7Y^\/1*S@N;"?%7LW;5-^3&",=D<]M+X^3RZO/932 M7J77IIUBUUDW^'2LID@W[T;HWA72R)JNV=? M>X)%->C@0>A4+:L4.5UZ745HCR8PAMY3:DU(5^.XZY"[Q[BHED;^[*@B[6BP M:_1Y-&H!)C7:NQ3);0:=C@(;W8*$0N"RD]\)6"O>0L;(U0:/&]`V'[0NEG$< M542V/&LU@7-%"4'\\AIY5OZXM`Y,WB_R0KGVQ)R*`#)675%&"4_.T44;80J- MV`1:J+)]6T&A9J,ZSJ.%4QL?.B6I5/L+$Q\-IG-Z8SG']1>T^+B(2#D[P/OCH;9(1&(E0$\9K-+DB.-(@;C M/`H3C<`;>3O>ZM3@"%F_B5FL_.P%F^J9L1CY!]9R?(0R]I8.>0<_DA\J^"7Y M;4'\%2UGJ/;T?"5^A#"9BTS^)(#QL*,H=K:2E=BB)R/P'^D.%Z:VDJ-)-^(R"AV?3BP]S5\VC0GU^A.!= M!%)^@#;J&%7'\;P0GA8650),9Q`2I9.[&GZPB%[M0XK6W'RO;9GX.3JK,;9G M)LBC5_H9T6N;'Q'8=@4_9)"7C3U*XKW4X]8:^K=7;.2>$5E<7D?HW%5"?D@T MZ.\-45,WPV@Z>K%B?-MM^J(@JISH/$_+)6*N!>K/4XQV%TZ1%P:F._=L]/K? MZ"TG_2Z_G*+,Q=S&2V2Q]I(9KFB#:"P(,$F`B%*?S5@!(E@6D8H,1Z$[):F. M?/#*_%W^O'O)2FJ94,%I\)U^KSO(TB+OGA5M)]_7@18>B58A@R3/PB]A)57< MNO"7IK-[S,/>STKY$K4I[RM]V,DPXTLD0,/FI%4)6? M7CHN"J9FB!9^P!_Q9$LI]=I,T_+G5G63*]SCA\_$@$2.+A<^`@PL!4:=/^''P,' MEH.CSL?SW2CKY#G`M4SP_'M-E"G:L90MI'(J)].R_*$M_>2^C$B`_AU)1^"` MTCB4S=7D.DUF@F8?KS[OIK.OOD=>G','V>*RRGU]1P'Y$UH&2)0, M^B,A-+FV%=_+T@#*5(,/EL:GECM%3KA/(J%=FL$F:NF;;QYYSL_.ZA81__!" M<\&[UE"^OE:.<9227W0:]F"FAXJ$@[1S;N2#;0--X6`E^&$U^/5QM,"UQ705 MF;"2`WXO32?XQ0Q^1R&[(_'F*9K5W7G&PJ*JC_'EZ"%[I1X<#F`_.KF72@*1 MJ.AV47#S%,_1JSVJMQ)(A@Y(XN-X*\$%-[B6$2YV4RJ]5P!S<2DY`.YM3 M=D56T-']4GV8)MNS^(ONUA%64=C)BO20GR08]KLIMD0T20G4/OE1'4IX,$I5 M'::,,Z;[R$+;-(511<=%B.MHYE3YBTQ&_4X!J;0?'5$AT%U>D<[HTO%,SW)8 M>@QQ1S:&T9H@)N641=0ZYFP)P9`S[@@G&*-PZGMAX#S2LUX>_'_XCA?^2DQ' M&N>-*.0JZQB62FDF/?KI0>)IW1U/(\,Y)AZDY(,''[`60-R$^M%K#$'D[#\DC=!Y=Q'3%']]^,?_E!U/7Q%APUW@9"2I' M`/)JR:]#C,9Q.FPDO\M!!"B^BTC=T+B;09JXN-H*,G_X0\%)@N MO>#>7I)(1"<$0Q*+9M$674YO4%1+84]=H(KT_F5CU(V7@F*)[&3@K$P0"]73 M!5>*%.XB-3,R=?:IDBZ9[D-E3--`=@EW.,O5;0[32NX,[@]'4)9OFK=!UP#\ M^Z4??Z^TO)FJ&;X&/L:W@6\A9.-+`F&.\=HD\-C]Z,EFN]RAB%Q-Y0-;*;5D M)T,[P^%@$(]R`W9>=RP94-$@D4UGA]-[+14/>6N`;#0""F MS`:8##KIW'=R_0$/LYJQ2:O/Q$3:U\"`XPBP,L(L+.12CX" M^;?:PRTQCBSAH04[HEVQ%_2.,(:N-_R#*)X>%LD;4E_DNB>C$G82>$$Z&Z^T M\NBTIX+\\-L8]S/Q:"-*>_I:)=#@`=#4T&B5N$QAW.9Q)Y&E=?ZX,8SYY)#!J8E">&PI8M&>8!C%)N%(LKJ.?327W MFL+!R"CDD];EW@IQ%G&J`:NX4BXIP2O-VP.)5@$R,;I`T=^Y-[$L?TV&E[?F M&[U,G$[-13=-I2YGXGO`(<+44/M.TE1W,F#8%W25/OZ2M*TAJ(FXLF ML..;O%(M:F-P[=9)[BZ+S+!*F<&,S1"?](O!NVL_)'\@^W7T7C/;CZ#)3A@X MU,;-B`\W*T3GZ+W%U%PYH>D6O_[)"M`:!WA:R5_+/.A"(?';`*U,Q[Y`3R@( MD!TOMI'`PX[VCO+(I%U&2IA6:LMH*#\KNVI;P MWBQ+9>VEAY39[.UK]/_E76USX[B1_BOXD*O-56D2B7J_?))?)G%NUO+9WMFZ MV@]7M`39K,BD0DJ>=7[]X86D2)$@`0I$@TJJDNS.B(WN!IX'#:#1V-_^OMH> M:(GGOP;!^H>W%0\$B4^-0K)>'^FE8G\V2G>/"UG]1#+Z8RH;)<)+%X@F`*G; M;N?$;C>VV\?`$)0?JWD$2CH(!H#)>2K?GR/*8C),Q*M9P<^-`JU M@\5F0Q;P9-U1^\R]F@P0+$DH)GVH/IK/)Z<`8QLA/%V9-T%?,CLV8L&[\RWZ MPM'K"_.X51CZY6"6=:FM"']:O>'U88N7F\RO:[=^SY5K&1-4*BN_YAKU5=FA MAY*F:5)N]C/X+62C;E,CDJ9NLXE?I("GRCGU/=(I'JHK_Z5!82+V^UG0Z M+*P$FF,*O.B8:<^57RR&SSK6!2,MM').53-SO/),C][/&%;\>\M8@BDE7Y%] MZ`R55RVL"8OAWL`%JHL5L0ML0GQN@*L"^^C%]A^[^H9?W>TM>X:H)%.Z[!>& MGK@Z:58Z<)U,)C&NF`1T&[_@!Y#\?+89CH(9)IZT$@R6Y#6K,ELA9J#ZU$F@ M?,@&:7R#V2"I-M=ZPB)]GKYJ!FBL_H2J_TS%9_.0(#F\)FW0AES`C`YDGF"W M9]^"[9J0#;^A5M])Y9_!C/=27>0/ZOKS?@$$+$S@@L#QH,&\T672_O MO]\^/M_1?WYXO/UZ^TC^$CT]+Z__&RWNXW_ZV_+;S>WCTT_H]G]^N7O^7YM! M6[4;JN1>8!!?'PA[UMZGKO@`!J@G6BB\:9Y47OF6G5UB<38!\RP+>3)\;)0M M2>_UHTX`HC)7@,`FB"):M=SS7[&_^KS'/ZZWKO<>T>>YU_>'BEQ6F2]-`JE> M'?G[R/U1,MG1@AD9L31I[@?BDMF+ZVOR)TPX$+AT6\U0QC^DYQ*[PYY7@UNQ MVK]DI-)[HZO@?4>:H7MZ&]H0*`+E!W`.BI*.TU(NC3^D]>1N\>(UQ%B8)E[S M8]-%T82:R`XIXH31G-=!BY]WH\)0*@VHV*\FNP9`=E67-]-D'+]>ND^>Y4ME M@14OJ\506J^LV@,0D^P]WE^[T=M#&'QX:[R^^OPEH@7'X]>7_-<%H=4/'A8P M2CJ0/XNOOP6^:*?S3*$&I^;S-)6OK>LD3\_2Q';:(DJ:I`]5_)&VBCS_/U': M,#JVW$/'MM&Q<9CM)Y,.FR0.6U&'[3(.VZ1NE30+:%2%=X9:E'?7YY.^ M=HJQ-:!IU8>E`-:1U%0Z].]/ MDWJV-6QS+//5K5V:5APV*0UH,O7`;`YH%!$D02DJ/NX>E30+:%2%=X9:FM1B M[^NF&%L#FE9]6!K0+!]N'Q<="&@:@DT?^]@0T!P?P!`/J\QOS'+"L6'YZGCS M429ZR+]JL]CO0^_EL&<)M?L`/;BAX,#2"%J;6I?N76S)IV"135/M)W7:&V2% MXN`_`?>)D>`877RXWI8.W^<@\[)6G&=YY4;>2J;#)*1`X;Q>->G1-G4&8B9( MFJ$TD'UN+FZIAUA;%H!+MT-R\$/N;K?U5HDCLF_0Q2U8`U#YD2^$L*0KM21T MW0?^[?MN&WQB?!6XX7JYN?%"O"*?1U_)B!$G=\E]:#K12THKV8$X[(_)_[.D M+R(7)8(1DTS??TQE(RH<*`>L!9,'=IA49E:7A"K4QFX$*@6<2I%)SE$@VZ6!GQYZ\ZV? M^'$8T6:;\/\S)54O@;1UYL M':ZPSMAF9=VXRVU+5CK$*MC4I1K4?F<#C)2O'XSGL[$$G.#/_/5:S":L92FV M8`_P94>G%,C`C]W3](!8(='1>_%W!L%4:%R^I-5\%I<;.:;/)$)@)J`S;FOW+PE\_D*Y/]NV6F_A6K+M](G^"95[-T2/; M)-!T**R0X#N:Q=#,M,NRGX\MLP*/V;9I3:BT=71L'GZB,^\\QY#SC/&'3C#F M&$=;WX!P%'MS>K4*#WA=+.`G&H[5'YEDE4I-%)XE3XKKQ&^P M>0H\\W(7+`;;\@G#Y]/A)<+_/-"2KBMWY]']'@(G?LV0#'P;,*L^],OPK.A% M*[#.'Q[X&>_?@G7F\379\2+Z'!+7`IWD9Y;)N`+-\4L=7'SVR5%+$*S%>H;; MV-)W;JF7RJ+$)?W.:',/S+D'?/Q*$+,V[X/!2)L3P.BL!MV5)%;E1!#J2EYT M8E<2Z6("\_VN1[S&[SOZSS=>M`H.POTD%0DF"4Q>+?D1/!O&N6ZI='YYMX?2 M!NA.ZK$)E+0!AN+6W##*^R%^$"QI`!2PZF,ZAUE%E\'#]L:C14#\=<3/S=(= MZKOW7<4^EHH(,.!6ZR5?3[R?O()^@ER4-M!+CG_3-A!OQ`[H:G5$*7;720OV M8%=N8(O!*^$T>/1^\TA,P$^=^%_0J.>[NSV(,L>E/P=#K5@GA<..))>O,-=F MI*.C^!YB#0`M&%HQGR_T<4C?,UR@@?,?58]Q]M`VXYSD0"B7"8Z"K4!EN<9J@C& MB'O`K?0`#!A%XU4,P5+/V0*\NR@Z*($N_@`8<%P+^2?P)H-!-=BX0'N`UL1` M19!Y0I,AD94?D'6HRKC)%D0M#_MH[_IKSW]5Z._L5\#8RJ@BGTT^3-*(1`#+ M2+4'98U-581:4&T\)-Y*AFL=Z$Z]!H\\^04?\-I.<1TS'8BV3)F@GD735@/+ ME$#T%S3N]?M]^M]B>-A#@]ZH[_3&Y"_YM,;.M3.P0^X>_?W@8S3L]Q`=4^P' M-WC%[KVCX8#]Z:AD'8C^<)1]*L0>,$LN!\%7?CO76R<7.OTUSVN,(KROR;N5 M^=(LJ.O4D=Y4'*8/)\12DUMF;(3&6;E,,G`BKG:CG:S1R=TS#EQF]2I^%-YE M30!C37;@GF!/RF,P6`Q6&*^CK\10.HNXQ`G+3:;"JG`4U'UG%(].2Y+N-=DJ4_/!=!`7*7Q^P_SE'\_?;(,?=*8+5C0=C^#,V[\A,ET@]YT>EJ.0 MA*K>!_D+-D3C\M=DUF2-TP"7_-8+8Z`&._ZX21:P?S);C:PMOY5P=.P$AE>Q M_0"UR=KR00EG97V0X^S$?!Y7[83O:ADI7*;.$FGY,D5?`H54.[)Z_7P@?;@G MBM%TM1TE%S+%BF[[%Q<#S&!;.RE(GN("`6+GS29Z63- M9/;AHWU^N7T&8X7:<7@2)E1[!0),CWA'NO_-)>NFUQ"SQ)-K.A'B<.<27>_= M=WP3O+O>Z:2M_KU!F$DK)?]`Z3RITYD5A*@D]!N7!73_L"5;'75;3>%.>O(V<2DPV M[Z`PI\U*IV#E^B@1%F42PS"/K#JG6(>FTE+;*E_:@BRUIR+Z\W&R%UZ'+Z"2 MTZT9W4VX%4M-JSK('NC=^6R)*2S75O<5..125>17,H,D>!3"S:-9PDRJ34!K M:&I2V?T+VW,CP5;XBEGE`<__LN,"4=@9#!8&;#W^\GX#PMX^]%;[^#RZ;J(K M^:U9G!45D"\F-IK,4W3%[*DP^M; M-_0]_S5:K%:']\.6G@#JX=)`B$51<^&XO1!)@X1>3P]%P9#>LR+=^*]DGR%';$O$MEG"DAU MXRX+GTJ/:#FG?WIY2TI#W/DK\9->I;\S??9>IH3L2>E@X@R'_)3]Z>IO:3T, M=E$9Z(&N\\T9`)A3?<1]ODU.J4U@1]15`$D/HX56Z\'HZ@VO#Y0)BB4_OY'9 M]6Z/WTO3:.0^-(YB&:UD.7_BC`;QH\&)7$K[)65KT6]4.&+230-=O\4#*RRN MX0+]9CLZS#;#&RJ@/1*)M,M:9Y9G6A15M5OY1S8Q"M-(^J'[.9F$)-F$";:( M2!H8*DKO MO;6W/>R]#_R$5X>0J7G[^VI[6.,U3;2]#MYWA^01CV1/+]F4*`L86FH$!NT: M-)?>!)Z04*V$$3(JH*,.*%&"YWYGU*`?I=OEZ?8>S)QN@T>+,4#['@5@*HU` M%K"9KI[K-N/)QR^Z&NHD\ZF&`@2IR3OH[6'5JA@*Q,&,#&]2A_(B"K^^>:LW MXL3#EL9?7K1'#X>07A73YZ-K=[NBYX#`U6W;HX)V>-.B:/'V?;<-/C$Q(_SP5ICI=^5&>$TM M(&$[?_EMRW2)*_ZN@E>?EN<@YG@!^5VT+]UE:KFHV[I>0:*() MBE7AN/_R0I5!66UZZ*@/K\.=:(2X2HCI9$LL">;A0DAITL/F>;(%V)=3I>X. MO0BVE`XX=;?79=94CHXFL[$YYK0I#@5U."=2&DA^N2KX-+WG\8AYNA\)1K/U M5Q"__DUK(F7^M(@LR\H%I6WT.C#;ECX,4_Q3C.D] MR@59YM1#0UTD#&_S'P7WXNNV5!`\?;5LNZ-H.P!O-![X`FIH MYE%8]`L(C/+[*W]L_.KS^)OX5:G%#S=3BTXN;*T\-(1VN/Q2[[O[V[XR9?=)Q[\*UW@I1ZTB`!;07@%)^KO)`MHLD#TF:IP9Y%A M$\$6A7CUVBH\W=-7B.UZISLSMG-7ZZX[9:BL?VSDI3,@I1*12;K9%H[)!HI9 MU6DM?1YA1M&!/VVJFN:JI1%@[FFNN?QF3%I)0<1#N25/@8A255!&%ZM9R913 M&4/]BKW7-QHV+3YPZ+[BG)=^B?CF^PTFAKS3BS9?72_D[X^PK)#X=RS8@GU. MJAWPUC';F5T%S')4X:O/ZZT;2:9F%+^`X9]3-12J2*87:;-DPACCY1,QB=9L M/IUG97$[2=I*`,R*AJ(`@*6NL0!-<6EVOF=^'^QQ`EE1,+6N)0A$Y@N3JP*Q&M*1[&@RS\^ZUY;@2[N13L[(Z$#+U:U) MF+[&_MHV="D,S5R87N,K$'25'DJ(.KO\QR8Q5:J!_&,._6D")\&Y'1"*-)B5 MR2#G9JVR*5)8_!*',;14#K4<4,3NL`\MNYT_FT&L79C,#*A,!>G!<8:Q)?4;&)!$SXDE%'=\5%G\O>L MVF[I>LH2U8SO`MAAMVPIV=%H-AO'VPWG$V1\K)`M;\"L0'MBQC&M(+6$O9+" M;.FAPF%Z6D*!&61XSZ.+O:AKFNM:+]9L['2Q*]DLFWP/,K':Y+OB]I,=>G5O ME5%K_]<@W&"/V)O8KSL`;:!!%]8HZF;)EWLFN3W5]LCM'5OHM-TAN770 M)I'UYY5+&'6[+>?LL]U%..@EZ*C#!J=/7_&G1ES:=H1:\MN<^\W'K[060C?] M-J)^^RHWPJQ?;C>?@+2LQAMVEN6+]5CI0VCCA%NZM=J=CT71MEQ\-+N.;]/!E+>39M:((;!5_ MTOQ%+.'S-DG?%W/Z(^/K=Z[JY2[>S^D*1M`5M^ZZO4H_:Y!6+M%?+;BH:)@N MS:PY2[K,\@5G7F-[UIH*>EW.,E/>:-DSJ+XS'\Y-KS!/IZQ_F\5E6_T'''+\ M>RTIV^K$NF"EXRM(]8G$P.)1L2\O:]UX'_`ZI>O[0]6U"6/M7\3*\<0HZ:A\ M..T;Y_%45_*/3-M6>)IGC-[Z0&=R9W4(.Y"[Y>_Y7+E;NL'7HH^>]FZX[Z"7 MQM1+5_C5\_T:1W5_]2@@33/+Q[)>NM`YZ3'8;K\&(?T(#@Q9)2YK=LI8)G\A M;SX:@4]1:56S"/U&C4"Q%5`7'2WN*B?M*M@7/$#(PC`AGW:2Y;MZF7<*[=G2 MDU7JG-O(P-_S;[>*WTF^&9%;S?*M>%7>Q`MEC,N?5G M,DV^H>&@ARBY0ZPKD9->=T!?QM12CTFUE0EO2-Y4O)JJEA M\4(^LG/KI[X5L6K;?;A46-K#'R;[I/Q_I.T#)OS&3T MZZ%$0Y2HB*B.'5O$M./Z>/42^R>M(QH*_&/]4D85Y5K6,$I=`T::+_66O:A8 M]HS#]\HRC>TT:)HF6[%"_MAZ5%>(52<_4MT`:=$"5^?Y<.MMV/LQ)$!"`9<- MSHJMPKA`A^UUR<4$C]^#+1&S)3&UZ?#QI.6N!Y!Y<^2?)!R/^^8H\JCDI061 MY[@_3YL?1Q_%Y'GPUSC7T4G8KYLJ(.\Q$$7 MM2ROPGEKQ"GLFT[1YC?/QW=[_![I'LY'P5T@OE1;^:*",VTO(J#?:/.(M=^U M5/N&CG/,.,YZ-BO`3PM=Y3NE4WQT'\1G1X6SI30Q1O<0EFFR"QPF88LY!3\6`"_>S5K]7M\U/T4,`4$:R$[V4Z`3?7B%^R6&Z+M[?MN M&WQB?..%9.4=A%%!J'F6JU,RE;TB;)YHL,IWUGHBLM*[Y'N=Q0TD.) M@BC5$,4JQM47Q>/!4%N\75VCNG-1MC;WCAJ\ M-6)]N%V/4BU1=DTG=)'8\O7)_AH&D?9-T(J6.D1L)>K+IP8Z,T<_L16+)#*M M.K9WJLN]G:[$K&V,G<2T<9)5I\LMUQ.53FX7=4'WN?WD&@+[RQL2KZ3'>D8& M=;T6G9T3:DV3+Z`^F^M+&%`IJLM^@JC2F3R#2YA0-/=-[F+5%S?V'F/9+VOJ MO0WUW@<5'%TT#TN32GL<+=>UG;HF4%Z,<;DIW1QON[4N7!"H-D'^^,EI@W& MVV34;V%;-5<^J[/%O?4X]U**>.OQQ@45ZZXC*)U1;;G7.\[G+1;9KFZLF\S> MI!+SV-'XKD,9O7>[#+9&)W>]W+44/%NBM//*5UO':PHUK4VWWDWFT_%F\F#4 M'[2P?K>[CK'5?7&Y@;$^'UUTN"Q;:!BBARYX"J*S[<94V"VKR.5-3!GKY"^D MCJ?Z*G0UFJ/`ZB=VI7=L+9L(3R(`5'W:BUT\R/MN[A2OM*D.'>&5Z:]0.V78 M0I[=]XLZO#O?P8(<,WXD!5_+L;62*YUCSA*'K$F0CL# M5$HQ6%/_=XN)EDD5+QXW*KT!KVU$-U*B$^S5Q#+Y?$I'YVWR\=>HRG%7+0P[6-^ZF3+%QR.PZ"AU75Z!(3*]HFC_G!6.'\3)J+ M2V_@7BH;M]HW3IR?%DN870?1_A&O@E??H_]*;Y%](_^-%)Z7 M%(NPH[B84#_IVDF3^6!072FLAV@K*-,,OU+*&[*BW)\+C9^'O3<9@(B6D%TO#Z2B^\L1$L#-;*@3]1L5`'9;H,OJG7[1_-DI+@B1`;'BXXTR!' MS2#CJ"@,IU(H?(,O^)^HLMQ]4`WY5[O'X^1)"K:SE-O0IO+0;UPB&"8TV`H>@MV*Y)C_)-BJH>S?_0-&9RK4OS M[)S\)P.56,A/R?->B_T^]%X.>S:D]@%Z((/*;^G<)]B[VUK4G&'EA%KY3%OA M[TVGMF(F#!PJI>.L@)"B`^P`1NTR1O@!*%"4U\W]67*%10$P%BQ?]!CN%`WG MZ/DON^!3O2JI](4=<+H/]OC&BU;;(#J$^!G_OK\B[?]#NGM%WX."3:"4_)[5 M<-ZOP!X5CX[RR7J!M(!8$];`3HL+XK#O_9V$LZP)N\!7,W:KL5CE(#!HTJ@: MKV\.(8FS>887#Z_O\0_V5^(C(JF/38.R5B/YG:SI.!L^(BX9<=%I2B:7WD-$ M/O\%U+7S%HS/U-.C>W@KCDH68"*/-04.3NG16T"FG*^L@R7[RY,+2\(:0NJ" M;(%KJ78*=^-F+514+KFR"/9,7=N^L^B)Y\9HD(:\V&%@\.?:U&]JYGYG&KS9 MQN4KM4ZGTUP:4_SHN@7;ELWM.:X=$[H`ATS9""H@HF"QGN1]*OI7-V3W!D3K MNZI?&D_%+U5#-L':F4S&_3CCG@V!1)+A1'H-1@R*1J#C2A,B)UZ#484E964' MF4EOKT3(,8M=;#W(S'1XB?`_#S2K\8/E,M;LBXI^;G*>$NB@- M35"IWIRL]`(46+RUYX:?RY"O#'[&^[=@?XW;[?8D'Y?;+?/9*:,".1I!%[1_WK;,0Q.K#UKV,-NMV7;@^[VQOOPUMA?1TO_FC[M%^Z]ERU^()_C,,1K%J67+EY491A? M]RHJ*+ONFCO3:7('/=,$2MM`9"EV^[1\0*MC4VB7M,6/&`ROGEMUQ:#&%5&P M,^Z*FH5WJ_Y@E)?LLP>;4WO1.O6.Y^?.G>!6[`WYX+B6;^)0B$#L&;_O@I!P M3L]H#F)=%-2R2Y)\7A'']?AS[)`Q3^.1GXUIFKG1.J#?^:OM@;[] M\!"$[$Y+3O-[XLS`WQ/'$JU>[WPRN$C`)EIRM="0+5312'OIG8;I=#B7YI)4 M%13K4F"7O#HHU<="OC'@UWI"(O](=&2NM)N;S@*K-'DU[Q,+V.V;1_YOS2]? ML'[&OK!THM2G<`Q4JH_\9-Q/*B04.24C&1U%6T$/&HRN!_PV8[]MB*\DI:#*9#40PC%,NCU*M0.!YIM:# M+^)6NY56`X%/-$XK<%?J+FL@QU/A5#H^_@(::EP-^>RLP4`XV\4PNQ-F,@-! MK(F)TO""S]N6&(^UL,JXR!I(9=Y+5.GM[&?0X,KH(I\O/)HZ-0C+B+4(9HV- ME<9:4&TW*.!*1FLMZDX]!@.].%&A)OFL^#NCX#II7/Y`V)FF86&2*`.>9W:F M.8Z2.>90(1A(>1B460XR[KW]%B\W=SX[&CNXVXK"I^6_-3G^RQ20'C23P3#! M`)5#SP>/DD!+G6JPRU&WRQ@BJH98#A5"-UB!C%^]_=LCWK(M#YHH\AS<^GLR MB56^?:HJ!1)-U:K)C\=A/ZY0EQ5&#PJX.."W2ULUVVEH-A@6Y09U)4HE_-<< MOQ%>_>DU^/CS&GL4NB/Z#Q2QHPQBR1_]WW/HTOCQZ?/])3CM^>+?&T!9H5'Y MX&8T3U8^_'O$!9B%RYGZ.W+ZMSWNA4.#CNAR$T'F&M+`U;54`GQL MWJ+I0E:QXLR\$7QK.4;#^7DCIA$?XRE^;!?7J)]V.2-:!4R6;'JMG_(UI)O& MADOR3?N&G\,XC:VOHYSC7UA*.8(#S@8^:Y5TE-=!=BV!5$)D9S:;]?OUA&+1 MLJ>!>;6T8=M2IX&-0G+X0_]/_<%QK?,7Y/1[_3[[;S%6Z:$9^8L!^\N,*'>/ M_G[P,1KV>XCBB&VYW.`5*U*%A@/VIR/K6$=M!:5]\<0N3,?U[$K+QHE_9YY+ MBDK(QL/SP=@9)13"Q21Q?ZL%Y"J8XUQC!L:-J>.)T>)TAJ*Q6B*G6"PO M![STL3AV$OS2=/14KH9L_#X9SD83'C\EO<\E(2(**(328=$`PJ+J.$J'6;PT M%*\HC#YB\X(/N@Y"G]@-X<*J:MRD@56%$R`FI;B6:F5=[?QO#$Y*N8:ELWAF MZ:--\??`E;3/L,+)6`$Y%Y6.DNQ<5+019#!C[_6-+%H6A`_<5WQ_H-HL-VP- MD]G#O'(C;[7PUS?>]K`7WOEK*,PD/!II*%\+=^[$>_Y)0RAN"?&F:"90\4)3 M#[$&^285;Q((=P;IS%2X]H2_H)77.6NP<8[@^"S`Y`FCN;(Z8 MV`W?B&#R[^3?R#_0UT?(O_P_4$L#!!0````(`-T]"D>=]-7FLR0``,PJ`P`5 M`!P`9V%L="TR,#$U,#8S,%]P&UL550)``,QC\A5,8_(575X"P`!!"4. M```$.0$``.U=:V_]T;^\O?7I3M9@P!! MW_MT=/KF[=$$>+;O0._IT]&W^^/I_<5L=O3WO_WQ#[_\Q_'QY.YN2_9Q\O.;L[,W[W-_ MN?,CS_DX>9?[U44`XH8=+-/'R=G;TY^.W_[U^-WIP^G/'T__^O'LP__E2_NK M30"?GL/)G^W_PH7?_G2,:[R;W+VY>Y/KY'].[GT/X=++E>5M)E/7G=R16FAR MA[L:K('S)OFHFW1W@B'UT*>C7`]?'P/WC1\\G>!FWIVD!8_^^(=)7/CC*X*% M"B_OTN*G)__X7:A(/E96]?3#AP\G]*]Q:00_(OJ5&]^F M*'$(.&&6(/\Z3HL=DU\=GYYAI-^$N?H;Z3!7P+?!7=@,:$R?`PW*_#I",'E MR@5'R>^>`[#X=/1DN2%!_J>W/[][2^K_Z=*WHR6919YSY84PW,R\A1\LJ=1' M$_+=;W>S@OCX&\`.H1<^X_FX`E$(;42G4IA,S!-2ZZ3RPR=MQ;[#-7^]QW,? MD#;FBVOHX<&"EGOK(TB:N'`MA.`"`J=5+SB;Z+,_MU8`V@V-0#OX2_@CEBN_ MAS.\\RW!U`U!X.%)L0:RNK3_8>FR7UCH^=KU7]#,#[ MT+=_.R1-\0F5R7`._I2^B!:PL&WRTW`O-%,LL^DPG4\JR7 M*D@74SE;2G2`:%-=S>G*MB1V;G\;D-RCB@8D=N,2NA'A&O?/F#6A'\_0?K[P M(Q>?&1"%MU&`(MSP@W_U"@(;(C)=HI#H%T3WH[+-L+H14,*,\.9(/_`#!."K M'V(^XT8.<&;>A>7:D2MSH?X]:PMGUS<]%E3WE;DZ,QX%4`T(._U;&V1!\EW!@32S^B:+?J MGT@[7?`W/7;RT.NI_4VD&BM(# M*=R.T'(92UC+3E'2A/-X$'(:*G&*6MN`^T5M?SJZU4`T>MT_DF1[:N M$2PHJ%U/)T9C:OK8Z>!7-MEU?[=:6S8%.Q_:ZC:[[O&5%7CX]$>W(*!+JNO> MLMM3UM-.IW-=J[VLX&??=4"`KOX=8>66E.V/9_&WWS42%;I,?W`("M$U)C-O M#5"8_$AXG;,FGDU<>+I88&:'RR'B]70B%Q#_R;9TUSA)$*SSE14](O#O"/]X MM>X#$G9[24]7.7\*6!$M5:-PESFX_*`*> MM$T]V@C8;Y[\]8D#X`D>@_?D!S(8[X_?GB;^[#_A7_TZQ4T[I/EKUWI*/^=: MC\#]=+3_]Y/.Y;F(`N(*O<9+UW+_":S@RG,N\8"5B,8L*B;E_C0EO_DU'99I MR;!,'U$86,0561"*OU[W.*9BQ.C@LQ+ZSC7^'2H!DEVV;SG)*/))F97L3\;< M2.+=`,SP-E(E:&EQ)=)29L0G:5RT/RGCV<9>Y.7E^I/O`7^V0BSZY^ZEB7>2 M"]Q@0(RG#GC]7[`I$:N\7&_R9>;[V,F1\V"PA:VJU)?DE_[2@AY3QN3/?4ES M#5T07.!Y_N0'[%$NENI+MCOP!,DAYH5?K679RB@MUKUT-P"?OG';TU=8MBWO MENA>IH?`HLZ[S?+1=TLD*OY]*T^>=4Z#HFQ68*-X9>,J4A`R@]P:@CM6QTQ8A@[BNLJM6GU-UE^.=EUF/7H1N--4$S:AB%IYI3H#6\GQY-M[<+/ M_F*R_=8D_=A?)KG/-;8A+2ST2+&.T/&39:V((>FG$^"&*/W-<9SGN[4H);_^ M=2=V,#F#=\Q+-86;V[Y:R;T3X5@K.J.\$NFWL"KJZ17Y'Q(4A5+/4L5!97(RPZA8@E>44-5#Q(=HG+* M[!93(>LE7$,'4QZ^`YQ56A?/:',<9R1DZ@F2]`FZGWT%X=4KR8/#4_&S[SLO MT&4=SUQ5]?)9-LN%42OA+ M?7FETN]Y)5ABWTB(W94@;XE9L^;TY*JJM$]E<ON`A^?/C,-EN''I_KI&L@FCQ<2ER3X]_%7' M=E$14+B,`-E1IE=PNCA$3(M$!I%>X>E\$'&9/#*(]`M/'VB8EIJY(NK8R,^@ M*L=!QH_T2B&2C%L>J";[]?"/M#9`549`9,#IN8NW`:Z!R2:#4Z\=7P:<5:4S MW/3*6)*\T3$B`#+TFJB%![7[\6@[C!AB73-3&J/$BEC6-2VE&5#,D+8,)CW) M6:TOM$`R2K0EW5D_V]VZ;WPI\R+H>=3QH<)_(&9XZ6GS%'&"%^E4T=$\FM4F ME$9X-CXX./;O;0:A02>_3>F;6,D?1;&U_]9X_'6]]$<,JL]0,U@XHDOUO5:H&:(55J,&MT0)&(Q.H"\^>(#M2:G4B0C M$6,W#RC,#MW5TX<+6!W@J*FX1_$]+=,H?,83^_=L#K)[LE=C$#V8(13Q2Y^4 M'H3D[)MUN:KHDCVJ5Z9ED2'?0'P0.73SC_]`7M'C3SJKJ*Z^;YP;2$VEH?2C MLWD[I:)NO,9)V9K#.3=6:RSCK.@HI?>L;_O/4#BF@AQ.:K[]F^ M%V*]#DOU-/.PG@X0\^ZG#AH:`%ZEO(OV;,HK7"2HH+K MGI?>"%F&LJY[5GHU5MR*G:Z/K$B`J>*0U#2UI358HWAV16RWJG-:CB:]11BE M/=ZEZ241S1%B++<;O[/UI]3-^ M\1=4)"ZD23@I(SNW$+2GGG,)W2AD!D'4U=(E@+LYKI^!AZ>/BS&9.DOHT>>K MR=1([KMDX%I72\U#1F1NWO@(7>/](3:,?@&8GCHS;PU0?"T5HS]\==7U:KL( M:Z(&6:752)XB%TN5&O&9HC.*F[2&&*"O(,RF*0/$8AGE4D[7%G1CATZ.]R<) M@G0OYND'QU>4]!0?LBM`]CWBH"+"5N^9[/*#DKYFAZFOIZ(W\U2D1!C6^M@O M-PAI:S!GEUUN5%92?;(.N8X,$,H]7]P!!RPI5[^$B%[EQNB)R!?4]W![ MC]@.'9@M5^Q))O0)-<]](8"U0G)Y_258`]>GST%4[[G5=4P*BS[I'C\`?'K& M*MUTC?><)_`U(D&2\P75^G(F1CZUL>''5%I!:O2$,1H332#ISASAYGS%AV98 M:ISNWM:&<'%9(73WO#;"KD*C:N=^'?Z]P[4J0?%BHDHFI'MZB1!6M?9-W3-- MA-`JT:/;I9D,?^7QN:TK4#1I`TRK@$D7X#P+3;Y`B86[7:B_+CN/F&FG6%#,O*VN,<6`K>.7/:H]J)TTI>0& M4[[7FTM!X*NK9:]^/1M0OS!/@,0%0%QTJY^,#PB4C'A+G!^]'#P^'9O-#].,#PJ5$06P_/W@_>G@X M-)L?HA]7GO@PV/0,3`$3*\C4Q@0X`&(4FKNZFB!HWP;`H>R>)-WC(P?,%SGG M!3/RN:Z>E+MQ\\W0S\Y7B8[WPPH"BP3P@,"&^\D+HK65A`DGC@_@8-P(#:W2 M=1F%33BVT(L"6_,O_TL"^U7T#"EGO4$2K58N_:CE;AWIBLTA0]0W3/:6Z$I3+=U?691#$VQ2/9V*?&Z[(Z< M60VMDN17=`2P/$$X&LA^/6N9,!^#=N4-7*'BAZR=PV`T3^I5Q$R,\7ZTZG@, MDX!J$E#+$E"S'81D:J/YXC8_1(X#8U%GWL(/EG%D@HS8G9+&]K;%?)Q.97DI MT40E+90%-%67'4Y6XC!R2(>5IZ97!LP\>+*\)!H+ZSS(=Y-WX?"`YF=F[FVB M[4Y7>T6UE&^KV/:Y=Y=6U+Z!)KX&P:,_U,.2:P<<'87@1H5CTO5)*$QD@]HK M&F5NS%73JW>%9B!,-8D;VEYJ*8/^)=^\P"6A;;D/`1Z5"Q_MI<[4%%9!!/;# MJ"ZB@$Q2QN'.+J]0^MO`7P"$Z&R[!IQ=8%52T8^KY MH=^#I-\T&E1PZ=544I1"2(X1E,9C6FZ=1>U^O>VTVS.G*CZTWP4K:T:L#T>O!$C`N-TX(H!(_(#!RADY)FG>PE2R>6 MH.10+-QP'F>HH#N`^1NT0UHO_1LQ^6?_2E)8E-R=FW60)BIM.Y;TB)Y5-$_\ MD70]35.HT=-:?E2E$>4>!&MH@_+4^*E+)8#Q_?^V_^3!W['\-`J(=HJE(W;5 MBBX&FLZ>G?\"R.7PC-'@JSN`Q]IODOE08I3BJ3&@'I1.)+XZQOP7HU3Y:%OE M?.>IJ>0>GRWID+,_5EX'U$E;!W]3E@);EQSF40BGZV8>Z:HB=$Q]A&X:TLS4 M)G".[U\8Q#PT=9^(7)R!^_W2]"C4U2K9.RJRK?=(XG7;CU+ND7W6&MS.# M:D-4NP3'IZ&5VR M;8:Q\(D%_RD.I#W?9&62X9V^6('#9Y9H^_WAF")R,K-$KK.72_CP0>&1^(RN M_6`!8(BW$#3SXM-#-D`5+1TB8I^I`RWMPN>`_71"%RT=(F*YEW+C%W0[PFN_ M'8.60#N*'IR4V(\[WW7Q-D/^V#UH^<8.'+>=9Z[3"RYO`ZQ]=`]D9>L&V8Y: M/_S57M4[LC@7?>T$O((,$F\FQT_ZN;WM-N4A74QIN4(<),XE]%@%TJ)B'"36 M16*M`F8!"=0\=^3;OY%KQ8%S&05XBXOEI%U"^9##5%3F+BO^(5T#!5I;P[D?]F"&J-1GH6M^HX+A::`N-4N6/*3'50YG>90Z09M=,6P& MJ)4Q\H8N!U6F%57W=YXU&5)!9T^SYZ3- MJ/8\JL*N)=T?K#Z0<97FZ&_XD'-3JC24$/#2:S0D7/5E5/A&]8KD[_@:DZ\^?=L' M[TQD)J,'+2_9(ON&O%8>I>AG9T?EM2'L\H> M2'S4I2/[F-U%R65E#5YAX>1=R@4'CH@ MN3F,#/1_OL?OYE0TD MT`OAHA.B=WAWFC\H;/="NE1G1+->H6@J1^PJGB]R1&'+$&J-7CVT>E"SQ60_ M2^G'CJ6>_O'2"@'1\*H>,>U;"F5(/];W\9'1QZW9)%V"I:N[Z]8.$;GO_<%6 MVM0@US53"\F\,IYSZUK>5VL)*F\;[J2I#L]68E_,66[)SG"#_XMVO1>-/J%B MK!]@2!3/F>?`-70BRZWPN967'834/V#X3#U"9"$]P]6#7V&T;/H5%3U-E,"* M4#.G.EV;IYV9AR`QW:I5A;L9@)U2N57*W0;/ST*E6.=HCW/]["TXR:=:# M4CCJ,W],_K2D=501B-`JI7ET&"L)=,SV=-961>Y6^V;I@.=T#-!I& M#^8.HMT+.;*EK*<"WQ8QOH3@;,7JJL/GB^*.J]YJ=N\U&U>ZM;IQ@P..\YV-\AM&%>O*T!T MWTMRBN-MZ@ZO&MF9LMSM'E2&9U6O'O#V6WFK1S<-:C,;O_N$1[IX#^I[/NZT M?/"(WD'TVS562V;XU,P+S])V#PK-/:MWA[=XF&0WD^QFDMWZ2'8S2)K\ ME\-PL/9(!TP>3*_AR1R:@TF%4;Y46+J(R7\9S-`4C1;]9;P,Q`Q\'RV75K"9 M+W9"&*B-=XH_M<:=T/$%#F./-O9H<^^TL:(/\^9<:X1NG_"K;&7::/RAL^_1W#`F/0[F-UMPSJ8N%Q;C> MC.M-_2SLW?5FKIXS]TP:/^8A#,&P/`#B2E4K?V;\*O=]:`6A&:9>KD4Q/LY! MC,^N[FPDK5[_Q&OX$X_G-7 MF?RP`M7>?N-'[\Z/WN*%>+I7$>A\#T-3:;@L+VN\_WK[T66_"EI[.EZ]@L"& M"+"N,4[_?HOW^%VP!B7:(/T8(XY7Z'TF)P+CTVF`A2BT/`=Z3\/9 MA'F%,MAV)I3P#M$[NE72,TP\0Y#HH/;=L4;F,6_X]Y.QWIL+Z6!+/W5XFE2" M86B%5/`=$QZJR+RJKJ.B%XD1NS*OIEC&A.^-+'R/RZR=QW1G3NF:XF["&DU8 MXR$AR7EPF3!'$^:H/&JA$SN(\I#(!I%"^H=$'L"0LL,G1_K$RG#'DDM!;1:U M]"$>/P^3D1`<>EC8<$>P73"FR(,\9D"',:"5H9L-GF49>.CF$(RPN?$=AKF] MY5.M@Z=)XQITD>`&75^"'=>("P88ZOJ:[+@&73@63]<';L]';/Y0Z< MQQU\IE2!\)N44$GO>_>WX+7/$N7QL!>>["WW4/;G=QM(DMHE='&A-:"S#_UX MAO;SA1^YSA7&+;R-`A1A>O[@I]-JOLCMZ#2U+3$<+24_WY1_H.HRX0Y;/$`$ZP+&I'U^.-C47LY66TU) MDN;NHJU.BF46UR7=5=?$T98+CB][5$HC:H(8\6F?9Z_D)H#*8,"J&LIZ$-/F M>KD+Y:2$=W]+=*F8:I5*P"YG`CYKK\'LGL\4;GRK/>!TC^&337_JT16F[+K& MDXJR+*Z06SV-.4T@*CDH=#>@B,!4<9KI?M55X]G$(DZZQX?5Z4[E"19RF+BN M![#))F"&:^'J(\I*&.CXW*A)4!B(2R5W[]_4<6`LXLQ;^,&R M@0N$84R8/CT%-!AUOL!P8O"9Z?&,DDJ,PKETF:E'`K"M[#$F0%Q:E:: M'$2_HJ*G%ZZ%T'Q!)T&=G;^\K!23$YF*$"$"QI2L3ILL@R<\$SX'/FDSG1"^ M#8"S*U^3+^ABXFY[HV.=BZ!82,I8TP%)!X)LT3-$G+=VG/^<[DAE8\Q9\_`= M!@SDOEC!;R"\Q_O\%&^5=!MA6V?9A57,MC1O_=H/L8A97(+3A/^>LI M<2Q8-$64M$\/UY0'L?P+K.**[TTE`IUOZ''$>1/J7@UE;ATR&8!S&='3*([P MIX:IK^"%_HE]S097917](A=N8XJ?<9N*T(KRLDHM9(\`/&//QU=X;PK41>O41W3PCW MA&)Q^OX>T!@Z0"*3223+.\%J#8)'?^AHE=L9&/>5[3-[75U"QC?&OL*(I=\9 M1U39R\ MG?G4LD9WVV2Y<+BKR?/FE#949J[CJJ+$-\8>VVP"U#A0Q+ZABU=J*'X4.?/@ M!NN%V7V"^PB^3.!"PU=;7LBVUL=6]6.R8N" MPS\+]:=DC*HM?11Z&%(]NN"&1 MZ15NP]*BNK"EMC$\7T#X[#NS.,\!U*8NUU0:1C_(7C9_\?"">X:KS"W&W256 M?2GZS;4%@^^6&Q$E&B$0DATW@(]1")P'_W]\O#J_X^:BO;@*PC`$ M-W!-KL,(L:H/\?E!Y43GFR_6O_R`6DTJEJK(%P;6PTRZVD4D^A4YD7/%O1S= MN#8[_HM=6`7J,P\?4H#H#L094KY>63.*KZZ:7E$7#T)W^$S';.49TZ]+L`:N MOV(&YXG55=.K+:HS#TLU==;$_.EB`5UHA6Q#4[-O#+67F4$Y5[K&XM/^ MNT-%HRK6CK^^L2H5O><8(1MO:0$XCQ!>$/@((1K@C-!=C"@&E`EW$2WI)7QKD(N' M3'6YZ0*OBJGKYKV/+&"DMZ/60LBVEN3M\P)[D:Y603'S2!8`R%:O=(_D;J#V MY^>=^KJM&P-I:C14_<6F/9`477/6VB->:<)G+=LRM:XUAKKFB5+L MY#80ZT[NA6WE=9%@[PU296=0*U.9]LD.K;`M-R:EF)F5*VCDV+>1I%!JFY+4 M"DK!,U[?\,\!QR^JF5;"GK3LY:I25U"K%U@/`"\9_J1J);IH,A])_.Q7GVQ? M/M[R\;X$+7?[;!BMJW?^BZDR6;502D5%51X`/=! M+!=[OYPN,;]ZQ;)LE\>>8KYWB]5>0:7R5EX?5BRD](ZJVO5>O!FGV#M=.8,A M3ZS')2OM8R6;;P:,GD[$\O4^N@2]>CBJ9M)H;LAFD[]DS:!;:T.0(YJK;0<1 M1@!:CUAO#0OI>@]8H'.77/.CCB(*BUK)'X6_9NC:$.E:,HHH'4;+K=,?JFH8 MPJD/X324:N>HY%@J8Z3>8HRS\5ED>*GAI8:7=L9+*;;=X/O@(N+ M.!<^"E'\#J:%@+-->E!I%N46^3$O<@WS:OE1%62@[="U!(+Q56,N'J(J8HAN MM^>/G#UIC!30J`J-N'#KS=\09$.0#4'NG""WM<\:FFS(88\7&BU7KK\!X!X$ M:VB#;%[GQWKJ4EGP3_/%';#])P_^CL>:/MU')P"_45AV>XH?M=U._.+2P),? MVGAUT%=JIIZS\YMO'B3NGQ"N\200M*IWT.0`,-R;`E3H.3TO6B'5Y,-#P2/9 M3*L3K!*%H&?^N,38M&C%JK5%KC5IKU%I)+A[I5&0T"B\GP,U/ M6MTOV6J.9)LS6O<;MQJA*IE-ZWX!ES%Z&:.7#*,774D_Z$.A4IR]QGIC="`I M.E"KB\;+)W51@*J2*M#:MEYCF-TO9[2>(9U`I:2G M$[H%`8WO4)I(O"M,#3EC%E=Q'+.!Y!/>).P:>CAF>EBW]@TU--20DQI6;,6& M%AI::&AA"UJH+GU6/3DT]*J7BPVQ(`YT(_(0[CVPHX!>)W;U:KL1GO+D&5<2 M?AZ%29:)*._NH"%#1PT=-734T-'Z6Q*E;6V&QQH>:W@L9]CE7OR-U.=DAL4* M6_!K"D\=JRX6,NQUA&RL5SEYER^K"[SUE7+-TI5G&*9AF+P,DW^9&.)HB*,A MCO7$$2MB2QC&M^=XSH5/'_4$GCVA13>-`]YP[,%P M;`5'1:/]Q)!40U(Y2:KH3FZ8JF&JAJG6,]69MP8H3'XDSUDY:UR$%)XN%M"% MN!S*7!"YTL;VN3VK&V-8PZ_;?_>@T*CCX1(^;-BP8<-]'$?2=@3#D`U#YF3( M,O9=PYH-:S:LF2,P('I$X-\1_O%JK249-G3G8.E.GW+N+(,:?899?`BRUP8# M,,L;CC2DHZR2(U4,NJ$^AOH,BOHHPJ5F2Q^&0EI*"W\Y(1*2)P;P/_X?4$L# M!!0````(`-T]"D<09-LS=`P``&9V```1`!P`9V%L="TR,#$U,#8S,"YX/=+>ZEH"7:)BJ1+DDE\7WZ&U*234LR(]G.QD'U$LCB MS'"&OQ$Y'(V8LU^>P@`]$"$I9^>-3NNH@0CSN$_9]+SQ^;[9O;_L]1J__/S] M=V?_:C;1<(BN.&,D",@"_>&1@`BL"!KA)\YXN$#WWHR$^$6$'XJI.7QL(V:S;2#+[$JI^ACZ_BX]=YJ&?*(^:?H MQ+IU*0A60(U\4.(4'1]U/C2/?FJ>=$:=CZ>=GTZ//_W7IN;SA:#3F4+OO!^` M^.A#$SA.T+`U;%E6_1O=#TOC^.Q33GCZ-14#7./2=E.>D39E4F'G$8@DH M^\O!H9OUF-N=Y%@2M3J?/GUJFU:+.I+-*<;S)?T$R[&A3AK:\>!V8'#7N=1B M3F0AFVDIYIOB0*VI!C>(IRA3,W"H.8D4]:1Q#TF`T:BCG(DSQ2J;FMN9J7W$OTCICYE\S1=6B!_V(T/3>0-0_ M;S@IEAJE.OED0ADUNG>..JB)4G;[$D2A6!:RA)VULQ*RPB-80P;L9W/MX<"+ M`L/8A]\)+@CDNC MUV6`I4R\36,W!(8_2S*XH815%BT%(;UV,I\PO:;#E>0!U2NNCRYPH-H=AO@=)(`0'E>$UW,]@_'X;C-&[-<5^J#&OBGD/PNN0=`-%!`-[ M'D@QN'DR-YH?RJ&Y))&(3]!@KN-W$%`_NY5QO,1R=A/P1]EC/A7`7(QCGLR- MX\=M<-2=(--+C6,I'&^Y(G+$ES/H:C@OL*1R,.EZ)EB';;`%:Q4N-\H_Z?B( M2B_@,A($?A@!&LH[:V1K,'<$,\%#WN$%'@>DRWRX(R+B]RD>TP`T)W(%PX@\ MJ8N`>W^5@GQ;V6['^$_6,1*AZ/IIKJ>!^@'?U2=6HPN3,P_UJ!HKAR30,^LE METK>SR#(N=`Y+$#7<%7SC5W[8BB\XB,AJK"NBZY;@!KF3!5D+0T:: M#@"6O:$>DTJ8%$H-^:Z07V/!("R3=T28B;<:W)NYW5`?9Z'NC"IBD-P!J&4V6X1(-H^ ME*\HTHW^^R+T$^DF%;XFOW:''=VA9UX\)9=Z$^8_Z'0E$'^C&[38?LF[S:S(RZ![\1'>%^OW+VEUV73&BL21_1W!Y_5#= M"S9SN\']F-NQ+06A6%(-[.ND>D::6+YDPB?IP>T@N7Q@-NV#WL5RZA`P^^G)[3BY?.&F7%#M0"^;%*K@%TX!;KASJ;_"!%&-]8NG#2K`_9P,)^+' MN93@>@JAAKIB`=1R*)-7=O;[MJ[O&P5QD"^+JL[GQC67!2Q\`Z@C@:5PNWH* MO;LB"M.Z`*,R[DEDE09667BSS6X4 MKW^&=C`WE2Q#V'D+ZID`:]EFTCK+7^DZF<7^6W3I]J=:I?=TF6C,,1B,9A8SM$%"0]4+7*^YJ)U.TDNPYC( MTHN'#3Y*Y=6([G<2*A4G5&%UXYU+#6Z<%.IH8=\.\)7H;W^(WWT`ABGI2AF% M\K%`,:5B)`RLGPC/)@D4^^O>C9-2[/W*M'M+KED8]HC2KI$5I](=ZH7 MCV6WF=?12=O]OMPS15*JA]EM[I.R?N^L8Z>GT)>#<4MI2&NQ*_&_YAP6__1ISD,R029@QI. M]=D$YPU)PWE`&LD]+#S-[S[BH3T7?$Z$KDUHIV)3`3GN]3,EC.]DQB_1*I4P M$V1RWM"G.333+^/_!([64QBD)(HJW8N]6FM!\D>$@Z#1/ES+UV$L83@P%!A^ MM13S1NP.\)@$)4T&V@*3^UK"&[$V^YB7,!I8"HQ>>VM78/M9VS[5`7ZMG_IP M!J9SH1`K/(]BP_$P*#Z!IL\](\C!HG\U4[ZFOM7L'#=/.JTGZ2EL[' M73393HOM5"@\#J>L5Z0,NM,/E1TA>RS1#GZ@[U1U@^=.]G&J4\27_FBNA&RA M2,$Y0>4TL1F7OYHK,=5UR1P^5$J-E$=?[-1Y]ABC4KTOF?;%;YYF#G\KUGC*9JPW])X<_ M&07.&TG9QR4LVG#<\06`SU4",!H&N$SMO M*-`!AB$"F51%>A!^%3R:I[U3Z'6#B=.I(%.LR&`R@9[9]`Z6"V+;MX'@+1A7 M4-0%,1S1:MH0NLEL0_5K%38M,C/6,6^E'XED\_TR]I@Z0;+M M?'4/(*ZR8]GD6Y%OEJ(^(!?=K&_64Y^E/%B'72\32UZAQZ]),O8Y*=?L,_2>86,R"K2/_T[",1%K=F2;DF?)'-AYZO,04_9J_I8>1]@M.-BPFZAB&5.. M_(">)UVV\3L6?Q&5%(WD_&PCQ"![VI'Y#[,5? M2J6SH6U728:7<^7]X1@_@_>`5!BI&/O)*)*_)#,M"> M&^V2@LSZ_UXEBY\/99?'(N;#PG%U1$2^6_+BS9])>D/ M*$QU:9S=^)6@/0%S/=W@DR($$G5;MXAGR$\*->,=87IKYQ1&PD/ MRJCEY_=K'VGHN6]JZ"X6N2_TNX^P(,3G0UGEB@-=A#.:899LX9TS M=?]I>S:+>C`:K>7!3)>OEW1XN4&YX6)"J-X"'@Y0E77Z9T!EDF*'@U(5=?X9 M`%GEW*^.3FE==H1FG_G^EQL-UQ`4Y#Y?6Y%#"E>W'8K;2$<[@XFUDUQN(3>] M"/@6G=EC2Z%A2L2!.;Q^)SXD'I_&99-76)&^/E[O>0]U<-IFZ_^@\(KSK^-, MZ=BV#01K<;-*[[^B(=%\'M_`P15]H#YAOAP`".Q!%V2"\/7XWS:Q,NM;R#Y\ M9CZ1=,K,X5YX3I4^!0BTO^5W.'X-80U!&>(#6ILVJ1M/*]U(S;B@_TN_=G9: MF&?9\?WFM[/3BBI*&[K&\P8L+>NH:SYZV-4]GTTA7;H&YA(6Q`L``00E#@``!#D!``!02P$"'@,4````"`#=/0I'I8]B;98*``!!A@`` M%0`8```````!````I(%$6@``9V%L="TR,#$U,#8S,%]C86PN>&UL550%``,Q MC\A5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`W3T*1RK&P(=0(@``,*T" M`!4`&````````0```*2!*64``&=A;'0M,C`Q-3`V,S!?9&5F+GAM;%54!0`# M,8_(575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-T]"D?S%Y+UYD```'>N M`P`5`!@```````$```"D@`L``00E#@``!#D!``!02P$"'@,4````"`#=/0I'G?35YK,D``#, M*@,`%0`8```````!````I(']R```9V%L="TR,#$U,#8S,%]P&UL550% M``,QC\A5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`W3T*1Q!DVS-T#``` M9G8``!$`&````````0```*2!_^T``&=A;'0M,C`Q-3`V,S`N>'-D550%``,Q HC\A5=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``+[Z```````` ` end XML 38 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies

8. Commitments and Contingencies

Shareholder Class Actions and Derivative Lawsuits

Between July 30, 2014, and August 6, 2014, three putative class action complaints were filed in the United States District Court for the District of Nevada (the “Nevada District Court”) against the Company and certain of its officers and directors on behalf of all persons who purchased or otherwise acquired the Company’s stock between January 6, 2014 and July 28, 2014. By order entered August 22, 2014, the Nevada District Court consolidated the three cases, relieved the defendants of any obligation to respond to the complaints then on file, and provided that defendants may respond to a consolidated amended complaint to be filed following appointment of a lead plaintiff(s) pursuant to the Private Securities Litigation Reform Act of 1995. By order dated January 5, 2015, the Nevada District Court granted the defendants’ motion to transfer the consolidated action to the United States District Court for the Northern District of Georgia (the “Court”). On March 24, 2015, the Court appointed Glyn Hotz as the lead plaintiff (“Plaintiff”). Plaintiff filed his Consolidated Class Action Complaint (the “Complaint”) on May 8, 2015. The Complaint asserts claims on behalf of a putative class of all persons who purchased or otherwise acquired the Company’s common stock between October 25, 2013 and July 28, 2014. The Complaint alleges that the Company and certain of its officers and directors (the “Class Action Individual Defendants”) violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and SEC Rule 10b-5 through allegedly false or misleading statements in certain SEC filings, press releases and other public statements. The Complaint further alleges that the Class Action Individual Defendants and one of the Company’s shareholders face liability for the alleged Section 10(b) and Rule 10b-5 violations pursuant to Section 20(a) of the Exchange Act. The Complaint seeks class certification, unspecified monetary damages, costs, and attorneys’ fees. The Company disputes the allegations and filed a motion to dismiss the Complaint on June 26, 2015.

On August 1 and 25, 2014, persons claiming to be Galectin shareholders filed putative shareholder derivative complaints in the Nevada District Court, seeking recovery on behalf of the Company against certain of the Company’s directors and officers. On September 10, 2014, the Nevada District Court entered an order consolidating the two cases, relieving the defendants of any obligation to respond to the initial complaints, and providing that defendants may respond to a consolidated complaint to be filed by the plaintiffs. On January 5, 2015, the Nevada District Court granted Defendants’ motion to transfer the consolidated putative derivative litigation to the United States District Court for the Northern District of Georgia. The plaintiffs filed a consolidated complaint on February 27, 2015. On April 6, 2015, the Company and defendants filed motions to dismiss the consolidated complaint. Rather than respond to those motions, the plaintiffs sought and obtained leave to file an amended complaint. Plaintiffs filed their amended complaint (the “Complaint”) on May 26, 2015. The Complaint alleges that certain of the Company’s directors and officers (the “Derivative Action Individual Defendants”) breached their fiduciary duties to the Company’s shareholders by causing or permitting the Company to make allegedly false and misleading public statements concerning the Company’s financial and business prospects. The Complaint also alleges that the Derivative Action Individual Defendants violated the federal securities laws by allegedly making false or misleading statements of material fact in the Company’s proxy filings, committed waste of corporate assets, were unjustly enriched, and that certain defendants breached their fiduciary duties through allegedly improper sales of Galectin stock. In addition, the Complaint alleges that the Derivative Action Individual Defendants and one of the Company’s shareholders aided and abetted the alleged breaches of fiduciary duties. The Complaint seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the Complaint on July 8, 2015.

On August 29, 2014, another alleged Galectin shareholder filed a putative shareholder derivative complaint in state court in Las Vegas, Nevada, seeking recovery on behalf of the Company against the same Galectin directors and officers who are named as defendants in the derivative litigation pending in the United States District Court for the Northern District of Georgia (the “Georgia Federal Action”). The plaintiff in the Nevada action subsequently filed first and second amended complaints. The second amended complaint alleges claims for breach of fiduciary duties, unjust enrichment, and waste of corporate assets, based on allegations that are substantially similar to those asserted in the Georgia Federal Action (except that the Nevada action does not allege violations of the federal securities laws and does not assert any claim against the Galectin shareholder named as a defendant in the Georgia Federal Action), and seeks unspecified monetary damages on behalf of the Company, corporate governance reforms, disgorgement of profits, benefits and compensation by the defendants, costs, and attorneys’ and experts’ fees. The Company and defendants filed motions to dismiss the second amended complaint on April 22, 2015. On April 29, 2015, the plaintiffs in the Georgia Federal Action filed a motion to intervene in the Nevada action which, among other things, raised questions regarding the Nevada plaintiff’s standing. Thereafter, the Nevada plaintiff filed a motion to join additional plaintiffs. At a hearing held on June 11, 2015, the Nevada court: (i) granted the Georgia Federal Action plaintiffs’ motion to intervene; (ii) directed the Georgia Federal Action plaintiffs to file a complaint in intervention; (iii) directed the Nevada plaintiff to file a motion for leave to file a further amended complaint to add additional plaintiffs; (iv) stated that the defendants’ motions to dismiss the second amended complaint were denied “at this point;” (v) ordered the Nevada action stayed until December 11, 2015; and (vi) directed the parties to submit a status report on December 11, 2015, updating the court on the progress and status of the Georgia Federal Action.

Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, are in the early stages of the proceedings, and are subject to appeal. In addition, because most legal proceedings are resolved over extended periods of time, potential losses are subject to change due to, among other things, new developments, changes in legal strategy, the outcome of intermediate procedural and substantive rulings and other parties’ settlement posture and their evaluation of the strength or weakness of their case against us. For these reasons, we are currently unable to predict the ultimate timing or outcome of, or reasonably estimate the possible losses or a range of possible losses resulting from, the matters described above. Based on information currently available, the Company does not believe that any reasonably possible losses arising from currently pending legal matters will be material to the Company’s results of operations or financial condition. However, in light of the inherent uncertainties involved in such matters, an adverse outcome in one or more of these matters could materially and adversely affect the Company’s financial condition, results of operations or cash flows in any particular reporting period.

Other Legal Proceedings

The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no other pending legal proceedings except as noted above.

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Galectin Sciences LLC
6 Months Ended

Jun. 30, 2015

Galectin Sciences LLC

9. Galectin Sciences LLC

In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as wells the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. As a result, the Company contributed the $93,000, $159,000 and $172,000 needed for the fourth quarter of 2014, first quarter of 2015 and the second quarter of 2015 expenses of the LLC, respectively. As a result, the Company’s ownership percentage in the LLC is 67.3% at June 30, 2015. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. The Company’s portion of the LLC’s net loss for the year ended December 31, 2014, prior to the change in accounting discussed previously, was $400,000, which includes the Company’s proportionate share of the non-cash charge associated with the contributed IPR&D of $200,000.

X

- Definition
The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

+ Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2015

Accrued Expenses

Accrued expenses consist of the following:

 June 30,
2015 December 31,
2014

 (in thousands)

Legal and accounting fees
 $ 255 $ 118

Accrued compensation
 377 604

Accrued clinical trial costs
 426 —

Other
 7 7





Total
 $ 1,065 $ 729





X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued Expenses (Detail) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Schedule of Accrued Liabilities [Line Items]

Legal and accounting fees $ 255 $ 118

Accrued compensation 377 604

Accrued clinical trial costs 426

Other 7 7

Total $ 1,065 $ 729

X

- Definition
Accrued Clinical Trial Costs
+ References
No definition available.
+ Details

Name: galt_AccruedClinicalTrialCosts

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Schedule of Accrued Liabilities [Line Items]
+ References
No definition available.
+ Details

Name: galt_ScheduleOfAccruedLiabilitiesLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Restricted Stock Grant Activity (Detail) - Restricted Stock - shares
6 Months Ended

Apr. 08, 2015

Mar. 12, 2015

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Beginning Balance 416,670

Granted 177,618 81,352 337,935

Exercised 0

Options forfeited/cancelled 222,615 0

Ending Balance 754,605

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (9,469) $ (8,539)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 4 5

Stock-based compensation expense 1,734 2,394

Loss from equity method investment in Galectin Sciences LLC 337

Changes in operating assets and liabilities:

Prepaid expenses and other assets 228 111

Accounts payable and accrued expenses (Notes 2 and 8) 205 (339)

Net cash used in operating activities (7,298) (6,031)

CASH FLOWS FROM INVESTING ACTIVITIES:

Equity method investment in Galectin Sciences LLC (400)

Net cash used in investing activities (400)

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of common stock and warrants 4,532 28,178

Proceeds from exercise of common stock warrants and options 2,187

Net cash provided by financing activities 4,532 30,365

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (2,766) 23,934

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 29,128 10,489

CASH AND CASH EQUIVALENTS, END OF PERIOD 26,362 34,423

NONCASH FINANCING ACTIVITIES:

Payment of preferred stock dividends in common stock $ 421 $ 488

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options and warrants.
+ References
No definition available.
+ Details

Name: galt_ProceedsFromStockOptionAndWarrantExercises

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Supplemental Dividends on ESOP convertible preferred stock
+ References
No definition available.
+ Details

Name: galt_SupplementalDividendsOnConvertiblePreferredStock

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.12)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 11

-Article 7

+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value of Financial Instruments
6 Months Ended

Jun. 30, 2015

Fair Value of Financial Instruments

5. Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximates their carrying value due to their short-term nature. There were no level 2 or level 3 assets held at fair value at June 30, 2015 or December 31, 2014.

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Common Stock Warrant Activity (Detail) - 6 months ended Jun. 30, 2015 - Warrant - $ / shares

Total

Shares

Beginning Balance 5,470,995

Granted 0

Exercised 0

Forfeited/cancelled (100,000)

Ending Balance 5,370,995

Weighted Average Exercise Price

Outstanding, December 31, 2014 $ 3.67

Granted 0

Exercised 0

Forfeited/cancelled 4.26

Outstanding, March 31, 2015 $ 3.64

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]
+ References
No definition available.
+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 67 137 1 false 22 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.galectintherapeutics.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Accrued Expenses Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses Notes 7 false false R8.htm 109 - Disclosure - Stock-Based Compensation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 8 false false R9.htm 110 - Disclosure - Common Stock Warrants Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockWarrantsTextBlock Common Stock Warrants Notes 9 false false R10.htm 111 - Disclosure - Fair Value of Financial Instruments Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments Notes 10 false false R11.htm 112 - Disclosure - Loss Per Share Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Loss Per Share Notes 11 false false R12.htm 113 - Disclosure - Common Stock Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Common Stock Notes 12 false false R13.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 13 false false R14.htm 115 - Disclosure - Galectin Sciences LLC Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock Galectin Sciences LLC Notes 14 false false R15.htm 116 - Disclosure - Subsequent Events Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 15 false false R16.htm 117 - Disclosure - Accrued Expenses (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) Tables http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 16 false false R17.htm 118 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 17 false false R18.htm 119 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockWarrantsTextBlockTables Common Stock Warrants (Tables) Tables http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockWarrantsTextBlock 18 false false R19.htm 120 - Disclosure - Loss Per Share (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Loss Per Share (Tables) Tables http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 19 false false R20.htm 121 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) Details 20 false false R21.htm 122 - Disclosure - Accrued Expenses (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses (Detail) Details http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables 21 false false R22.htm 123 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToCommonStockOptionsRestrictedCommonStockAndCommonStockWarrants Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) Details 22 false false R23.htm 124 - Disclosure - Summary of Stock Option Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity Summary of Stock Option Activity (Detail) Details 23 false false R24.htm 125 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGranted Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) Details 25 false false R26.htm 127 - Disclosure - Summary of Restricted Stock Grant Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSummaryOfRestrictedStockGrantActivity Summary of Restricted Stock Grant Activity (Detail) Details 26 false false R27.htm 128 - Disclosure - Common Stock Warrant Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockWarrantActivity Common Stock Warrant Activity (Detail) Details 27 false false R28.htm 129 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureDilutiveSharesWhichCouldExistPursuantToExerciseOfOutstandingStockInstrumentsAndWhichWereNotIncludedInCalculation Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) Details 28 false false R29.htm 130 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation Common Stock - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Galectin Science LLC - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureGalectinScienceLLCAdditionalInformation Galectin Science LLC - Additional Information (Detail) Details 31 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 2, 4, 8 are contained in other reports, so were removed by flow through suppression. galt-20150630.xml galt-20150630_cal.xml galt-20150630_def.xml galt-20150630_lab.xml galt-20150630_pre.xml galt-20150630.xsd true true XML 47 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Jun. 30, 2014

Dec. 31, 2013

Basis of Presentation [Line Items]

Unrestricted cash and cash equivalents $ 26,362 $ 29,128 $ 34,423 $ 10,489

X

- Definition
Basis of Presentation [Line Items]
+ References
No definition available.
+ Details

Name: galt_BasisOfPresentationLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.64%	1.58%
Expected life of the options	6 years	6 years
Expected volatility of the underlying stock	104.00%	114.00%
Expected dividend rate	0.00%	0.00%

Common Stock - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 30, 2014
Class of Stock [Line Items]
Proceeds from issuance of common stock			$ 4,532,000	$ 28,178,000
At Market Agreement
Class of Stock [Line Items]
Aggregate offering price						$ 30,000,000
Commission to sales agent as a percentage of gross proceeds						3.00%
Shares of common stock issued		1,279,416			217,622
Price of common stock per share					$ 5.49
Gross proceeds from sale of common stock					$ 1,196,000
Commissions					36,000
Proceeds from issuance of common stock	$ 0	$ 4,532,000			$ 1,159,000

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	11,428,358	11,299,127
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	5,370,995	5,450,995
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	3,192,325	3,311,029
Unvested Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	337,935
Contingently Issuable Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	2,527,103	2,537,103

Commitments and Contingencies - Additional Information (Detail)	Aug. 06, 2014 LegalMatter
Commitment And Contingencies [Line Items]
Number of putative class action complaints filed	3

Galectin Science LLC - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Jan. 31, 2014	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Investments in and Advances to Affiliates [Line Items]
Equity method investment in Galectin Sciences LLC							$ 400,000
Loss from equity method investment in Galectin Sciences, LLC					$ (67,000)		$ (337,000)
Galectin Sciences, LLC
Investments in and Advances to Affiliates [Line Items]
Equity method investment in Galectin Sciences LLC	$ 400,000
Subsequent capital contribution		$ 172,000	$ 159,000	$ 93,000
Equity Method Investment, Ownership Percentage	50.00%
Ownership Percentage						67.30%
Loss from equity method investment in Galectin Sciences, LLC								$ (400,000)
Non-cash charge for in-process research and development								$ 200,000
Galectin Sciences, LLC \| SBH Sciences, Inc \| In Process Research and Development
Investments in and Advances to Affiliates [Line Items]
Estimated fair value of the IPR&D Contributed by SBH	$ 400,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 26,362	$ 29,128
Prepaid expenses and other current assets	305	533
Total current assets	26,667	29,661
Property and equipment, net		1
Intangible assets, net	12	15
Total assets	26,679	29,677
Current liabilities:
Accounts payable	775	906
Accrued expenses	1,065	729
Accrued dividends payable	68	68
Total liabilities	$ 1,908	$ 1,703
Commitments and contingencies (Note 8)
Stockholders' equity:
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at June 30, 2015 and December 31, 2014
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,402,500 issued and outstanding at June 30, 2015 and December 31, 2014, liquidation value $1,402,500 at June 30, 2015	$ 567	$ 567
Common stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2015 and December 31, 2014, 23,788,913 and 22,277,283 issued and outstanding at June 30, 2015 and December 31, 2014, respectively	23	22
Additional paid-in capital	146,217	139,531
Retained deficit	(128,930)	(118,925)
Total stockholders' equity	17,877	21,195
Total liabilities, redeemable convertible preferred stock and stockholders' equity	26,679	29,677
Series B-1 12% redeemable convertible preferred stock
Current liabilities:
Convertible preferred stock, value	1,740	1,731
Series B-2 12% redeemable convertible preferred stock
Current liabilities:
Convertible preferred stock, value	3,431	3,325
Series C super dividend convertible preferred stock
Current liabilities:
Convertible preferred stock, value	$ 1,723	$ 1,723

Stock-Based Compensation - Additional Information (Detail)			1 Months Ended		3 Months Ended			6 Months Ended
	Apr. 08, 2015 USD ($) Director shares	Mar. 12, 2015 USD ($) Director shares	May. 31, 2015 USD ($) Director shares	Jan. 31, 2014 shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2014 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost \| $					$ 3,492,000			$ 3,492,000
Unvested option					828,596			828,596
Unrecognized compensation cost, recognition period								1 year 8 months 1 day
Weighted-average grant-date fair values of options granted \| $ / shares								$ 2.78	$ 11.38
Number of options granted								304,000
Number of options vested								76,000
Stock-based compensation expense \| $					$ 800,000	$ 745,000		$ 1,734,000	$ 2,394,000
Options vesting over 3 years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested option					228,000			228,000
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense \| $							$ 25,000
Common stock options granted, shares				3,000
Fair market value of shares \| $							$ 25,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period								3 years
Stock-based compensation expense \| $								$ 173,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted	177,618	81,352						337,935
Non-cash stock-based compensation expense to be recognized \| $	$ 0
Restricted stock awards cancelled	222,615							0
Restricted Stock \| Non Employees Seven Board Of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted		77,784
Number of non-employee directors \| Director		7
Non-cash stock-based compensation expense to be recognized \| $		$ 280,000
Share based compensation, cliff vest in full date		May 20, 2016
Restricted Stock \| Non Employees Two Board Of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted		3,568
Number of non-employee directors \| Director		2
Non-cash stock-based compensation expense to be recognized \| $		$ 12,845
Share based compensation, cliff vest in full date		May 21, 2015
Restricted Stock \| Non Employee Board Of Directors Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted	71,378
Number of non-employee directors \| Director	1
Non-cash stock-based compensation expense to be recognized \| $	$ 236,975
Share based compensation, cliff vest in full date	May 20, 2016
Restricted Stock \| Non Employee Board Of Directors Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted	7,587		7,587
Number of non-employee directors \| Director	4		4
Non-cash stock-based compensation expense to be recognized \| $	$ 23,500		$ 23,500
Share based compensation, cliff vest in full date	May 20, 2016		May 20, 2016

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Undesignated stock, par value	$ 0.01	$ 0.01
Undesignated stock, shares authorized	20,000,000	20,000,000
Undesignated stock, shares designated	8,001,000	8,001,000
Series A 12% convertible preferred stock, shares authorized	5,000,000	5,000,000
Series A 12% convertible preferred stock, issued	1,402,500	1,402,500
Series A 12% convertible preferred stock, outstanding	1,402,500	1,402,500
Series A 12% convertible preferred stock, liquidation value	$ 1,402,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	23,788,913	22,277,283
Common stock, outstanding	23,788,913	22,277,283
Series B-1 12% redeemable convertible preferred stock
Convertible preferred stock, shares authorized	900,000	900,000
Convertible preferred stock, shares issued	900,000	900,000
Convertible preferred stock, shares outstanding	900,000	900,000
Convertible preferred stock, redemption value	$ 1,800,000
Convertible preferred stock, liquidation value	$ 1,800,000
Series B-2 12% redeemable convertible preferred stock
Convertible preferred stock, shares authorized	2,100,000	2,100,000
Convertible preferred stock, shares issued	2,100,000	2,100,000
Convertible preferred stock, shares outstanding	2,100,000	2,100,000
Convertible preferred stock, redemption value	$ 4,200,000
Convertible preferred stock, liquidation value	$ 4,200,000
Series C super dividend convertible preferred stock
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, shares issued	176	176
Convertible preferred stock, shares outstanding	176	176
Convertible preferred stock, redemption value	$ 5,660,000
Convertible preferred stock, liquidation value	$ 1,760,000

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 07, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	GALT
Entity Registrant Name	GALECTIN THERAPEUTICS INC
Entity Central Index Key	0001133416
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		22,788,913

Summary of Stock Option Activity (Detail) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Shares
Beginning Balance	3,332,617
Granted	304,000
Exercised	(95,574)
Options forfeited/cancelled	(348,718)
Ending Balance	3,192,325
Weighted Average Exercise Price
Beginning Balance	$ 5.79
Granted	3.45
Exercised	1.80
Options forfeited/cancelled	4.42
Ending Balance	$ 5.83

Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Schedule of Accrued Liabilities [Line Items]
Legal and accounting fees	$ 255	$ 118
Accrued compensation	377	604
Accrued clinical trial costs	426
Other	7	7
Total	$ 1,065	$ 729

Summary of Restricted Stock Grant Activity (Detail) - Restricted Stock - shares			6 Months Ended
	Apr. 08, 2015	Mar. 12, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance			416,670
Granted	177,618	81,352	337,935
Exercised			0
Options forfeited/cancelled	222,615		0
Ending Balance			754,605

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,469)	$ (8,539)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4	5
Stock-based compensation expense	1,734	2,394
Loss from equity method investment in Galectin Sciences LLC		337
Changes in operating assets and liabilities:
Prepaid expenses and other assets	228	111
Accounts payable and accrued expenses (Notes 2 and 8)	205	(339)
Net cash used in operating activities	(7,298)	(6,031)
CASH FLOWS FROM INVESTING ACTIVITIES:
Equity method investment in Galectin Sciences LLC		(400)
Net cash used in investing activities		(400)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants	4,532	28,178
Proceeds from exercise of common stock warrants and options		2,187
Net cash provided by financing activities	4,532	30,365
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,766)	23,934
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	29,128	10,489
CASH AND CASH EQUIVALENTS, END OF PERIOD	26,362	34,423
NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock	$ 421	$ 488

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Basis of Presentation [Line Items]
Unrestricted cash and cash equivalents	$ 26,362	$ 29,128	$ 34,423	$ 10,489